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Abstract
This thesis describes the isolation and structural elucidation of 17 new secondary
metabolites from Tongan marine sponges including examples of alkaloids, polyke-
tides and terpenoids. In the process of this work, 19 sponge specimens were subjected
to preliminary NMR-guided investigation. Nine organisms were selected for further
analysis on the basis of the structural novelty perceived within the HMBC spectrum
of crude fractions generated by the first chromatographic purification of their crude
extracts, and the apparent rarity of the specimen.
Investigation of two different demosponge specimens afforded the γ-hydroxybutenolide
sesterterpenes (23 and 24), and small quantities of the potently cytotoxic alkaloid
14-bromohomofascaplysin (29).
The analysis of two samples of a dictyoceratid sponge yielded the new labdane
diterpenes luakuliides A–C (33–36), characterised by a bridging hemi-acetal
function on the B-ring of the labdane bicycle. Luakuliide A (33) and its methyl
acetal derivative 34 were found to display interesting immunomodulatory activity.
Seven new α-pyrone polyketides, lehualides E–K (69–75), were isolated from a
Plakortis sp. Lehualides H–K (72–75) display a range of sulfur functionalities,
the natures of which were determined by spectroscopic comparison with synthesised
model compounds.
Another plakinid sponge specimen contained four new polyketides (95–98), all
of which possess different cyclic peroxide moieties. Cyclic peroxides 95, 97 and
98 displayed potent cytoxicity against human promyelocytic leukemia cells (HL-
60). Chemical genetic and phenoytypic profiling studies of 95 were undertaken
in Saccharomyces cerevisiae yeast using the homozygous diploid and heterozygous
diploid deletion libraries. These studies indicate that 95 acts to disrupt Ca2
homeostasis, leading to elevation of intracellular Ca2 levels.
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Chapter 1
Introduction
1.1 Natural products as therapeutic agents
For millennia human societies have relied upon nature for their fundamental needs,
and for medicines in particular.1 Egyptian documentation of this relationship dates
back to 4000 BC,1 however, the treatment of human disease is still a pressing and
costly concern. Care and support of cancer patients alone in the US totaled more
than 124 billion USD in 2010.2 As the leading cause of death in New Zealand, cancers
account for 29.4% of all deaths at an estimated cost of 511 million NZD per year.3
As such, the development of new therapeutic agents is beneficial to society, if only
to lessen these financial burdens.
Naturally-derived compounds continue to play an integral role in the treatment
of human disease, and the pharmaceutical landscape is heavily populated by non-
synthetic compounds.4 Over the past 30 years roughly 60% of the introduced small
molecule pharmaceutical leads have been natural products, derivatives thereof, or
synthetic mimics of natural product pharmacophores.4–7 One such entity is the
microtubule stabiliser paclitaxel (1, TAXOLR￿, Bristol-Myers Squibb). Isolated from
the Pacific yew tree, Taxus brevifolia in 1967, paclitaxel has been marketed from the
early 1990s and is estimated to have extended the lives of several hundred thousands
of lung, ovarian and breast cancer patients.8 Annual sales of TAXOL R￿ peaked at
1.6 billion USD in 2000.9 Another significant example is the immunosuppressive
macrolide rapamycin (2, RapamuneR￿, Wyeth). First developed as an antifungal
agent, rapamycin has been used widely since 1999 for the prevention of organ
transplant rejection.4 In 2011 a total of 94,493 life-saving organ transplants were
carried out in the US alone, with each patient then requiring immunosuppressive
treatment for an average cost of more than 24,000 USD per annum.10
These two structurally different and important therapeutic agents are both products
of a living organism’s secondary metabolism. Secondary metabolites are non-
essential to the immediate survival of an organism as they are not involved in
1
normal growth, development or reproduction.11 Significant biochemical input is
required during their synthesis, justified by the physiological advantages they
confer upon the producing organism.12 Organisms devoid of formal cellular immune
systems and/or adequate forms of physical protection are thought to rely upon
secondary metabolites to deliver an alternative chemical defence system against
assault.13 Consequentially, a chemical arsenal of metabolites have been isolated
from such organisms and display activities including antifungal, antimicrobial,
and cytotoxicity.14 While these metabolites may not have co-evolved with human
receptors they have been evolved to interact with biomolecules in general.6 It is this
innate and varied biological activity that has made secondary metabolites and their
derivatives integral to the development of medicinal chemistry to the point where
they are estimated to have more than doubled the average life-span of human beings
in the 20th century alone.15
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In response to growing demand for new therapeutic agents, the 1990s saw the
advent of high-throughput screening (HTS) methods and combinatorial chemistry
techniques. These new HTS techniques made screening entire compound libraries
faster than it was to isolate and characterise a single natural product. However, the
use of molecular scaffolds and combinatorial techniques has resulted in libraries of
topographically similar molecules,16 many of which have not demonstrated biological
characteristics appropriate for clinical trials. Sorafenib (3, Nexavar, Bayer) is the
only compound developed by these methods to have gained FDA approval,4,17
marketed since 2005 for the treatment of renal carcinomas.
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Structural trends have been observed between artificially designed and naturally
occurring molecules, and although subtle, these differences between the compound
classes appear to induce drastic differences in target specificity and biological
potency.5,18,19 Compounds of natural derivation generally exhibit a greater number
of chiral centres, and corresponding steric complexity. Oxygen-based functions
predominate those of nitrogen, sulfur and the halogens, providing a high number of
hydrogen-bond donors. There is also a trend towards greater aromaticity within the
structures.20–23 As many of these aspects are readily incorporated into synthetic
strategies, synthetic chemistry will maintain an integral role in pharmaceutical
development. Although, our improving understanding of the genetic basis to the
production of some natural products may offer new possibilities for large-scale
production of such compounds in the future. It is clear, however, that the unmatched
structural diversity and complexity evident within natural products will continue to
inspire synthetic chemists in years to come. Natural products chemistry will remain
essential to drug discovery,18,24 in the continued search for new and unexplored areas
of chemical space.25,26
1.2 Marine natural products
Oceans encompass 70% of the Earth’s surface,27 forming a myriad of ecosystems that
are home to an estimated 90% of all species.27 Of the 38 identified animal phyla,
26 are exclusively aquatic and 19 of these are exclusively marine. In comparison,
Onchyophoria (the velvet worms) is the only living, solely terrestrial phylum. It
is therefore unsurprising that environments such as coral reefs and the deep sea
floor are estimated to house a greater diversity of flora and fauna than tropical
rainforests,14 and are believed to contain a similar degree of chemical diversity.
As of 2011 more than 24,000 novel marine natural products have been reported,28
displaying a diverse array of structures and chemical functionality.24 Owing to
the availability of chlorine and bromine in seawater, halogen atoms are frequently
observed in marine metabolites, in comparison to their terrestrial counterparts.24
Cyanate (4), isothiocyanate (5) functions have appeared primarily in the marine
environment, while the dichloro-imine function of compound 6 has only been
observed in sponge metabolites.24 Structural singularity in marine natural products
also extends to carbon skeletons. The ladder-like cyclic polyether structure is
characteristic of the marine toxins, exemplified by maitotoxin (7), the largest non-
proteinaceous toxin known.29
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Many of the organisms investigated from the marine environment are sessile
invertebrates, most of which lack both physical defences and formal cellular immune
systems and require potent and diverse chemical defences.13 Owing to the intrinsic
dilution factor of the marine environment, compounds for chemical defence must be
highly potent to elicit an effect upon release into the surroundings.4
The isolation of potent toxins, particularly those known to humans, initially
dominated the natural products field. Tetrodotoxin (8) was widely utilised in
Voodoo practices in the creation of the ‘living-dead’.30 The neurotoxin acts by
binding to site 1 of the fast voltage-gated Na channels found in most forms of muscle
tissue detrimentally affecting muscle contraction and silencing neural activity.31
Tetrodotoxin (8) is produced by the bacteria Vibrio alginolyticus, which is harboured
by Taricha sp. newts, Atelopus sp. toads, and the blue-ringed octopusHapalochlaena
sp.32 Occurrence of the bacteria within species of puffer fish led to the infamy of 8
as a source of lethal food poisoning.31,32
The release of toxic chemical entities by sponges and other marine organisms is not
solely restricted to defence. Pheromones are released for communication between
organisms of many species, for instance quorum sensing by dinoflagellates preceding
algal blooms.33 Another dinoflagellate isolate, saxitoxin (9), has gained notoriety as
the source of human paralytic shellfish poisoning (PSP) in tainted shellfish. The
molecule shares the tetrodotoxin binding site, and has also been isolated from some
species of puffer fish.34
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Investigation of marine cone snails of the genus Conus from the west and
south-western Pacific eventually led to development of ziconotide (10, Prialt R￿,
Neurex/Elan), the first true marine natural product to gain FDA approval.35 The
fish-hunting cone snails spear their prey with harpoon-like hollow teeth filled with
incapacitating venom. The peptidic toxins are highly potent and selective, acting
as both agonists and antagonists of the ligand- and voltage-gated ion channels, and
G-protein-coupled-receptors.36 Intrathecal delivery of the synthetic ω-conotoxin 10
was approved by the FDA and EU in 2004 and 2005 respectively.35 As the most
potent non-opioid analglesic, the development of ziconotide has been a particularly
important success in the marine natural products field.
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1.3 Sponges
Sponges (phylum Porifera), are the oldest metazoans (multicellular organisms)37
and have been in wide-spread existence since the pre-Cambrian era, ca. 560 million
years ago.38 Taxonomy within the Porifera phylum is uncertain, with reclassifications
frequently taking place even at class level. Environmental factors exert a dramatic
influence over physical characteristics of sponges such as size, colour and shape,
preventing the use of macro-morphological and -physical characteristics as tools
in sponge description.38 Instead, skeletal networks form the basis of classification,
dividing phylum Porifera into three classes. The class Demospongiae encompasses
80–90% of all sponge species, and the organisms contain siliceous and/or spongian
fibres. Calcarea sponges exhibit calcite CaCO3 spicules, while Hexactinellida
sponges have a siliceous spicule network that comprises most of the mass of the
organism (see Figure 1.1).
Sponges are devoid of features commonly found in other animals including developed
circulatory, digestive, nervous and muscular systems.38 In combination with a low
level of cellular organisation and vegetative appearance, these absences prevented
the classification of the phylum into Animalia until the 18th century.38 These
5
sessile filter feeders are also devoid of a formal cellular immune system, and rely
upon their secretion of toxic secondary metabolites to ward off unwanted bacterial,
fungal, and parasitic infections.13,37 These metabolites also offer protection against
encroachment,13 and surface encrustation resulting in the disruption of their water-
pumping systems.38 Perhaps unsurprisingly, sponges are the source of over 30% of
the marine natural products isolated over the last few decades.28,39,40
Kingdom Animalia
Phylum Porifera
Class Calcarea (calcareous sponges)
Order Clathrinida
Order Murrayonida
Order Leucosolenida
Order Lithonida
Order Baerida
Class Hexactinellida (glass sponges)
Order Amphodiscosida
Order Hexactinosida
Order Aulocalycoida
Order Lychnicosida
Order Lyssacinosida
Class Demospongiae (spongin fibres)
Order Homosclerophida
Order Spirophorida
Order Astrophorida
Order Hadromerida
Order Chondrosida
Order Poecilosclerida
Order Halichondrida
Order Agelasida
Order Haplosclerida
Order Dictyoceratida
Order Dendroceratida
Order Halisarcida
Order Verongida
Order Verticillitida
Figure 1.1 Taxonomic classification within the phylum Porifera to order level, after
Hooper and van Soest.38
An early foray into the metabolite profile of the sponge Cryptotethia crypta by
Bergmann, Feeney and Burke yielded the unusual arabinosyl nucleosides spon-
gothymidine (11) and spongouridine (12).41–43 Subsequent development of synthetic
analogues generated the anticancer agent Ara-C (13) and the antiviral agent
azidothymidine or AZT (14, RetrovirR￿, Glaxo-SmithKline).44,45 AZT provided a
major break-through in the AIDS therapy in 1990s, helping to dispel the notion
that HIV/AIDS was a death sentence,45 and is still in use today. Recent efforts
have seen a synthetic reproduction of the pharmacophore of the macrocyclic-
6
polyether halichondrin B, isolated from Halichondria okadai, gained FDA approval
in November 2010. The microtubule-targeting qualities of halichondrin B were
recognised shortly after its reported isolation in 1986, and administration of the
derivative Halaven (15, Eisai Co.) for the treatment of non-small cell lung cancers,
prostate cancer, sarcoma and breast cancers was approved 24 years later.46,47
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1.3.1 Microbial symbiosis in marine sponges
Many sponges are known to host an array of microbial symbionts, which can
account for up to 60% of the living tissue in some sponges.48,49 The true extent of
microbial contribution to the secondary metabolite profile of sponges is not known,
primarily due the difficulties associated with ex-host culturing of many of these
microbial symbionts.24,49 Microbial origins are often inferred when isolates from
a single organism display unusual structural diversity, or conversely, metabolites
classes are isolated from several unrelated sponges. Structural motifs typical of
bacterial metabolism are also indicative of microbial origin, such as the polyketide
cyclic peroxides frequently encountered in Indo-Pacific Plakortis and Plakinastrella
sponges. Cellular localisation of many typical Plakortis simplex metabolites in cells
of the Sphingomonas strain PS193 has been demonstrated, although polyketide
cyclic peroxides were not among these.50 Physical separation of sponge cells from
their associated symbiotic cyanobacteria has also been successful. Such work has
indicated cyanobacterial origins (Oscillatoria spongelia) for 13-dimethylisodysodenin
7
(16), which was previously classified as a metabolite of the sponge Dysidea
herbacea.51
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Investigations of Svenzea,52 Mycale,53 Myxilla and Haliclona sponges54 by Lee
et al. have shown that up to 75% of sponge-associated bacteria are vertically
transferred during embryogenesis, as opposed to horizontal transfer from the
environment.52 This demonstrates a species-specific relationships between sponges
and their bacterial communities.54
1.4 The Tongan marine ecoregion
While the VUW marine natural products program has traditionally investigated
organisms from New Zealand, the past few years have seen frequent recollection of
the same organisms and the isolation of similar metabolites. Therefore in this study
new collection areas were selected to provide new organisms for investigation. The
Kingdom of Tonga was chosen as such a site (Figure 1.2).
The Tongan archipelago is located in the south-west Pacific Ocean, bordered to
the west by the Fijian islands, and to the north by the Samoan territories. The
Territorial Sea with and Exclusive Economic Zone of the kingdom comprises of
660,000 km2 encompassing 171 islands, 52 of them inhabited,56 which are divided
into three main groups – Vava’u, Ha’apai and Tongatapu. The subtropical Tongan
marine environment offers a range of habitats, which coupled with geographical
isolation intrinsic to the island nation and a number of major ocean currents in the
region create diverse marine communities.
Although Tonga is home to an abundance of marine life, there have been very
few reports of secondary metabolites isolated from Tongan marine organisms. The
last compound reported from Tongan waters was in 2001, although a number of
polyketide and terpenoid structures were reported during the 1980s.57,58 However,
environmental similarity across the Indo-Pacific region should allow parallels to
be drawn with metabolites isolated from organisms collected in the neighbouring
Fijian islands, while the change in geographical location may induce subtle chemical
8
Figure 1.2 The Kingdom of Tonga.55
differences. Chemical analysis of a Fijian Cacospongia mycofijiensis specimen
during the 1980s yielded the macrolides laulimalide (17), latrunculin A (18) and
mycothiazole (19).57–59 The hypothesis of chemical similarity across the Indo-Pacific
region was proven by analysis of an ‘Euan C. mycofijiensis specimen within this
laboratory, which afforded both 19, 18, and isomers of 17. However, the ‘Euan
specimen was also found to contain small quantities of zampanolide (20),60 which
had not been reported since its initial isolation in 1996.61 The potent microtubule
stabilising activity of 20 was subsequently uncovered by Field et al.62
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1.5 Organism selection and screening
There are several approaches to the selection of organisms to screen. Organisms
with ethnopharmacological history are frequently investigated as probable sources
of potently bioactive compounds, albeit without structural novelty. Taxonomy
is also considered; organisms closely related to species proven to produce unique
and bioactive molecules are frequently collected.63 Random sampling of organisms
from several locations is a fruitful approach in discovering new metabolites,
although laborious and expensive.63 As the microbial populations within sponge
specimens and their metabolites profiles vary in response to changes in environment
stresses,39,60 the investigation of well-known species from different environments
should culminate in isolation of new compounds.
The Indo-Pacific in general has been well examined by natural product research
programs,57–59,61 and similar species diversity is observed across the region. Hence,
this study will focus on the investigation of encrusting organisms that are difficult to
collect, and those with cryptic colouration and sparse distribution. Such organisms
are less likely to have been subject to prior investigation in Tonga and more likely
to yield structural novelty. Analysis of organisms from unexplored or geographically
isolated areas will also be undertaken, although logistical difficulties may hinder the
recollection of organisms collected from remote areas.
1.5.1 Bioassay-guided isolation
Bioassay-guided isolation has been the governing paradigm in natural products
research since the early 1980s. Used successfully for decades, the approach involves
screening crude biological extracts from target organisms against assays for specific
modes of activity. Although the method guarantees a biologically useful end-
product, it is not without flaws. Such studies culminate in structural elucidation only
Ethnopharmacology entails the study of plants used in traditional medications and their active
constituents.
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after iterative cycles of chromatography and bioassay assessment, hence frequently
result in isolation of known compounds.24 The monetary value of a bioactive
compound is significantly lessened without structural novelty: one can claim rights
to a specific use, but not governing ‘ownership’ rights to the structure. Assessing
crude extracts also precludes the use of more sophisticated biological assays. Assay
bias may also disregard a wide range of metabolites present in an organic extract,
and risk an incomplete understanding of a given compound’s full biological potential.
Pharmaceuticals such as rapamycin (2) are currently marketed for a use unrelated to
the application for which they were initially intended. Furthermore, in vitro testing
cannot adequately assess a compound’s in vivo activity.
From a practical perspective, the wide range of polarities present in a crude extract
can render a compound insoluble in the assay media, further excluding potentially
bioactive compounds. Potent activity of a low-level compound can also be masked by
the mild activities of compounds present at high-levels, while synergistic interactions
between compounds within an active fraction can smear a positive biological activity
across many fractions during purification.64
1.5.2 Spectroscopy-guided isolation
Spectroscopy-guided isolation uses chemistry to narrow the isolation focus. As
opposed to a positive bioactivity, interesting and uncommon structural motifs are
tracked throughout chromatographic cycles. Such focus on unusual structural
motifs facilitates structural dereplication at an early stage, increasing the chances
of discovering a novel structure free from prior patent claim.
Nuclear magnetic resonance (NMR) spectroscopy is an ideal tool for organism
screening and monitoring expedient isolation procedures. Sample preparation
and spectral acquisition is quick to perform, and the non-destructive technique
allows sample recovery. The ability to discern chemical functionality from 1H
NMR spectra is useful in optimisation of chromatographic conditions; from the
selection of an appropriate stationary-phase through to the use of ion-exchange
media and pH buffers for acidic and basic chemical moieties. Comparative
insensitivity of the technique relative to other forms of spectroscopic analysis is a
significant disadvantage. However, new powerful instruments fitted with cryogenic
electronics and micro-probes can accommodate small sample sizes (<1 mg) and
have dramatically improved the detection of minor compounds. The use of such
technologies in 2D correlation experiments allows facile observation of comparatively
insensitive nuclei such as 13C and 15N.5,65
In comparison to NMR, greater sensitivity is offered by mass spectrometry (MS), and
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by MS-coupled liquid chromatography and gas chromatography systems (LC-MS
and GC-MS). However, ionisation susceptibility can differ widely between molecular
classes, hence assessment by NMR can prove more all-encompassing. Additionally,
sub-structure identification offered by 2D NMR spectra can be more informative
than that obtained from MS fragmentation patterns.
1.5.3 Advances in NMR screening
The use of NMR screening within the VUW marine natural products program
has been well developed over the past decade. Expansion from analysis of
1H NMR spectra (Figure 1.3) to digital compilation of 2D heteronuclear single
quantum coherence (HSQC) spectra has led to the isolation of many structurally
unique biologically active secondary metabolites from New Zealand sponges and
red algae.48,60,66 The spectral ‘masks’ of compiled HSQC spectra proved highly
useful in organism selection.48,60,66 By masking out the common correlations is it
relatively simple to determine the degree of structural novelty present within a given
spectrum. However, the HSQC spectrum is fundamentally limited to the observation
of protonated centres and the application of New Zealand spectral masks to Tongan
organisms is questionable. Drastic changes in the metabolite composition of crude
extracts may circumvent the ‘masking’ function of the HSQC screen technologies.60
Figure 1.3 A generic 1H NMR spectrum.
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HMBC screening
Analysis by an heteronuclear multiple bond correlation (HMBC) experiment at the
first stage of purification is the natural progression in NMR screening. The HMBC
spectrum (Figure 1.4) provides multiple-bond correlations from 1H nuclei to both
protonated and non-protonated 13C centres. As such, the experiment should prove
a powerful tool allowing the identification of entire families of compounds at an
early stage of isolation.60 In combination with an HSQC screen, an interesting
one-bond correlation can be extended upon by multiple-bond correlations in the
HMBC spectrum. Although sub-structure screening can also be performed using
the shorter COSY experiment (20 min vs 8 14 h), only protonated linkages are shown
in the COSY spectrum and the experiment delivers less spectral dispersion as the
1H spectrum forms both the real (F1) and synthetic (F2) dimensions.
Figure 1.4 A generic HMBC spectrum.
Sub-structure analysis via the HMBC experiment was recently demonstrated by
Bertelli et al. in the identification of sugar syrup contamination in various types
of honey.67 The experiment allowed discrimination between spectroscopic signals
of very similar chemical moieties in very similar molecules, namely the anomeric
hydroxyls of sugars. Spectral correlations were statistically grouped according to
their relative integrations across several fractions, allowing the identification of
adulterated honey samples, and for the degree of adulteration to be quantified.67 The
same approach has been used to determine the geographical origin of foodstuffs68
and to assess age-related tainting.69 Natural product studies have employed the
techniques for chemotaxonomy, identifying the general classes of metabolites present
within organism extracts. One such study allowed distinctions to be made between
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the extrudes from the conifer families Araucariaceae, Cupressaceae, and Pinaceae
and the resins produced by the angiosperm family Fabaceae.70
The premise behind NMR-based screening methodology is that a novel structure
often corresponds to a novel biological activity, however, a novel structure still
requires a biological application and as such, bioassay methods cannot be ignored.
As the antithesis of bioassay-guided isolation, ignorance of potential biological
application is the primary disadvantage of this structure-guided isolation method.
For this reason, spectroscopy-guided isolation will in all likelihood remain sub-
ordinate to bioassay-guided studies, although the approach is a viable alternative for
research groups without access to a wide variety of sophisticated biological assays.
1.6 Assigning biological applications
Assigning biological application to small molecules isolated in the absence of
biological assessment requires a broad-spectrum assay approach. A viable option is
to test pure compounds individually, or as part of a compound library against a series
of selected cell lines or protein-based assays. Although library generation via either
synthesis or isolation requires significant time and labour, the approach delivers
highly specific and wide-ranging bioactivity information. Accurate determination
of biological activities is invaluable to progression of drug leads through pre-clinical
and clinical testing phases.
It is often assumed that structurally similar molecules will display similar modes of
activity. This is not always the case, however. Despite structural similarities between
members of the resorcyclic acid lactone family, the compounds display a wide variety
of biological activities.71 Radicicol (21) potently and selectively competes for ATP-
binding pocket of HSP90, a molecular chaperone responsible for the maturation and
stability of several oncogenic genes.72 Conversely, zearalone (22) interacts with the
estrogen pathway, and has been shown to adopt a conformation mimicing that of
17-estradiol,73 and interact with the estrogen receptor in direct competition with
the sterol.74
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In light of these findings assay selection requires great consideration. The most
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logical approach would to test a pure compound or library against common screening
assays, followed by more specific and sophisticated assays. This is, however, strictly
limited by the type of assays available, and by the quantities of purified material.
Ideally, one could assess multiple activities with a single assay, making judicious
use of the compound. This can be delivered by microarray profiling assays, such as
those carried out in the eukaryote model Saccharomyces cerevisiae (baking yeast).
Although the assays may not identify the exact mechanism of a compound, the
profiles will hint towards a given biological function indicating which protein-based
assays would be most informative to deciphering a compound’s biological function.
1.6.1 Chemical genetic profiling
Chemical genetic profiling via microarray analysis delivers broad-ranging informa-
tion about biological interactions. During chemical genetic profiling assays, a pooled
population of mutant yeast strains is assessed for growth under a certain growing
condition, such as the presence of a xenobiotic. Each of the mutant strains carries
the deletion for a single non-essential gene, which is replaced by a unique molecular
barcode. These barcodes allow the growth characteristics of each strain to be
quantified relative to a control population.
A fundamental assumption in chemical genetic screening is that small molecules bind
specifically to a cellular component and alter its activity, functionally mimicking a
mutation at the corresponding gene locus.75,76 Increased sensitivity of a specific
deletion mutant strain to a small molecule indicates that the deleted gene is related
to the molecule’s cellular target in either function or pathway. These “guilt by
association” interactions show that the deleted gene is required to buffer the effects
of the small molecule, and can be used to elucidate its cellular target.
1.6.2 Gene expression profiling
Orthogonal to chemical genetic profiling, gene expression profiling analysis quantifies
the up- and down-regulation of messenger RNA (mRNA) expression of genes in
response to an exogenous substance. Fluctuations in levels of specific mRNA
sequences suggest a changed requirement for the protein coded by the sequence;
for example, cells or tissues will increase levels of mRNA encoding alcohol
dehydrogenase in response to increased levels of ethanol in their environment.77
Both chemical genetic profiling and gene expression profiling techniques assess
both the non-essential and essential gene cassettes simultaneously. However, under
stress conditions, multiple gene products may be expressed but not be required for
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expedient adaptation to environmental changes,76 while genes essential for growth in
particular environments may have an unchanged expression profile as their response
is post-transcriptional.76 Chemical genetic profiling therefore has the power to
identify the specific target of a small molecule inhibitor in the absence of any change
in mRNA-expression.76
Chemical genetic profiling is an ideal form of biological assessment for small
molecules isolated without knowledge of their biological activity. The profiles
obtained from the assays will indicate which cellular functions are affected by a
small molecule, aiding the identification of its precise cellular target and elucidation
of its mechanism of action.
1.7 Research objectives
This thesis will encompass the isolation and structural elucidation of new secondary
metabolites from Tongan marine sponges. To maximise the discovery of novel
metabolites, the study of specimens with cyptic colouration and sparse distribution
in geographically remote areas will be undertaken. This approach will hopefully
uncover structural novelty from a well-examined region.
The principles of NMR-guided isolation will be applied throughout the chromato-
graphic process, and the value of the HMBC experiment as a screening tool will
be assessed through the identification of molecular substructures from within semi-
purified fractions.
Following isolation, all metabolites will be assessed for activity against the human
promyelocytic leukemia cell line HL-60. Inhibition of Saccharomyces cerevisiae
yeast will also be assessed with the aim of identifying compounds with antifungal
activity that is sufficient to allow characterisation of their biological mechanisms
with chemical genetic techniques.
1.8 Summary
With its multiple island groups spanning many latitudes, the Kingdom of Tonga
offers a host of different marine environments, providing an ideal location to
study marine natural products. In comparison to New Zealand, Tonga should
offer a multitude of organisms whose investigation will hopefully culminate in the
characterisation of new and interesting secondary metabolites.
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Bioassay-guided isolation has been used in the successful isolation of biologically-
active secondary metabolites for decades. However, the partnership of spectroscopy-
guided isolation practices and chemical genetic screening offers an alternative.
Chemical genetic screening techniques have the potential to identify the specific
mode of activity of such biologically active metabolites. The approach is unbiased
towards any particular mode of biological activity, and complements a structure-
based isolation approach. Used in tandem, the two have the potential to uncover
new metabolites and fully characterise their biological activities.
17
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Chapter 2
Organism Screening and Selection
Over the course of this study, 19 Tongan sponges were subjected to an NMR-based
screening and selection process. 1D and 2D NMR spectra were acquired from the
semi-purified screening fractions from each sponge, and the HMBC experiments
in particular were assessed for apparent structural novelty. Nine specimens were
selected for more thorough investigation on this basis. The metabolite profiles of
each of these organisms is briefly detailed, and more comprehensive accounts of the
structural classes from three organisms can be found in Chapters 3, 4 and 5.
2.1 Collection areas
Two excursions were made to the Kingdom of Tonga for sample collection yielding
260 sponge samples. In some cases multiple collections of the same organism
were made, allowing study of changes in low-level metabolite profiles of specimens
collected from geographically distinct locations. Collection sites visited during the
first expedition in November 2008 included areas about the capital Nuku’alofa on
the main island Tongatapu, the Houma blow-holes on the south side of the island,
and the island of ‘Eua to the east of Tongatapu. Several locations in the northern
Vava’u island group were explored in November 2009.
2.2 Organism selection
Nineteen sponges that had been collected in small quantities from the Tongan islands
were screened according to laboratory protocol (Appendix A). The crude methanol
extracts of each sponge were individually partitioned over a column of HP20 resin
beads, generating three Me2CO in H2O fractions of differing polarities, 30%, 75%
and 100% Me2CO in H2O. Full NMR data sets of the 100% and 75% Me2CO in H2O
fractions, including HMBC experiments, were acquired. Organism selection was
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largely based upon the structural motifs evident within the crude HMBC spectra,
with an emphasis placed on sub-structures including non-protonated carbon centres.
Using these guidelines, nine specimens were chosen for further investigation. The
remaining ten samples were discontinued when the spectral interest offered within
was superseded by others, and when insufficient quantities of the organism had
been collected (<10 g). A compilation of the masses of screened sponge fractions
extracted is presented in Table 2.1.
2.3 The Vava’u group
The northern island group of Tonga, Vava’u, was visited in November 2009, and
over 100 sponge samples were collected from eight dive sites within the island
group. Comparison with sponge specimens also collected from ‘Eua Island revealed
subtle changes in metabolite profile between the two locations. In the case of the
dictyoceratid sponge “luakuli” (PTN3_21E), new metabolites were isolated (see
Chapter 3). Conversely, Vava’u collections of Cacospongia mycofijiensis investigated
by Singh were deficient in the sought-after microtubule stabiliser zampanolide
(20).60,62
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Figure 2.1 The Vava’u island group.
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2.3.1 PTN3_37F and PTN3_45E
Figure 2.2 Surface photo of the sponge PTN3_45E.
Extraction of the demosponges PTN3_37F and PTN3_45E yielded two new
diterpenes, iso-secothorectolide (23) and 1-hydroxyluffarin Q (24). The metabolites
dominated the 1D and 2D NMR spectra of the 100% and 75% Me2CO in
H2O HP20 fractions (Figures 2.3 and 2.4). Concurrent isolation of the two
unreported metabolites within this laboratory from a bright orange ‘Euan sample
of Fascaplysinopsis sp. (order Dictyoceratida, family Thorectidae) by Taufa78 aided
structural elucidation of the compounds.
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Figure 2.3 1H NMR spectrum (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_45E.
Figure 2.4 HMBC experiment (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_45E.
23
2.3.2 PTN4_10B
Figure 2.5 Surface photo of the sponge PTN4_10B
Several collections were made within the Vava’u island group of an unidentified
demosponge, PTN4_10B. The lipophilic HP20 screening fraction (100% Me2CO)
of PTN4_10B was dominated by two compounds: ambliol B (25) and luffarielolide
(26), while the 1H and HMBC NMR spectra of the 75% Me2CO in H2O fraction
indicated the presence of other metabolites (Figures 2.6 and 2.7). Further analysis of
this specimen was not undertaken in this study, although subsequent investigations
by Woolner79 yielded several new members of the fascaplysin and homofascaplysin
classes.
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Figure 2.6 1H NMR spectrum (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN4_10B.
Figure 2.7 HMBC experiment (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN4_10B.
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2.4 ‘Eua Island
‘Eua is the most ancient of Tongan islands, geologically distinct and geographically
isolated from the other island groups.39 No report has been made of natural product
investigations in the area, and it was hoped that the unique marine environment
about ‘Eua would produce novel chemistry.
A number of the specimens to receive further investigative attention during this
work were collected at a depth of ca. 15 m in November 2008 from a marine cave
on ‘Eua island. A second collection venture to the area was intended, but had to be
abandoned due to safety concerns. Recollection of particularly rich sponges, such as
the Plakortis specimen PTN3_20A was attempted in the Vava’u group, although
such attempts were for the most part unsuccessful, owing to organism rarity or
difficulties in sample recognition.
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Figure 2.8 The Tongatapu island group.
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2.4.1 PTN3_19D
Figure 2.9 Surface photo of the plakinid specimen PTN3_19D.
Investigation of the thinly-encrusting black plakinid sponge PTN3_19D (50 g)
yielded four new polyketide metabolites and two 5α,8α-epidioxysterols. Evident
within the HMBC experiment of the 75% Me2CO in H2O fraction were correlations
from the protons of deshielded diastereotopic methylenes to oxycarbonyls and
oxyquarternary centres (Figures 2.10 and 2.11). These interesting oxygenated
structural fragments encouraged investigation of the specimen.
Figure 2.10 1H NMR spectrum (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_19D.
27
Figure 2.11 HMBC experiment (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_19D.
Two members of the 5α, 8α-epidioxysterol class 27 and 28 were isolated from
PTN3_19D. The metabolites were first reported in 1978 by Gunatilaka et al. and
have subsequently been encountered in a number of different sponge species,80–82
the gorgonian Eunicell cavolini and the ascidian Trididemnum inarmatum.83
Stereochemical analysis of the sterols was not undertaken during this study.
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Investigation of PTN3_19D also afforded four new polyketide cyclic peroxides, the
isolation and structural elucidation of which is detailed in Chapter 4. Biological
assessment of the metabolites in Saccharomyces cerevisiae yeast follows in Chapter
5.
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2.4.2 PTN3_20A
Figure 2.12 Surface photo of the Plakortis specimen PTN3_20A.
One of the first specimens to be analysed with our NMR-based screening protocol
during this study was a dark purplish-brown Plakortis sponge, PTN3_20A. As
detailed in Table 2.1, the 20 g screen sample yielded unusually high masses for
the three Me2CO in H2O fractions. This was fortuitous as recollection of the sponge
was never achieved.
Analysis of the 1H NMR spectra of the 75% and 100% Me2CO in H2O fractions
drew attention to unusual combination of signals, including shielded methyl protons,
oxymethyl protons, aromatic protons, and evidence of a long alkyl chain (Figure
2.13). However, the HMBC spectra indicated the most interesting structural
relationships: correlations between deshielded, methyl groups, methylene centres
and two isolated, highly polarised and substituted carbon double bonds (Figure
2.14). The seven new isolates from this organism are discussed in Chapter 4.
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Figure 2.13 1H NMR spectrum (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_20A.
Figure 2.14 HMBC experiment (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_20A.
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2.4.3 PTN3_20B
Figure 2.15 Surface photo of the slimy, mottled-green sponge PTN3_20B.
Analysis of the slimy, mottled-green demosponge PTN3_20B yielded the cytotoxic
metabolite 14-bromohomofascaplysin (29). The alkaloid was present at low levels in
the 1H and HMBC NMR spectra of the 75% Me2CO in H2O HP20 fraction (Figures
2.16 and 2.17). A new addition to the homofascaplysin class, 29 was later isolated
in greater quantities from PTN4_10B by Woolner.79 The metabolite is a potent
inhibitor of the HL-60 cell line, IC50 33.8 nmol L 1, and cell cycle analysis indicated
that 29 induces S-phase delay.84 14-bromohomofascaplysin (29) was cytotoxic to
wild type yeast with an IC50 value of 4.58 µmol L 1.
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The des-bromo analogue 30 was isolated by Taufa from the orange ‘Euan specimen
PTN3_13A,78 allowing direct spectral and biological comparison between the
compounds. Consistent with the trend observed by Crews et al,85 HL-60 cells
exhibited increased sensitivity to the brominated form. The presence of this class of
compounds in three apparently unrelated organisms (PTN3_13A, PTN3_20B and
PTN4_10B), may indicate spongal origin of the compounds, or that the producing
bacterial symbiont is not specific to sponges of a particular class.
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Figure 2.16 1H NMR spectrum (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_20B.
Figure 2.17 HMBC experiment (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_20B.
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2.4.4 PTN3_21D
Figure 2.18 Surface photo of the sponge PTN3_21D and diod spicules recovered from
the the organism.
Extraction of the blood red sponge specimen PTN3_21D (ca. 50 g) led to the
isolation of the polyketide halenaquinone (31).86 The compound dominated the 1H
and HMBC NMR spectra of the 100% and 75% Me2CO in H2O fractions from the
initial HP20 screening column (Figures 2.19 and 2.20).
Identification of 31 was difficult; low level protonation about the fused penta cycle
hindered structural elucidation. Connections between the tri-substituted furan and
the adjoining α,β-unsaturated ketone were particularly difficult to establish. Further
inspection of the 1D and 2D NMR spectra indicated the presence of the known
dihydroxy reduction derivative 32,87 and other related compounds. Analysis of the
sponge was problematic however; only MeCN appeared to dissolve the metabolites
adequately, but also caused degradation of the metabolites. In light of solubility
and stability issues and the presence of known metabolites within the organism,
investigation of this specimen was discontinued. Diod spicules were recovered from
the organism following HNO3 tissue digest (Figure 2.18).
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Figure 2.19 1H NMR spectrum (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_21D.
Figure 2.20 HMBC experiment (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_21D.
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2.4.5 PTN3_21E and PTN3_50B
Figure 2.21 Surface photo of the Vava’u collection of the dictyoceratid sponge
PTN3_50B.
A small quantity of an unidentified dictyoceratid sponge (see Figure 2.21) was
collected from ‘Eua island (PTN3_21E; 90 g, November 2008), and dubbed
“luakuli” owing to its unappetising appearance. Two closely related metabolites
dominated the 75% and 100% Me2CO in H2O fractions; correlations characteristic
of a gem-dimethyl pair were immediately apparent in the HMBC spectum, while a
3-substituted furan ring was evident in the 1H and HMBC spectra (Figures 2.22 and
2.23).
Figure 2.22 1H NMR spectrum (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_21E.
Luakuli, Tongan term for the product(s) of canine stomach upheaval.
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Figure 2.23 HMBC experiment (CD3OD) of the 75% Me2CO in H2O HP20 fraction of
PTN3_21E.
Subsequent study generated large quantities of a new labdane diterpene and its
methyl acetal derivative. Targeted recollection of the “luakuli” sponge was achieved
in the Vava’u group, and two minor metabolites were identified. An account of their
isolation can be found in Chapter 3.
2.5 Concluding remarks
Investigation of nine Tongan sponges culminated in the isolation of a variety of
terpene, alkaloid and polyketide metabolites. As postulated, the metabolite profiles
of sponges, such as the dictyoceratid specimens PTN3_21E and PTN3_50B, were
seen to vary subtly depending on the geographical origin of the specimen.
Organisms collected from the most ancient of the Tongan islands,88 ‘Eua, appear
to be chemically distinct from those collected in the Tongatapu and Vava’u island
groups, yielding a greater proportion of new structures. Although the Vava’u island
group boasts a wealth of marine life, organisms collected within the Vava’u group
have displayed chemistry more similar to that observed in organisms from the
neighbouring Fijian islands. This indicates that further investigation of organisms
from ‘Eua island in particular should be undertaken.
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Chapter 3
Luakuliides A–C
Analysis of an unidentified dictyoceratid sponge yielded three new labdane diterpenes;
luakuliides A–C, which exhibit interesting immunomodulatory activity. Investigation
of the specimen was undertaken following identification of the gem-dimethyl motif,
characteristic of the cyclised labdane skeleton, in the HMBC screening spectrum.
3.1 The order Dictyoceratida
Dictyoceratida is an order in the class Demospongiae (sub-class Ceractinomorpha),
and further divided into four families: Dysideidae, Irciniidae, Spongiidae and
Thorectidae (Figure 3.1). Dicytoceratid sponges are characteristically devoid of
an easily classified skeletal component, such as spicules, making their taxonomic
identification particularly difficult. In place of spicules, they possess complex and
ordered network of spongin fibres. This produces a tough, flexible tissue with a soft
texture, while the textured surface is typically reticulated or conulose (marked with
cone-shaped elevations). Modulation of surface pigmentation is frequently observed
in demosponges – changes in light exposure can affect differences within the same
organism. Hence, organisms growing in light exhibit a dark exterior with interiors
ranging from white through to yellow and pale brown.38
Order Dictyoceratida
Family Dysideidae
Family Irciniidae
Family Spongiidae
Family Thorectidae
Subfamily Phyllospongiinae
Subfamily Thorectinae
Figure 3.1 Taxonomic classification of Dictyoceratida, after Hooper and van Soest.38
Owing to frequent phylogenic restructuring and the ensuing taxonomic inconsisten-
cies within the literature, a detailed account of dictyoceratid sponge metabolites is
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difficult to present and would be outside of the scope of this study.
3.2 Labdane diterpenoids from the dictyoceratid
sponge “luakuli”
The sponge PTN3_21E was initially collected from a dimly illuminated marine cave
on the island of ’Eua, at a depth of ca. 15 m in November 2008. Tentatively assigned
as belonging to the order Dictyoceratida, the sponge is porous and firm, with a
reticulated surface and oscules of two size classes (see Figure 2.21). The organism
contains no silicaceous spicules and there is little difference in the pigmentation of its
pinky-beige exterior and interior. Its nondescript appearance and sparce distribution
made recollection in the Vava’u group difficult (November 2009), and only one small
specimen (PTN3_50B) was recovered from the vertical interior of a cave.
3.2.1 Isolation and identification of luakuliides A–C
The methanol extracts of a ca. 20 g screening sub-sample were chromatographically
separated over HP20 resin (see Appendix A). Both the 100% and 75% and Me2CO
fractions displayed interesting NMR spectral signals, which appeared to belong
to two closely related metabolites. The 1H NMR spectrum contained the broad,
deshielded signals of three heterocyclic olefinic methines, a hemi-acetal methine,
deshielded diastereotopic methylene protons and shielded methyl singlets. Similarly,
the 1H and HMBC spectra of these fractions contained patterns characteristic of a
gem-dimethyl pair and a 3-substituted furan system (Figure 3.2).
Portions of both HP20 fractions were partitioned further over HP20SS. The labdane
diterpene luakuliide A (33) eluted in 60% and 70% Me2CO in H2O fractions, while
further normal-phase purification of the 90% and 100% Me2CO in H2O fractions over
DIOL yielded the presumed methanol artifact 34, in the 100% CH2Cl2 fraction.
Flash chromatography on DIOL of the 80% Me2CO in H2O HP20SS fraction
generated further quantities of 33, while the methoxy congener 34 eluted in the
10% CH2Cl2 in hexanes fraction.
The Vava’u specimen was extracted and partitioned over HP20 and HP20SS in
a similar manner to the ‘Eua specimen. Quantities of 33 and 34 were isolated
following DIOL flash chromatography of the 100% Me2CO in H2O HP20SS fraction,
and further purification of the 33% EtOAc in CH2Cl2 DIOL fraction by reversed-
phase HPLC (C18, 70% MeCN in H2O) yielded luakuliides B and C (35 and 36).
An overview of the isolation of the individual luakuliides is depicted in Figure 3.3.
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Figure 3.2 Proton to carbon correlations evidencing substructures in the HMBC spectrum
of the 75% Me2CO in H2O HP20 screen fraction of PTN3_21E. A: the gem-dimethyl pair
and B: the 3-substituted furan ring.
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Luakuliide A (33)
Luakuliide A (33), [α 25.4D 10.8 (c 18.5, CHCl3) was isolated as a colourless oil (92.7
mg in total). Positive-mode HRESIMS analysis of 33 revealed a [M + Na]+ pseudo-
molecular ion peak at m/z 341.2093, indicative of the molecular formula C20H30O3,
requiring six degrees of unsaturation. The 13C NMR spectrum contained 20 distinct
resonances, including four sp2 centres, while the fully-coupled HSQC spectrum
accounted for 29 of the 30 protons, indicating the presence of an exchangeable
proton.
Analysis of the 1H and HSQC NMR spectra (CDCl3) suggested the presence of a
3-substituted furan system [(δC 111.0, δH 6.26), (δC 138.9, δH 7.21) and (δC 142.9,
δH 7.34)], a hemi-acetal methine (δC 98.0, δH 5.33), two deshielded diastereotopic
methylene pairs [(δC 25.8, δH a 2.52, b 2.29) and (δC 26.0, δH a 1.88, b 1.72)], a
deshielded methyl singlet (δC 23.0, δH 1.31), two methines [(δC 51.7, δH 1.18) and
(δC 57.4, δH 1.15)], a gem-dimethyl pair [(δC 21.7, δH 0.89) and (δC 33.0, δH 0.88)]
and a region of diastereotopic methylene protons integrating for 10 resonances.
Four spin systems were identified in the COSY spectrum: the sp2 hybridised furan
system, two isolated segments of contiguous deshielded diastereotopic methylenes
and a methine, and a further isolated segment of three contiguous diastereotopic
methylenes. Immediately apparent from the HMBC were the characteristic patterns
of a gem-dimethyl pair and the 3-substituted furan system.
Olefinic methines CH-16 (δC 138.9, δH 7.21) and CH-14 (δC 111.0, δH 6.26)
share reciprocal allylic COSY couplings and strong three-bond HMBC correlations.
Vicinal COSY and HMBC correlations were observed between CH-14 and CH-15
(δC 142.9, δH 7.34) and further HMBC correlations were observed from the three
methines to the non-protonated olefinic carbon centre C-13 (δC 125.1), as depicted in
Figure 3.4. Methines CH-16 and CH-15 both display large 1JCH couplings of 203 Hz
and 201 Hz respectively, consistent with oxygen-substituted sp2 centres, whereas
CH-14 displays a smaller coupling consistent with carbon substitution. The 13C
chemical shifts of the four centres were consistent with oxygen substitution of CH-
15 and CH-16. Placement of the oxygen between CH-15 and CH-16 completed the
3-substituted furan system, accounting for three degrees of molecular unsaturation.
As depicted in Figure 3.5, connection between CH2-12 (δC 25.8, δH a 2.52, b 2.29)
and CH2-11 (δC 26.0, δH a 1.88, b 1.72) was evidenced by strong correlations in
the COSY spectrum, corroborated by reciprocal HMBC correlations. Protons of
CH2-11 shared further COSY correlations with methine CH-9 (δC 57.4, δH 1.15),
and reciprocal HMBC correlations were observed between the centres.
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Figure 3.4 COSY and selected HMBC (H C) correlations observed within the furan
system of 33.
The third COSY spin system extends from methine CH-5 (δC 51.7, δH 1.18) to CH2-
7 (δC 39.8, δH a 1.62, b 1.42). Strong COSY coupling was observed between CH-5
and methylene CH2-6 (δC 21.0, δH a 1.69, b 1.48), with the large coupling (17.4
Hz) between H-5 and H2-6a indicating an anti-periplanar relationship. Protons of
CH2-6 further correlated with those of CH2-7, with the connectivities corroborated
by HMBC correlations as shown in Figure 3.5.
Identification of the final spin system by the COSY experiment began with the
diastereotopic methylene CH2-1 (δC 29.6, δH a 2.21, b 1.03), the protons of which
shared reciprocal COSY correlations with CH2-2 (δC 19.9, δH a 1.47, b 1.38). CH2-2
displayed further COSY correlations to a third methylene CH2-3 (δC 41.9, δH a
1.39, b 1.16). Selective irradiation of the H-1a methylene proton with a 1D-
TOCSY experiment provided further evidence of the C-1 to C-3 segment. Over
spin-lock mixing times of 20–60 ms, geminal partner H-1b, both H2-2 protons and
the resonances of H2-3 were sequentially revealed, proving connection of CH2-1 to
CH2-3 in this order (Figure 3.5).
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Figure 3.5 COSY, selected HMBC and 1D TOCSY correlations establishing the
connectivities C-9 to C-12, C-5 to C-7 and C-1 to C-3 in 33.
A gem-dimethyl pair, CH3-18 (δC 21.7, δH 0.89) and CH3-19 (δC 33.0, δH 0.88)
was evidenced by reciprocal HMBC correlations between the methyls, and shared
correlations to a quaternary centre C-4 (δC 34.1), methine CH-5, and methylene
CH2-3. Further HMBC correlations from the protons of CH2-3 to C-4 and CH-5,
and from CH-5 to C-4, established the connection between the C-1 to C-3 methylene
series and the gem-dimethyl pair (Figure 3.6).
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Figure 3.6 HMBC correlations establishing the gem-dimethyl substructure in 33, and its
connection to the C-1 to C-3 methylene segment.
The protons of methyl singlet CH3-17 (δC 23.0, δH 1.31) shared weak COSY
correlations with H-9 and H2-7, and correlated strongly in the HMBC experiment
with the two protonated centres and C-8. These correlations completed the linear
sequence extending from CH2-1 to CH-9 as shown in Figure 3.7.
CH3
O
9
8
17
5
1
3
18 19
HMBC
COSY
Figure 3.7 COSY and selected HMBC correlations establishing the linear connections
from C-7 to C-9 and methyl substitution of C-8 in 33.
Observation of HMBC correlations from the protons of CH2-2 to the quaternary
centre C-10 established the bond between C-1 and C-10, extending the linear
sequence by one carbon atom. Similarly, an HMBC correlation from H-1b to C-9
established the C-10–CH-9 bond. Corroborating correlations were observed from H-9
to the oxygen-substituted C-8 (δC 84.0) and fully carbon-substituted C-10 (δC 51.9)
quaternary centres. These correlations completed the cyclodecane system C-1 to C-
10, accounting for a further degree of molecular unsaturation. Connection between
the furan system (C-13 to C-16) and the substituted cyclodecane segment C-1 to
C-12 was established by HMBC correlations from the protons of the diastereotopic
methylene CH2-12 to the sp2 centres C-13, CH-14 and CH-16. This completed the
carbon skeleton from C-1 to C-16 as shown in Figure 3.8.
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Figure 3.8 Selected HMBC correlations establishing the cyclodecane system of 33, and
attachment of the furan moiety.
All but the carbon resonance, CH-20 (δC 98.0, δH 5.33, 1JCH 170 Hz), was accounted
for the by furan-subsituted cyclodecane system, C-1 to C-19. The deshielded
chemical shift and large 1JCH value of CH-20 are consistent with a hemi-acetal
functionality. The exchangeable hydroxyl was evidenced by the IR and 1H NMR
spectra (νmax 3394 cm 1, δH 4.08), and a COSY correlation observed with H-20. The
hemi-acetal methine H-20 displayed HMBC correlations to C-10, and the methines
CH-5 and CH-9, and a further HMBC correlation was observed from H-5 to C-
10. These correlations established the bond between CH-5 and C-10, forming the
two fused six-membered rings of the [4.4.0]-bicyclodecane system in luakuliide A
(33), accounting for another double-bond equivalent in the fused bicyclic system.
A weak HMBC correlation was observed from H-20 to the oxygen substituted C-8
(δC 84.0) establishing a hemi-acetal bridge. Somewhat surprisingly, reciprocal five-
bond correlations were observed in the COSY experiment between H-20 and H3-17,
providing further evidence of their connection. The hemi-acetal bridge between C-
10 and the oxygen-substituted C-8 completed the structure of 33 and accounted for
the final degree of unsaturation in the tricyclic diterpene (Figure 3.9).
Requisite of the fused tricyclic system is the 1,3-diaxial positioning of the hemi-
acetal, CH-20, and oxygen substituent of C-8, placing CH3-17 in an equatorial
position on ring B. A weak COSY coupling between H-5 and CH3-19 established
their 1,2-diaxial relationship on ring A, and the large coupling (12.8 Hz) between
H-5 and H-6a indicated their 1,2-diaxial relationship on ring B (Figure 3.10).
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Figure 3.9 COSY and HMBC correlations establishing the hemi-acetal bridge between
C-10 and C-8 in 33. Dashed lines and arrows indicate a weak correlations.
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Figure 3.10 The trans-fused [4.4.0]-bicyclodecane system of 33 as evidenced by 1H–1H
coupling between H-5 and H-6a (3JHH = 12.8 Hz) and COSY correlations between H-5
and H3-19.
Following selective irradiation of the hemi-acetal methine H-20 in a 1D NOE
experiment, positive enhancements of H3-19 and axial H-6a were observed, placing
these protons on the same face of the [4.4.0]-bicyclodecane system. Irradiation of H-
11a with a 1D TOCSY experiment revealed H-9 (δH 1.15) after a 20 ms mixing
time. The excited H-9 resonance provided a resolved target for a selective 1D
NOE experiment. The experiment produced positive enhancement of the equatorial
methyl H3-17, and the protons H-5 (δH 1.18), H-1b (δH 1.03) and H-7b (δH 1.42),
placing them on the same face of the bicycle (Figure 3.11). These correlations
firmly established the trans-fusion of the [4.4.0]-bicyclodecane system, and equatorial
attachment of the furan-bearing segment to ring B.
45
HH3C
O H
HO
Hb
H
O
CH3
Hb
Ha Hb
17 11 9
1
5
7 19
18
Ha
6
1D TOCSY
1D NOE
Figure 3.11 1D TOCSY-NOESY and 1D NOE correlations used to determination the
relative stereochemistry about the trans-[4.4.0]-bicyclodecane system in 33.
Isolation of the methyl-acetal analogue 34 and facile conversion of 33 into 34
confirmed the hemi-acetal functionality of luakuliide A (33). Positive ion-mode
HRESIMS of the derivative 34 generated a pseudo-molecular ion corresponding to
the molecular formula C21H32O3 (m/z 355.2249 [M+Na] , ∆ 2.3 ppm), and the two
displayed similar optical rotations; 33, [α 25.4D 10.8 (c 18.5, CHCl3) and 34, [α 25.4D
-75.0 (c 0.14, CHCl3). With the exception of the strong methoxy singlet signal
(δC 55.4, δH 3.34) and the up-field shift of the acetal position (from δC 98.0, δH 5.33
to δC 104.9, δH 4.83), the two compounds proved to be very spectroscopically similar
as shown in Table 3.1.
Table 3.1 NMR Spectral Data for the Acetal Moieties of 33 and 34, (600 MHz, CDCl3)
O
O
RO
H
1
5
10
11
13
15
16
20 17
18     19
33 R = H
34 R = Me
33 34 Difference*
Position mult δC (ppm) δH (ppm) δC (ppm) δH (ppm) ∆δC (ppm) ∆δH (ppm)
8 C 84.0 83.7 -0.3
9 CH 57.4 1.15 57.5 1.15 0.1 0.0
10 C 51.9 52.0 0.1
20 CH 98.0 5.44 104.9 4.83 5.9 -0.50
OCH3 CH3 55.4 3.34
*∆δ = δ34 δ33
Absolute configuration is arbitrary.
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Luakuliide B (35)
Analysis of luakuliide B (35) by positive ion-mode HRESIMS revealed a [M + Na]+
pseudo-molecular ion peak at m/z 373.1996, corresponding to the molecular formula
C20H30O5. The 13C NMR spectrum displayed all 20 expected resonances, and
analysis of the fully-coupled HSQC spectrum in conjunction with the 1H NMR
spectrum accounted for all but two hydrogens, indicating the presence of an
additional exchangeable proton relative to compound 33.
Inspection of the 1H, 13C NMR spectra and HSQC experiment of luakuliide B (35)
revealed much structural similarity with that of 33, particularly in the aliphatic
region. As such, the structure was elucidated in the same fashion as luakuliide A
(33). The characteristic furan signals were, however, replaced by an ester carbonyl
(C-16: δC 171.5), an olefinic methine (δC 143.0, δH 6.87), a non-protonated olefinic
centre (δC 131.0) and a hemi-acetal methine (δC 96.7, δH 6.10, 1JCH 176 Hz).
As illustrated in Figure 3.12, the methylene centres CH2-11 and CH2-12 appear
at a slightly higher chemical shift, relative to those in 33 [(CH2-11: δC 23.6,
δH a 1.91, b 1.73) and (CH2-12: δC 26.0, δH a 2.41, b 2.21)], and share reciprocal
COSY and HMBC correlations with each other and the methine CH-9 (δC 58.0,
δH 1.22). Connection from CH-5 to CH2-7 [(CH-5: δC 51.8, δH 1.22), (CH2-6 δC 21.0,
δH a 1.50, b 1.72) and (CH2-7 δC 41.9, δH a 1.68, b 1.42)] was evidenced by COSY
correlations between the centres, and corroborating HMBC correlations. Further
COSY and HMBC correlations established the C-1 to C-3 spin system [(CH2-1:
δC 29.6, δH a 2.21, b 1.08), (CH2-2: δC 19.9, δH a 1.51, b 1.39) and (CH2-3: δC 39.8,
δH a 1.43, b 1.19)], which was confirmed by a 1D TOCSY experiment as seen in 33.
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12H
H
H
H
H 75
H
H H
HH
H
1 3
HHHH
H
HMBC
COSY
1D TOCSY
Figure 3.12 COSY, HMBC and 1D TOCSY correlations establishing the connections
from C-9 to C-12, C-5 to C-7 and from C-1 to C-3 in 35.
The gem-dimethyl pair [(CH3-18: δC 21.8, δH 0.90) and (CH3-19: δC 33.0, δH 0.90)]
was again evidenced by the display of reciprocal HMBC correlations between the
methyls and shared correlations to CH-5 (δC 51.8, δH 1.22), C-4 (δC 34.2) and
CH2-3. As with 33, HMBC correlations were observed from H2-3 and H-5 to the
quaternary carbon C-4, and from H2-3 to CH-5, establishing the linear connections
from C-1 to C-5 (Figure 3.13).
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Figure 3.13 HMBC correlations establishing the gem-dimethyl substructure in 35 and
the connections from C-1 to C-5.
As observed in compound 33, the methyl singlet of 35, CH3-17 (δC 23.3, δH 1.31)
shared weak COSY correlations with H-9 and CH2-7 (δC 41.9, δH a 1.68, b 1.42),
and displayed HMBC correlations to the oxygen-substituted C-8 (δC 84.0), CH-9
and CH2-7. Protons of the methylenes CH2-2 and CH2-1 correlated to C-10 and
C-9, respectively, completing the linear connectivity from C-1 to C-10, corroborated
by HMBC correlations from H-9 to quaternary centres C-8 and C-10 (Figure 3.14).
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18 19
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17
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Figure 3.14 COSY and selected HMBC correlations completing the cyclodecane system
of 35.
The hemi-acetal methine CH-20 (δC 98.0, δH 5.35), displayed strong HMBC
correlations to C-10 and weaker correlations to C-5 and C-9. These correlations
reestablished the [4.4.0]-bicyclodecane system. Again, a weak HMBC correlation
was observed from H-20 to C-8, establishing the hemi-acetal link in 35, as shown in
Figure 3.15.
As required by constraints of the fused tricyclic system, CH-20 and the oxygen-
substituent of C-8 occupy 1,3-diaxial positions on ring A, with CH3-17 equatorial
at C-8. As in 33, the large 3JHH coupling between H-5 and H-6a (13.6 Hz) was
indicative of their 1,2-diaxial relationship on ring B. Similarly, the observation of
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a weak COSY correlation between H-5 and H3-19 placed these resonances as 1,2-
diaxial with respect to ring A, confirming trans-fusion of the [4.4.0]-bicyclodecane
system. The 1D TOCSY-NOESY experiment utilised in 33 to establishing
configuration at CH-9 could not be employed here owing to small sample size.
However, similarities in chemical shift and 3JHH couplings of CH-9 between 35
and 33 suggests retention of relative stereochemistry about C-9, placing the CH2-
11 to C-16 substructure in an equatorial position.
3 5
18 19
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Figure 3.15 COSY and selected HMBC correlations used in completion of the [4.4.0]-
bicyclodecane system and assignment of the bridging hemi-acetal moiety in 35. Dashed
lines and arrows indicate weak correlations.
Remaining unaccounted for by the tricyclic system were three sp2 carbon resonances
[(C-13: δC 131.0), (CH-14: δC 143.0, δH 6.87 1JCH 177 Hz) and (C-16: δC 171.5)],
and an oxygen-substituted methine (CH-15: δC 96.7, δH 6.10, 1JCH 176 Hz). On
the basis of chemical shift and 1JCH couplings the resonances were assigned as a
tri-substituted alkene, an ester carbonyl and a second hemi-acetal methine. The
vicinal positioning of CH-14 and CH-15 was evidenced by reciprocal COSY and
HMBC correlations. The C-12 to C-13 bond was established by HMBC correlations
H-14 to quaternary C-13 and CH2-12. Further HMBC correlations were observed
from the CH2-12 methylene protons to quaternary C-13, CH-14 and carbonyl C-16
confirming bonds from C-13 to C-14 and C-16. This established the α, β-unsaturated
ester function, C-16–C-13–CH-14 (Figure 3.16).
The substituted [4.4.0]-bicyclodecane tricyclic system (C-1 to C-20) and the C-
14 to C-16 enoate accounted for all but one degree of unsaturation associated with
the molecular formula. The combination of chemical shift and high 1JCH for CH-15
(δC 96.7, δH 6.10, 1JCH 176 Hz) is consistent with dioxy-substitution of the centre.
As such, an α-substituted γ-hydroxybutenolide moiety linking the hemi-acetal CH-
15 and carbonyl C-16 is proposed (Figure 3.17). This final substructure satisfies the
oxygen count and unsaturation requirements of the molecular formula.
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Figure 3.16 COSY and HMBC correlations evidencing the substituted α,β-unsaturated
ester (C16–C-13–C-14) and γ-hemi-acetal methine (C-15) in 35.
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Figure 3.17 The α-substituted γ-hydroxybutenolide moiety of 35.
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Luakuliide C (36)
The observation of a [M + Na]+ pseudomolecular ion peak (m/z 373.1990) by
positive ion-mode HRESIMS analysis of luakuliide C (36), indicated that 36 has
a molecular formula of C20H30O5, like that of 35. The differences in HPLC
retention times between 35 and 36 implied an isomeric relationship between the
metabolites. Inspection of the 1D and 2D NMR spectra of 36 indicated that the
[4.4.0]-bicyclodecane system (C-1 to C-12) observed in 33–35 is conserved. However,
subtle changes in chemical shift of the 1H and 13C resonances associated with the
γ-hydroxybutenolide moiety suggested some change in functionality.
Consistent with the isomeric relationship between 35 and 36, the resonances
C-13 to C-16 were assigned once more as an ester carbonyl (δC 171.0), a tri-
substituted alkene (δC 168.9; δC 117.9, δH 5.90, 1JCH 181 Hz), and a hemi-acetal
methine (δC 98.6, δH 5.99, 1JCH 177 Hz). Interpretation of COSY and HMBC
correlations between the resonances, centres were assigned as a β-substituted-γ-
hydroxybutenolide (Figure 3.18). The change in polarisation of the C-13 to CH-14
double bond in 36, δC 168.9 and 117.9, compared to that of 35, δC 131.0 and 143.0,
is consistent with the change in alkyl substitution relative to the carbonyl centre.
O
HO
H
15
13
16
O
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HO
Figure 3.18 The β-substituted-γ-hydroxybutenolide moiety of 36.
The same trends in chemical shift are also observed in the γ-hydroxybutenolide
moieties of iso-secothorectolide (23), luffarin Q (24) and luffarielolide (26) isolated
during this study (Tables C.1, C.2 and C.4). Similar trends in bond polarisation
are also observed in the γ-hydroxybutenolides teuponin (37)89 and acuminolide
(38)90, which were isolated from the terrestrial organisms Teucrium japonicum
and Neouvaria acuminatissima, respectively.89,90 Single crystal X-ray analysis of
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teuponin (37) and acuminolide (38) confirmed the substitution patterns of the two
γ-hydroxybutenolide groups. Differences in hybridisation of the carbonyl and hemi-
acetal centres, and lengths of the C-O and C=O bonds are clearly illustrated in
the crystal structures. Comparisons of the 1H and 13C NMR spectra of 35 and 37,
and 36 and 38, are shown below in Table 3.5, providing support for the structural
assignment of 35 and 36.
O
O
O
H
OH
O OHO
H
37
O
H
O OHO
OH
38
Table 3.5 NMR Spectral Data for the γ-Hydroxybutenolide Moieties in 35–38.
35*and 36* 37†and 38‡ Difference§
Position mult δC δH δC δH ∆δC ∆δH
O
O
OH
1
3
4
35 and 37
O
HO
O
1
3
4
36 and 38
1 C 138.7 135.8 -2.9
2 CH 142.8 6.87, brs 147.7 7.67, brs 5.1 0.8
3 CH 96.6 6.10, brs 100.5 6.61, brs 3.9 0.51
4 C 171.3 169.4 -1.9
1 C 168.9 169.0 0.1
2 CH 117.9 5.90 117.2 6.02 -0.7 0.12
3 CH 171.0 170.9 -0.1
4 C 98.6 5.99 98.4 6.26 -0.2 0.27
*CDCl3, 600 MHz
†d5-pyridine, 400 MHz
‡CDCl3, 300 MHz
§∆δ = δ37 38 δ35 36
The high 1JCH values of the methines CH-15 and CH-16 in the γ-hydroxybutenolide
moieties of 35 and 36 are noteworthy at 177 Hz and 181 Hz, respectively. An
equivalent carbon-substituted sp2-hybridised centre could be expected to have a
1JCH value of ca. 160 Hz, and the coupling constants appear to have increased
in magnitude due to the inductive electron-withdrawing qualities of the nearby
oxygen atoms and strain imposed by the five-membered ring. Easily extracted
from 13C-coupled HSQC spectra, 1JCH values are frequently invoked in functional
group determination, there is value in comprehensively compiling J-coupling values
associated with these commonly isolated heterocycles, in addition to those found
in more unusual synthetic substrates. Such a resource would be invaluable to
spectroscopic structural elucidation.
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3.2.2 Biological activity of the luakuliides
Labdane diterpenes have been associated with antimicrobial, antiinflammatory,
immuno- and enzyme-modulatory biological activities.91 As such, 33 and 34 were
assessed for cytoxicity, antifungal and immunomodulatory activity.92 In a standard
48 h proliferation MTT assay 33 and 34 displayed weak inhibition HL-60 cell line
with IC50 values of 21.7 and 43.5 µmol L 1, respectively, and negligible inhibition of
a drug-sensitive S. cerevisiae strain.93 Their immunomodulatory activities were far
more significant. Luakuliide A (33) and the methyl acetal 34 inhibited production
of nitric oxide (NO) in stimulated splenocytes, while 34 also affected an increase
in interferon-γ (INF-γ).94 Increased production of the proinflammatory cytokine,
tumor necrosis factor-α (TNF-α) in stimulated macrophages was also observed and
lesser response was affected in non-stimulated cells.92
Inflammation is fundamental to many pathological conditions, from triggering and
perpetuating autoimmune diseases through to immune responses to foreign bodies.95
The macrophage white blood cells line are key to both the initiation and direction
of inflammatory processes via TNF-α and NO.96 TNF-α acts in transduction of
signals pertaining to cell activation, proliferation and apoptosis, enhancing the
overall inflammatory response.97 Nitrous oxide has roles in the innate and adaptive
immune systems including macrophage phagocytosis, neutrophil migration, and
natural killer T-cell activity.98 Hence, small molecules which affect the regulation of
T-cell activation and influence NO and TNF-α are of interest with respect to the
treatment of autoimmune and inflammatory disorders.92,99
3.2.3 Labdane diterpenes
As products of the ubiquitous isoprenoid pathway, cyclised diterpene metabolites
have been extensively isolated from terrestrial sources, especially the Angiosperm
families Asteraceae and Labiatae.100 The skeleton name is derived from “labdanum”,
a resin extracted from the rockroses Cistus (family Cistaceae), from which the first
members of the class were initially obtained.101
The labdane skeleton is infrequently encountered within the marine environment,
examples including cacofurans A (39) and B (40), isolated from an Okinawan sponge
specimen of Cacospongia sp. (order Dictyoceratida, family Thorectidae).102 As seen
in the luakuliide skeleton, oxidation of C-8 and subsequent nucleophilic attack on
the CH3-20 methyl (aldehyde) generates the C-8 to C-20 ether or hemi-acetal bridge.
The source of differentiation between the luakuliides and cacofurans is oxidation at
C-11 compared to further oxidation at C-20.102 Investigation of another Cacospongia
specimen from the Philipines yielded several furano and meroquinone diterpenes
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metabolites, including 41, where the C-8 methyl substituent is replaced by an
exocyclic methylidene. Sesterterpene luffariellolide (26, isolated from PTN4_10B)
was encountered during the same investigation, illustrating the promiscuity of the
compound.103
H
O
RO
O
39 R = H
40 R = Ac
H
O
41
Furan moeities, such as that of luakuliide A (33), frequently undergo further
oxidation forming the entities such as butenolide or 2-furanone functions, and the
γ-hydroxybutenolide moieties featured in 35 and 36. Many metabolites featuring
both these functions have been reported, although this oxidation could conceivably
occur naturally within the organism or during isolation.104
Intertidal limpets of the Trimusculus genus, are also rich sources of such cyclic
diterpenes. Collections from central Chile of T. peruvianus yielded four new
diterpenes metabolites with the characteristic labdane bicycle and an acyclic
terminal isoprene unit.105 Further investigation of the same species led to the
isolation of several new additions to this class including 42–47, which differ in
oxidative substitution of the labdane bicycle.106,107 South African collections of T.
costatus yielded similar labdanes,108 in addition to 5α,8α-epidioxy sterols similar to
27 and 28 isolated from the plakinid sponge PTN3_19D.109
3.2.4 Biogenesis of luakuliides A–C
Isoprene biosynthesis and formation of the different terpene classes is well docu-
mented. Formation of many carbon skeletons, including that of the labdanes, has
also been well explored and confirmed via both the mevalonate and non-mevalonate
pathways.110
Cyclisation of geranylgeranyl pyrophosphate (GGPP) by either of two ways forms
the four diastereomers of the labdane skeleton, differing in configuration at C-
5 and C-9.104 The labdane skeletion is a precursor to many other diterpenes
skeletons; diastereomers of the labdadienyl cation can undergo a series of 1,2-hydride
and methyl shifts. Concerted migrations generate a trans-decalin product, and
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cis- relationship between C-8 and C-10 methyls. However, the series of stepwise
migrations pauses at the C-5 cation intermediate, giving rise to either cis- or trans-
fused clerodane products depending on which of the two C-4 methyl substituents
migrates. This process is depicted in Scheme 3.1 for one labdadienyl diastereomer.
Alternatively, capture of the C-5 cation of the halimane skeleton by an exogenous
nucleophile generates species including ambliol B (25),111 isolated in this study from
PTN4_10B. This theory of dual mechanisms is supported by the high proportion of
trans- over cis-decalin products, and the isolation of partially rearranged labdanes
such as the halimane 25.
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Historical confusion within the literature has arisen over the absolute stereo-
chemistry of the labdane, halimane and clerodane skeletons and the governing
nomenclature. Stereochemical classification is now made in reference to the original
isolate clerodin (48); those with the same absolute configuration are neo- while the
enantiomeric forms are ent-neo-labdanes and -clerodanes. As indicated in Scheme
3.1, further division is made in reference to the cis- or trans-decalin ring junction.
Relative orientation of C-8 and C-9 methyls is the final source of differentiation
within the skeletons.
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trans-Clerodane                    cis-Clerodane
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Scheme 3.1 Formation of the labdane, halimane and clerodane skeletons via cyclisation
of geranylgeranyl pyrophosphate.
In the case of luakuliides A–C, the electrophilic C-8 of the labdadienyl cation
most probably undergoes enzyme-mediated hydration, forming an internal hydroxyl
nucleophile. As shown in Scheme 3.2, oxidation of the C-20 methyl centre to a
aldehyde function, and subsequent nucleophilic attack of the carbonyl by the C-8
hydroxyl generates the bridging hemi-acetal of 33–36 in its entirety. Surprisingly,
few C-8 hydration products have been reported,104 exceptions being the Cacospongia
isolates cacofurans A and B (39 and 40), the luakuliides and 49, a recent isolate
from the essential oil of Acalypha plicata leaves.112 The furan function is thought to
be installed via oxidative cyclisation, ejecting the OPP moiety. Further oxidation
of the diene, potentially via addition of molecular oxygen across the diene generates
the γ-hydroxybutenolide functions of 35 and 36. Lastly, although the relative
configuration of the luakuliides has been determined, it is not yet known whether
the molecules can be categorised as either neo- or ent-neo-labdanes.
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Scheme 3.2 Proposed pathway for generation of the hemi-acetal functions, furan and
γ-hydroxybutenolide moieties of luakuliides A–C (33–36).
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3.2.5 Concluding remarks
Labdane metabolites are infrequently encountered in marine organisms. In this case
their characteristic gem-dimethyl feature was identified early during analysis of the
HMBC spectra from crude fractions, prompting further purification and eventual
isolation of the luakuliides. Differentiating these structures from other labdanes is
the hemi-acetal bridge from C-20 to C-8, which also provides evidence for capture
of the C-8 labdadienyl cation. The 1D TOCSY-NOESY NMR experiment was
integral to assigning the trans-fusion of the [4.4.0]-bicyclodecane system and relative
stereochemistry of the luakuliides.
Luakuliide A (33) and it methyl acetal derivative (34) display interesting biological
activity. The metabolites have significant macrophage stimulatory activity, promot-
ing a proinflammatory response, which is complemented by increased activity in T-
cells. Although in contrast to antiinflammatory properties frequently demonstrated
by labdane diterpenes, these findings illustrate the potential of the luakuliides as
new immunomodulatory agents.
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Chapter 4
Chemical Analyses of Plakinid Sponges
Investigation of two plakinid sponge specimens yielded several new polyketide
metabolites: the α-pyrones lehualides E–K and four cyclic peroxides. Analysis of
the HMBC experiments of semi-purified fractions from each of the organisms was
integral to their selection for further study. During the selection process the α-pyrone
of the lehualides, and the oxygenated backbones of the cyclic peroxides were partially
elucidated, prompting further investigation of the organisms.
4.1 The family Plakinidae
Plakinidae, the sole family of the order Homosclerophorida113 encompasses several
valid genera: Plakina, Plakortis, Plakinastrella, Placinolopha, Corticium, Pseudo-
corticium, and Oscarella (Figure 4.1). Except for Oscarella, these genera possess a
siliceous skeleton, formed by either a uniform arrangement of calthropes, diod and
triod spicules, or a combination of the two. Found mainly in warm waters, the
encrusting sponges are generally dark purple and grey in appearance, with a lighter
tan and beige interior. With cork-like, dense and rubbery textures, their velveteen
surfaces are frequently covered with wide, shallow nodules.38,113
Order Homosclerophorida
Family Plakinidae
Genus Plakina
Genus Plakortis
Genus Plakinastrella
Genus Placinolopha
Genus Corticium
Genus Pseudocorticium
Genus Oscarella
Figure 4.1 Taxonomic classification of the order Homosclerophorida, after Hooper and
van Soest.38 Genera encountered during this study are shown in blue.
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4.1.1 The Plakortis and Plakinastrella genera
The phylum Porifera is notorious for its taxonomic uncertainty. In the case of the
closely related genera Plakortis and Plakinastrella, their simple spiculation makes
generic distinction and further speciation particularly difficult to establish. The
spicule profile of Plakortis specimens is mainly composed of irregular diods in a
single size-class and the occasional triod, while Plakinastrella sponges are thought
to exhibit up to three size-classes of diods, triod spicules and calthropes.
A range of biologically active compounds have been reported from species within
these two genera. A series of β-carbolines, the plakortamines (50–52), were isolated
in conjunction with epiplakinic acids.114 These simple brominated alkaloids are often
associated with ascidians (phylum Chordata), such as the antiviral eudistomins from
the Caribbean ascidian Eudistoma olivaceum.115 Although uncommon, this class
of metabolites is precedented within sponges, sharing structural features with the
polycyclic fascaplysin alkaloids, such as 14-bromohomofascaplysin (29).
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Chemical investigations by Costantino and co-workers of Caribbean collections
of Plakortis simplex have also yielded a series of iodoindole metabolites.116,117
Plakohypaphorine E (53) and others of the class represent the first naturally
occurring iodoindole metabolites. Subsequently, the same research group reported
the pyridinium derivatives simplakidine (54)118 and simplexidine119 from the same
organism. Simplakadine combines the pyridinium nucleus shared by simplexidine
with the polyketide framework observed in plakortether B (55), an archetypal isolate
of sponges from this family.
A rich complement of type I polyketide metabolites have been isolated from
Plakortis sponges. The type I polyketide synthesis pathway (PKS1) is also active in
macrolactone biosynthesis, although the Plakortis metabolites generally feature an
acid-substituted five- or six-membered heterocycle within a long, largely saturated
carbon skeleton. Such carbon backbones, in combination with a terminal carboxylic
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acid, contributed to their assumed origins in fatty acid synthesis.120 The mechanisms
of PKS1 and fatty acid synthesis both involve chain growth by C2, however, PKS1
utilises a great variety of starter units, and the different propagation units specify
acetate, propionate, butyrate and methyl-propionate groups.121 These generate a
carbon skeleton featuring methyl, ethyl, propyl and gem-dimethyl side-branches, as
observed in plakortether B (55, Figure 4.2). Products of PKS1 frequently exhibit
great variation in oxidation, and the various reduction units used in PKS1 are also
enantiospecific.
O
H OH
OMe
O
Figure 4.2 Depiction of the PKS1 propagation units used in the biosynthesis of
plakortether B (55). The metabolite comprises three acetate, one propionate and two
butyrate units.
Cyclic peroxides are a distinctive class of polyketide metabolite frequently isolated
from both the Plakortis and Plakinastrella genera. The first example, plakortin
(56), a potent antibiotic, was isolated from a Plakortis halichondrioides specimen in
1978.122 Rich augmentation of both the acid-substitued 1,2-dioxolane nucleus and
substituents of 56 has given rise to a contingent of structurally related compounds
categorised into several arbitrary classes. Plakortide F (57), retains the acid-
substituted peroxide nucleus of 56 although the compounds differ in absolute
configuration. Variation in substitution about the cyclic peroxide core at C-4 and
C-6 reflects a change in propagation units during biosynthesis, while the inclusion of
an additional acetate monomer during formation of 57 (C-7–C-8) accounts for the
difference in chain length.
O O OH
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Cyclisation of the acid forms the peroxy-lactone bicyclic system, characteristic of
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the plakortolide class. The first example was described in 1980, although not
fully characterised until 1991 by Davidson et al.123 The absence of the free acid
in the plakortolide skeleton frequently corresponds to decreased biological activity
compared to the carboxylic acid analogue. Although the ring fusion is exclusively
cis, varied configuration at C-6 forms two diastereomeric carbon skeletons. The
two are easily distinguishable by NOE correlations between the C-4 and C-6 methyl
substituents and changes in the 1H chemical shift of H-5a, ca. 0.1 ppm.
Ring-opening of the plakortolide cyclic peroxide generates the seco-plakortolide diols.
Loss of ring-strain lessens diastereotopic differentiation of the CH2-5 methylene
protons allowing spectroscopic distinction between the two forms. Upon isolation,
seco-plakortolides are known to undergo facile intramolecular condensation and
Michael-type addition of the C-6 hydroxyl to C-3 of a butenolide intermediate
forming hydrofuran derivatives, plakortones (Scheme 4.1).124 Co-isolation of all three
forms of the same carbon skeleton could cast doubt over the natural origins of seco-
plakortolide and plakortone structures.125 However, plakortone skeletons bearing
ethyl substituents at C-4 and C-6 have been isolated in the absence of plakortolide
analogues from Caribbean Plakortis halicondrioides and P. simplex specimens.126,127
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O O
H
- H2O
Plakortolide                              seco-Plakortolide
Plakortone
Scheme 4.1 Conversion of plakortolides to plakortones via seco-plakortolides by reduction,
intramolecular condensation and Michael-type addition, after Yong et al..124
This parade of polyketide metabolites displays further structural variation. Isolated
from a Dominican Plakortis halichondrioides specimen, glánvillic acids A and B
(A, 58),128 for which stereochemistry has not been defined, bear an aromatic furan
ring (C-3–C-6). A host of other Plakortis metabolites bear an alkyl group varying in
saturation, branching and chain length. Further additions to the contingent of cyclic
peroxides are the plakinic and epiplakinic acids, which were first encountered from
Palauan specimens of P. nigra. As demonstrated by 59 and 60, the two classes
possess lengthy methyl-branched alkyl backbones terminating in a phenyl ring,
derived from a benzoate starting unit.114 These structural characteristics are shared
with members of the plakortolide class.124 The two acid classes are differentiated by
66
the orientation of the C-3 and C-5 methyl substituents about the 1,2-dioxane ring,
cis- in the plakinic acids (59), and trans- in the epiplakinic acids (60). One example
of epiplakinic acid decarboxylation has been reported.129
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O O OH
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Spiculoic acids A and B (61 and 62) were isolated from a P. angulospiculatus
specimen,130 and possess an unprecedented carbon skeleton. The biosynthetic
origins of the polyketide-derived structures are not clear, but the skeleton is thought
to incorporate a phenyl acetate starter unit and four butyrate units. A post-assembly
enzyme-catalysed intramolecular [4+2] cycloaddition is proposed for formation of the
fused bicycle, which contains the expected cyclohexene ring.130 Recent investigation
of a P. zyggompha specimen by Berrue et al. uncovered three further spiculoic acids,
and two zyggomphic acids (63 and 64).131 Common to both classes is the fused
bicyclic nucleus, with structural variation arising from the inclusion of different
PKS1 monomers.
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While this series of polyketide metabolites are most probably of bacterial origin, they
appear to be exclusive to sponges of the Plakortis and Plakinastrella genera, indi-
cating a taxonomically-specific symbiosis. Another class of polyketide metabolites
unique to plakinid sponges is the lehualides. The class differs from more common
plakinid isolates, bearing α- or γ-pyrone moieties in place of the cyclic peroxides.
The first members of the class have a pseudo-terpenoid appearance owing to the
number of methyl-substituted alkene functions present in the extended alkyl chain.
Terminal substituents encountered in the lehualides include phenyl rings, and a
variety of sulfur functionalities of which the biosynthetic origins are unclear. The
first members of this series, lehualides A–D (65–68), were reported in 2005 from a
Hawai’ian Plakortis specimen,132 and the succinct synthesis of lehualide B (66) was
reported in 2010 by Jeso et al.133 Seven additions to this class, lehualides E–K (69–
75), were isolated during this study from a Tongan Plakortis sp. and are detailed
in the following sections.134
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4.2 α-Pyrone metabolites from Plakortis sp.
The sponge specimen PTN3_20A (Figure 2.12) was collected at a depth of 12–15
m from the ceiling of a large cave on ‘Eua Island in November 2008. Identified
as a species of Plakortis, similar to P. ceylonica (Dendy, 1905), the sponge
morphologically formed small oval pendant encrustations about 3 cm thick, with
a cork-like, rubbery and dense texture. Smooth to the touch, the surface was dark
chocolate-purplish brown in colour and covered in wide shallow nodules ca. 3 mm
high. Diod spicules (180–250 µm long, Figure 4.3) were isolated via centrifuge
following HNO3 treatment of the tissue, aiding classification of the organism as
a Plakortis species. Attempts were made to recollect the organism in the Vava‘u
group but were unsuccessful. The nondescript appearance and growth of the sponge
68
in dimly-lit caves may have both been contributing factors leading to specimens
going unnoticed.
Figure 4.3 Diod spicules recovered from the Plakortis sponge PTN3_20A.
4.2.1 Isolation and identification of lehualides E–K
Methanolic extracts of the Plakortis specimen PTN3_20A were partitioned over
reversed-phase HP20 resin, generating three fractions with differing polarity; 30%,
75% and 100% Me2CO in H2O. NMR analysis of the less polar 75% and 100%
Me2CO in H2O fractions showed the presence of one major component and several
closely related compounds. Immediately apparent in the 1H NMR spectra of the two
fractions were the resonances of an aromatic system, olefinic methines (δH 5.20 ppm),
methoxy groups (δH 3.80–4.20 ppm), deshielded methylenes and methyls (δH 2.60–
3.20 and 1.60–1.90 ppm), and a large aliphatic methylene envelope (δH 1.15–1.30
ppm).
Analysis of correlations within the HMBC spectra of the 75% and 100% Me2CO in
H2O fractions confirmed the value of investigating the organism further. Protons
of deshielded methylene doublets displayed correlations to two separate methyl-
substituted carbon double bonds (Figure 4.4). One of the double bonds appeared
to be oxy-substituted, and another deshielded methylene correlated to a mono-
substituted phenyl ring. Interpretation of these structural fragments indicated
that the structure in question could be closely related to the Plakortis isolates
lehualides A–D (65–68). The lehualides were originally isolated from a Plakortis
sponge collected from the vertical interior of large caves on Niihua Island, Hawai’i,
which appeared morpholigicaly similar to the specimen from ‘Eua.132 The moderate
toxicity associated with lehualides A–D, coupled with subtle variations in the NMR
69
spectra of the ‘Eua sample pointed towards a targeted and spectroscopically guided
chemical evaluation of the Plakortis sp.
CH3
O
H3C
a             c                e
b             d
f
HH
Figure 4.4 Proton to carbon correlations evidencing the methyl-substituted carbon double
bonds present in the HMBC spectrum of the 75% Me2CO in H2O screen fraction of
PTN3_20A.
Following the initial partitioning over HP20, the non-polar fractions derived from
PTN3_20A were subjected to further reversed-phase chromatography (HP20SS,
Me2CO in H2O). All fractions retained signals associated with the oxy-substituted
double bond and tri-substituted double bond, indicating the separation was
dependent upon a secondary structural feature. Relatively good separation was
apparent on silica gel thin layer chromotography (TLC) plates, however, the α- and
γ-pyrone groups present in 65–68 were suspected to be acid-sensitive. In light of
this, and given the small quantities of the specimen available for analysis, DIOL was
chosen as a normal-phase material for isolation. The closely related compounds were
found to elute from DIOL in CH2Cl2, and final purification of the DIOL fractions was
completed by C18 HPLC. The overall isolation strategy of lehualides E–K (69–75)
is summarised in Figure 4.5.
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Lehualide E (69)
The positive-ion mode HRESIMS data of 69 showed a [M+Na] pseudo-molecular
ion peak at m/z 385.2399, consistent with the molecular formula of C24H32O4,
requiring nine degrees of unsaturation. The 13C NMR spectrum contained 22 distinct
resonances, including 11 sp2 centres, indicating some form of molecular symmetry,
while interpretation of the 1H and the fully-coupled HSQC NMR spectra accounted
for all of the 32 protons.
Immediately apparent in the CDCl3 1H NMR spectrum were the resonances of a
mono alkyl-substituted benzene ring (δH 7.27–7.16) an olefinic methine (δH 5.18),
two methoxy singlets (δH 4.19, 3.81), a deshielded methylene doublet and triplet
each integrating for two protons (δH 3.17, 2.57), two olefinic methyl singlets (δH 1.85,
1.66) and an aliphatic methylene envelope integrating for 12 protons.
Three spin systems were identified from the COSY spectrum: a mono alkyl-
substituted phenyl ring, an isolated methyl-substituted alkene and an extended
aliphatic chain. As illustrated in Figure 4.6, COSY and HMBC correlations allowed
the facile assembly of the mono alkyl-substituted benzene ring C-16 to C-21 [(C-16:
δC 143.1), (CH-17 and CH-21: δC 128.3, δH 7.27, 2H), (CH-18 and CH-20: δC 128.5,
δC 7.17, 2H) and (CH-19: δC 125.7, δH 7.16, 1H)]. The ring accounted for four
of the 11 observed sp2 resonances, four of the degrees of unsaturation required by
the molecular formula and the element of molecular symmetry indicated by the 13C
spectrum. HMBC correlations were observed between the protons of a methylene
triplet CH2-15 (δC 36.1, δH 2.57) and C-16, while reciprocal correlations between the
methines CH-17/-21 and CH2-15 established the attachment point of the aromatic
ring.
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Figure 4.6 The mono alkyl-substituted benzene ring (C-16 to C-21) of 69 as evidenced
by COSY and HMBC correlations.
The protons of the upfield olefinic methyl singlet CH3-23 (δC 16.4, δH 1.66)
showed HMBC correlations to two sp2 carbons CH-8 (δC 118.2, δH 5.18), and C-9
(δC 138.7), and shared an allylic COSY correlation with H-8. A further HMBC
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correlation from H3-23 to a methylene carbon CH2-10 (δC 39.7, δH 1.96), and a
COSY correlation from H-8 to the protons of another methylene CH2-7 (δC 30.2,
δH 3.17) established an isolated, tri-substituted double bond. The E geometry of the
alkene was established from selective irradiation of H3-23 in a 1D NOE experiment
and subsequent enhancement of H2-7 and H-11. Methylenes H2-7 and H2-10 were
similarly enhanced after irradiation of H-8, confirming the E geometry of the tri-
substituted double bond (Figure 4.7).
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Figure 4.7 COSY, HMBC and 1D NOE correlations confirming the geometry and
connectivity of the C-7 to C-11 segment in 69.
The remaining five non-protonated sp2 carbons C-2 (δC 162.7), C-3 (δC 128.3), C-4
(δC 159.0), C-5 (δC 108.3) and C-6 (δC 154.8) could only be accounted for by two
fully substituted carbon-carbon double bonds and a carbonyl. HMBC correlations
were observed from H2-7 to C-5 and C-6, indicating the double-allylic character of
H2-7, consistent with its chemical shift (δC 30.2, δH 3.17). An HMBC correlation
from H-8 to C-6, established the C-6–C-7 bond. Further HMBC correlations were
observed from the protons of the final olefinic methyl CH3-22 (δC 10.1, δH 1.85) to
C-4, C-5 and C-6, which combined with a homoallylic COSY correlation between
H2-7 and H3-22 established attachment of the methyl at C-5 and the connections
from C-4 to C-5 and from C-5 to C-6 (Figure 4.8).
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Figure 4.8 COSY and HMBC correlations firmly establishing the C-5 to C-8 connections
in 69. Dashed lines indicate weak correlations.
The substructure was extended by an HMBC correlation from the protons of a
methoxy OCH3-4 (δC 60.5, δH 4.19) to C-4, while a second methoxy OCH3-3
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(δC 60.4, δH 3.81) correlated with C-3, revealing the final carbon-carbon double
bond. Reciprocal NOE correlations between OCH3-3 and OCH3-4 established the
C-3 to C-4 connectivity and the cis relationship of the methoxy substituents. NOE
correlations between OCH3-4 and H3-22, and H2-7 to H3-22 confirmed the tetra-
substituted diene C-3 to C-6, with CH2-7 and CH3-22 on the same side of the C-
5 to C-6 double bond. With one carbon and two oxygen atoms remaining from the
molecular formula and two double-bond equivalents, the remaining sp2 centre C-2
(δC 162.7), which must be a carbonyl was therefore assigned as an α, β-unsaturated
ester on the basis of its shielded chemical shift (Figure 4.9). The shielded chemical
shift of the oxygenated C-3 (δC 126.2) is also consistent with the attachment of the
carbonyl.132,135
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Figure 4.9 HMBC and 1D NOE correlations used to establish the C-3 to C-6 tetra-
substituted diene in 69, and the geometry of the substituents. Double headed arrows
indicate reciprocal correlations.
All but one degree of unsaturation associated with the molecular formula were
accounted for by the phenyl ring, the isolated double bond C-8–C-9, and the C-
2 to C-6 dienoate. Furthermore, the four oxygen atoms required by the molecular
formula are accounted for by the two oxymethyls and the ester functionality. The
deshielded chemical shift of C-6 (δC 154.8) is consistent with oxygen substitution,
and therefore an α-pyrone moiety, C-2 to C-6, similar to that of lehualide A (65), is
established (Figure 4.10). UV absorption maxima (λmax 291 nm), and IR stretching
frequencies (νmax 1686, 1649 cm 1) support this assignment,136 while the chemical
shifts of the sp2 carbon resonances are consistent with those reported for similar
systems.132
A series of sequential COSY and HMBC correlations, beginning at the H2-15
methylene triplet, and terminating with H2-10 established a C6 methylene chain
linking the mono alkyl-substituted benzene ring and the C-2 to CH2-10 segment.
Selective excitation of the methylenes CH2-10 (δC 39.7 δH 1.96) and CH2-15 (δC 36.1
δH 2.57) with mixing times of 20–120 ms revealed the resonances within the
methylene envelope (CH2-12 – CH2-14: δC 27.8, 29.9, 29.3, 31.6 δH 1.24–1.38) and
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gave reciprocal revelation of CH2-10 and CH2-15 (Figure 4.10). This completed the
structure of lehualide E (69). NMR data for 69 is presented in Table 4.1.
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Figure 4.10 1D TOCSY correlations confirming connection between the extended α-
pyrone segment (C-2 to C-11) and the mono alkyl-substituted benzene ring (C-15 to C-21)
in 69.
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Lehualide F (70)
Lehualide F (70) was isolated as a white solid. Positive-ion mode HRESIMS analysis
of 70 revealed a [M + Na]+ pseudo-molecular ion peak at m/z 393.2042. This
indicated the molecular formula C23H30O4, differing from that of 69 by an additional
CH2 equivalent. The multiplicity-edited HSQC spectrum accounted for 32 of the 33
protons, indicating the presence of one exchangeable proton, while the 1H spectrum
of 70 displayed resonances for a mono alkyl-substituted benzene ring (δH 7.22–7.16)
an olefinic methine (δH 5.17), a deshielded methylene doublet and triplet (δH 3.20,
2.57), two olefinic methyl singlets (δH 1.85, 1.66) and an aliphatic methylene envelope
integrating for 12 protons. As demonstrated in Figure 4.11, the 1H NMR spectrum of
70 appeared very similar to that of lehualide E (69), except for the broad resonance
of an exchangeable proton (δH 6.50), the presence of only one methoxy (δH 3.90) and
slight downfield change in the chemical shift of the CH3-22 methyl signal (δH 1.96).
Figure 4.11 1H NMR spectra of lehualides E (69) and F (70); differing in the number of
methoxy signals and chemical shift of CH3-22 (69 δH 1.85; 70 δH 1.96).
As with 69, COSY and HMBC correlations allowed the facile assembly of the mono
alkyl-substituted benzene ring C-16 to C-21 [(C-16: δC 143.0), (CH-17 and CH-
21: δC 128.5, δH 7.17, 2H), (CH-18 and CH-20: δC 128.4, δH 7.22, 2H) and (CH-19:
δC 125.6, δH 7.16, 1H)]. Substitution of the aromatic ring was established via HMBC
correlation from protons of a methylene triplet CH2-15 (δC 36.1, δH 2.57) to C-16,
and reciprocal correlations between the methines CH-17/-21 and CH2-15 (Figure
4.12).
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Figure 4.12 COSY and selected HMBC correlations establishing the C-17 to C-23 segment
of 70.
The isolated double bond C-8–C-9 was again assembled on the basis of HMBC
correlations from protons of the olefinic methyl singlet CH3-23 (δC 16.3, δH 1.68) to
the sp2 carbons CH-8 (δC 117.2, δH 5.17), and C-9 (δC 139.0). A further HMBC
correlation from H3-23 to a methylene carbon CH2-10 (δC 39.7, δH 1.96), and a
COSY correlation from H-8 to the protons of another methylene CH2-7 (δC 30.2,
δH 3.17) extended the sp2 substructure. Selective irradiation of H3-23 in a 1D NOE
experiment induced enhancement of H2-7 and H2-11, while H2-7 and H2-10 were
similarly enhanced after irradiation of H-8. This established the E geometry of the
C-8 to C-9 alkene.
An α-pyrone (λmax 298 nm) similar to that of 69 was quickly identified. The oxy-
substituted double bond between C-5 and C-6 was established on the basis of the
strong HMBC correlations from the protons of the sp2 methyl H3-21 and methylene
H2-7 to both C-5 and C-6. Evidence of weak homoallylic COSY coupling between
H3-21 and H2-7 confirmed the CH2-7–C-6–C-5–CH3-21 bonds (Figure 4.13).
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Figure 4.13 COSY, HMBC and 1D NOE correlations confirming the tri-substitution
of the E alkene C-8–C-9, and the tetra-substituted alkene C-5–C-6 in 70. Dashed lines
indicate weak correlations.
A further HMBC correlation from H3-22 to C-4 (δC 162.1) was observed, the
deshielded chemical shift again indicating oxygen-substitution of C-4. However,
the methoxy observed in 69 was absent suggesting a hydroxyl functionality. This
accounted for the exchangeable proton (IR: νmax 3250 cm 1, δH 6.50 ppm). HMBC
78
correlations from protons of the lone methoxy OCH3-3 (δC 60.0, δH 3.86) to C-3
(δC 125.0) were observed as in 69, as was an NOE correlation between the protons
of CH2-7 and CH3-21 (Figure 4.14).
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Figure 4.14 HMBC and 1D NOE correlations establishing the C-4–C-5 bond and methoxy
substitution of C-3 in 70. Double headed arrows indicate reciprocal correlations.
The α-pyrone system was completed by the α, β-unsaturated ester carbonyl C-2
(δC 160.4), Figure 4.15. All other chemical shifts and correlations observed in the
NMR spectra were essentially identical to that of 69, thereby establishing 70 as the
C-4 des-methoxy congener of 69. NMR data for 70 is presented in Table 4.2.
O
OH
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O
Figure 4.15 The α-pyrone system present in 70, the des-methoxy congener of 69.
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Lehualide G (71)
A [M+Na] pseudo-molecular ion peak observed in the positive-ion mode HRESIMS
spectrum for lehualide G (71) at m/z 421.2355, indicated a molecular formula of
C25H34O4, differing from 70 by an additional C2H2 equivalent. Detailed analysis of
the 1D and 2D NMR spectra of 70 and 71 determined that the two were chain-
length congeners. The only perceivable differences between the spectra of the two
compounds were the methylene regions of the 1H and 13C spectra (Figure 4.16).
Figure 4.16 1H NMR spectra of lehualides F (70) and G (71). The compounds differ
only integration of the methylene region (δH 1.28–1.45 ppm, 69 6H, 70 8H).
Much of the 1D and 2D NMR data of 71 were consistent with the α-pyrone moiety
present in 70, and UV and IR spectroscopic data (λmax 235 and 291 nm, νmax 3250
cm 1) supported this assignment. The extended methylene chain of 71, C-10 to C-
17, was established by selective 1D TOCSY irradiation of CH2-17 (δC 36.1, δH 2.61).
As the mixing time was increased from 0 to 120 ms, the methylene resonances H2-
16 to H2-10 (C-10: δC 40.5, δH 2.01) were sequentially revealed. Analogous 1D
TOCSY irradiation of H2-10 coupled with COSY and HMBC correlations within
the chain provided confirmation of this assignment and the connection between the
methylenes (Figure 4.17).
HSQC-TOCSY analysis of 71 in CD3OD over a selected band-width, δC 10–50 ppm,
allowed elucidation of the aliphatic chain: [(C-12 to C-15: δC 32.8, 30.6, 30.5, 30.3,
δH 1.25–1.29) and (C-16: δC 30.1, δC 1.22)]. Using this method the overlapping
methylene resonances from C-12 to C-16 were clearly resolved, while the TOCSY
correlations aided concise ordering of the resonances. NMR data for 71 is presented
in Table 4.3.
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Figure 4.17 1D TOCSY and bsHSQC-TOCSY correlations established the connection
between methylenes CH2-10 and CH2-17 in the extended aliphatic chain of 71.
The structural similarities between lehualides F and G made resolution of the
chain-length congeners impossible under normal-phase chromatographic conditions.
With no discernable difference in polarity, the two compounds would co-elute in
an approximate 1:20 ratio. Exploitation of the differences in lipophilicity granted
separation of the two congeners under reversed-phase conditions (C18 HPLC, 85%
MeCN in H2O). Conversely, resolution of mixed fractions of lehualides E and F
could be nearly achieved under normal-phased conditions. Although the lipophilic
chains induced streaking across the stationary phase, polarity differences between
the methoxy and hydroxyl forms were sufficient to afford some separation.
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Lehualide H (72)
Positive-ion mode HRESIMS analysis of lehualide H (72) generated a [M + Na]+
pseudo-molecular ion peak at m/z 407.1864, suitable for the formula C20H32O5S,
requiring five degrees of unsaturation, and incorporation of a sulfur atom. Analysis
of the 1H NMR spectrum of 72 revealed, in contrast with the lehualides E–G, the
absence of the phenyl moiety, olefinic proton, and doubly allylic methylene signals.
Similar 2D NMR, IR and UV spectroscopic data to that of 69, and the presence of
two methoxy signals indicated retention of the dimethoxy α-pyrone. This accounted
for four of the five oxygen atoms, and four degrees of molecular unsaturation. As
with 69, the non-protonated α-pyrone ring was assigned on the basis of HMBC and
NOE correlations between H2-7, H3-21 and the methoxy groups OCH3-4 and OCH3-
3. The doubly allylic methylene doublet of 69, CH2-7 (δC 30.2, δH 3.17), is replaced
in 72 by a singly allylic methylene triplet, CH2-7 (δC 30.9, δH 2.44), as evidenced by
homoallylic COSY correlation between CH2-7 and H3-21, and HMBC correlations
to C-5 and C-6 (Figure 4.18). These data confirmed the absence of the isolated
double bond and associated olefinic methyl of the previously described structures.
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Figure 4.18 The dimethoxy-substituted α-pyrone and singly-allylic methylene substituent
of 72 as evidenced by COSY, HMBC and 1D NOE correlations. Double headed arrows
indicate reciprocal correlations, and dashed lines indicate weak correlations.
The long alkyl chain characteristic of the lehualides extended between CH2-7 and
CH2-16 (δC 29.2, δH 2.86), selective 1D TOCSY irradiations of methylenes H2-7 and
H2-16, with increasing mixing times (0–200 ms) established the connection between
the two centres.
The final substructure began at the deshielded methyl singlet terminus (δC 30.8,
δH 2.35). Strong HMBC correlations from the protons of both the methyl and H2-
16 to an ester carbonyl (δC 196.3) were observed. The large 1JCH coupling constant
and low 1H and 13C chemical shifts of the C-16 methylene (δC 29.2, δH 2.86, 1JCH 141
Hz) indicated sulfur attachment.137,138 The chemical shift of the acetate carbonyl
(δC 196.3) is consistent with the thioacetate moiety previously observed in lehualide
84
C (67). As illustrated in Figure 4.19, reciprocal weak HMBC correlations observed
from the protons of methylene H2-16 and methyl terminus to the respective carbons
confirmed the thioacetate linkage. Elucidation of this substructure accounted for the
sulfur atom, the fifth oxygen atom, and the final degree of unsaturation required by
the molecular formula. This completed the structure of lehualide H (72), the NMR
data of which is presented in Table 4.4.
H3C S
O
16
H H
HMBC
Figure 4.19 The thioacetate moiety of 72 as evidenced by HMBC correlations. Dashed
arrows indicate weak correlations.
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Lehualides I and J (73 and 74)
The sulfur functionalities in lehualides I and J presented challenges during structural
elucidation of the compounds, beginning with establishing their respective molecular
formulae. Interpretation of the positive-ion mode HRESIMS spectrum of lehualide
I (73) led to a proposed molecular formula of C19H32O5S (m/z 395.1867 [M + Na]+,
m/z 379.1920 [M – 16 + Na] ). A pseudo-molecular ion peak correlating to the
same formula was also observed in the HRESIMS spectrum of 74: C19H32O5S
(m/z 395.1868 [M + Na]+) (Figure 4.20). Relative peak heights of the [M + Na]+
and [M – 16 + Na] signals in the spectrum of 73 varied slightly between
injections, suggesting they may not be products of fragmentation. Following further
interpretation of the HRESIMS and NMR spectra of both compounds, the formula of
73 was revised to C19H32O4S (m/z 379.1920 [M + Na]+, 395.1867 [M + 16 + Na] ).
This new formula contains one less oxygen atom than that of 74, and the strong
[M + 16 + Na] peak was thought to represent an oxygen adduct formed in the
positive-ion mode conditions.
Lehualide I
Lehualide J
Figure 4.20 Positive-ion mode HRESIMS spectra of lehualides I and J. Both compounds
appear to have the same molecular weight and corresponding chemical formula.
Analysis of the 1D and 2D NMR spectroscopic data of lehualide I (73), in
conjunction with IR and UV spectra, confirmed the same C-6 alkyl-substituted
α-pyrone system present in 72. This accounted for the four degrees of unsaturation,
and the four oxygen atoms required by the molecular formula. The alkyl chain was
again elucidated by irradiation of methylenes H2-16 and H2-7 using a 1D TOCSY
pulse with sequentially increasing mixing times. When acquired in CDCl3, the 13C
NMR spectrum was devoid of one methylene resonance, although no discernable
differences in peak height or line width were observed between resonances in the
region. Analysis of 73 in both C6D6 and CD3OD allowed resolution and observation
of the missing methylene centre.
Similar to lehualide H (72), a methyl singlet (CH3-17: δC 15.6, δH 2.09) was observed
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in the 1H spectrum of lehualide I (73). Inspection of 2D NMR spectroscopic data
revealed weak HMBC and COSY correlations between CH3-17 and the CH2-16
methylene (δC 34.3, δH 2.49), indicating the presence of a heteroatom between them
(Figure 4.21). The high 1JCH values and shielded chemical shifts of the aliphatic
centres CH2-16 (1JCH 137 Hz) and CH3-17 (1JCH 137 Hz) indicated the linkage was
a sulfur atom.137 This was corroborated by a weak C-S stretch present in the IR
spectrum at 698 cm 1 indicative of a sulfide function.
H3C
S
1617
H H
HMBC
COSY
Figure 4.21 The methyl sulfide function of 73 as evidenced by COSY and HMBC
correlations. Dashed arrows indicate weak correlations.
As shown in Figure 4.22, acquisition of the 1H NMR spectrum of lehualide I (73)
in CDCl3 resulted in broadening of the signals for the centres adjacent to the sulfur
(CH3-17 and CH2-16) after an hour in solution. The effect was initially attributed
to acid-catalysed H-D exchange. Acidic α-protons of dicarbonyl sulfone centres
have been observed to undergo H-D exchange,139 although presence of the function
was negated by the HRESIMS evidence. Dissolution of the compound in a polar
solvents such as CD3OD alleviated the broadness, presumably due to hydrogen-
bonding between the solvent and the sulfur centre. The broadness observed in
CDCl3 is therefore attributed to fluctuating intramolecular interactions between the
sulfur and the pyrone core in the absence of intermolecular hydrogen-bonding.
The 1H NMR spectrum of lehualide J (74) was very similar to that of lehualides
H and I (72 and 73), the primary difference being the presence of a deshielded
diastereotopic methylene (δC 54.9, δH a 2.73, b 2.66), observed in the HSQC
experiment. As with compounds 72 and 73, the C-6 alkyl-substituted α-pyrone
system was identified through detailed analysis of both 1D and 2D NMR data,
corroborated by UV and IR spectroscopic data. In this case, the aliphatic chain
extending from the pyrone terminates in the methylene centre CH2-16 (δC 54.9, δH a
2.73, b 2.66), the diastereotopic nature of which indicated close proximity to a chiral
centre. A deshielded methyl singlet CH3-17 (δC 38.7, δH 2.56) was also observed at
significantly higher chemical shift to that of 73. As depicted in Figure 4.23, the
centres displayed weak reciprocal COSY and HMBC correlations, indicating the
presence of a heteroatom between them, while the large 1JCH couplings associated
with the centres (CH2-16: 1JCH Ha 137 Hz, Hb 135 Hz; CH3-17: 1JCH 137 Hz)
in conjunction with their chemical shifts was again indicative of a bridging sulfur
functionality.137 Incorporation of an oxygen-bearing stereogenic sulfoxide centre
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AB
Figure 4.22 1H NMR spectrum of lehualide I (73) acquired in A: CDCl3 and B: CD3OD.
Broadening of the methylene and methyl signals (δH 2.48, 2.08 ppm) adjacent to the sulfur
centre is apparent after 60 min in CDCl3, but not observed in CD3OD.
accounted for both the diastereotopic nature of CH2-16 and deshielded chemical
shifts of the methylene and CH3-17, while incorporating the remaining oxygen
indicated by the molecular formula. The IR stretch of the functionality was observed
at 1027 cm 1.140 It is unclear, however, whether the apparent lack of optical activity
([α]19.1D 0.0 (c 3.69 10 3, CHCl3)) is due to natural occurrence of lehualide J (74)
as a racemic mixture or small sample size. NMR data for the structures of lehualides
I and lehualide J (73 and 74) is presented in Tables 4.5 and 4.6.
H3C
S
O
HbHa
16 HMBC
Figure 4.23 The stereogenic sulfoxide centre of 74 as evidenced by HMBC correlations.
Dashed arrows indicate weak correlations.
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Lehualide K (75)
The final addition to the lehualide suite, K (75) was not isolated in any purity
exceeding approximately 85%. Persistent impurities of 70 and 72 remained within
the sample despite multiple normal phase column chromatographic purifications,
and attempted isolation by C18 and DIOL HPLC under various solvent conditions.
The 1H and 13C NMR spectra of 75 are remarkably similar to those of 72, except
the absence of the acetyl group. As is typical of the latter lehualides, compounds
72–74, the terminating methylene of the extended aliphatic chain, CH2-16 has
a large 1JCH value (δC 39.3, δH 2.67, 1JCH 139 Hz) and shielded chemical shift,
consistent with a terminal sulfur-containing functional group. Further analysis of
both the 1D and 2D NMR spectra suggested 75 to be the thiol analogue of 72.
The signal attributed to the S-H proton diminished during the purification process,
however, while the positive-ion mode HRESIMS spectrum showed a [M + Na]+
pseudo-molecular ion peak at m/z 705.3477. This mass was consistent with the
molecular formula C36H58O8S2, indicating formation of a disulfide dimer. In light of
the isolation of the thiol lehualide D (68), dimerisation of 75 during the isolation
process is suspected. NMR data for the disulfide 75 is presented in Table 4.8.
4.2.2 Bioactivity of the lehualides
Lehualides F–I (70–73) displayed mild growth inhibition (60–70%) of a drug-
sensitive Saccharomyces cerevisae strain at 100 µmol L 1, and mild cytotoxicity
against the human promyelocytic leukemia (HL-60) cell line (Table 4.7). Unfortu-
nately, the limited quantities of material available for assessment combined with
compound instability prevented further biological investigation of the lehualides.
Table 4.7 Inhibition of HL-60 Cells by Lehualides F–I (70–73).
Compound IC50 (µmol L 1)
70 6.2
71 5.4
72 14.6
73 10.8
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4.2.3 Determination of sulfur functionalities
The NMR-silent nature of the 32S nuclei present in lehualides H–K (72–75) presented
particular difficulties during characterisation of the compounds via NMR. A suite of
sulfur functional groups were prepared in order to confirm the structures of 72–74
through comparison of spectroscopic data (Scheme 4.2).
Br
i. Thiourea, 1.5 eq.
ii. KOH(aq), 2.4 eq.
MeOH:H2O, 1:1
SH
S
O
S S
Ac2O, excess
 ∆, 14 h
MeI, 1 eq.
   ∆, 20 min
Methyloctylsulfide, 40%Octanethioacetate, 80%
MeI, 1.2 eq.
∆, 30 min
di-methyloctylsulfide, 90%
S S
O O
O
KIO4, 1.5 eq. 
or H2O2 (30% aq.), 1.5 eq.
MeOH, ∆ 12 h
MnO2:KMnO4, 3:1, excess
CH2Cl2, ∆ 96 h
Methyloctylsulfoxide, 100% Methyloctylsulfone, 100%
Scheme 4.2 Synthesis of the spectroscopic model compounds of lehualides H–J:
octanethioacetate, methyloctylsulfide and methyloctylsulfoxide.
Octanethiol was prepared and derivatised to yield octanethioacetate,141 the mono-
and di-methylsulfide products and the corresponding sulfoxide and sulfone species.
The thioacetate proved a spectroscopic match for the aliphatic portion of lehualide
H (72), supporting the proposal of 72 as its final structure. Methyloctylsulfide was
found to have identical spectroscopic characteristics to the aliphatic portion of the
natural product 73, confirming the methylsulfide substructure of lehualide I and
its final structure as 73. Stoichiometric oxidation of methyloctyl sulfide with both
H2O2 and KIO4 provided the sulfoxide product;142,143 a spectroscopic match for the
aliphatic portion of the metabolite 74 in chemical shift and 1JCH coupling constants,
confirming the structure of lehualide J as 74 (Figures 4.24–4.26).
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Figure 4.24 1H NMR spectral comparison of lehualide H (72) and octanethioacetate.
The methylene (δH 2.86 ppm) and methyl (δH 1.84 ppm) centres adjacent to the sulfur
moiety share chemical shifts.
Figure 4.25 1H NMR spectral comparison of lehualide I (73) and methyloctylsulfide. The
methylene (δH 2.49 ppm) and methyl (δH 2.09 ppm) centres adjacent to the sulfur nucleus
share chemical shifts.
Figure 4.26 1H NMR spectral comparison of lehualide J (74) and methyloctylsulfoxide.
The methylene (δH 2.73, 2.66 ppm) and methyl (δH 2.56 ppm) centres adjacent to the
sulfoxide centre share chemical shifts.
For further spectroscopic comparison with the natural products dimethyloctylsulfide
and methyloctylsulfone were prepared via established methods,144 and were found
95
to display significant spectroscopic differences (see Table 4.9). Analysis by TLC of
the three model compounds and the natural products gave corroborating evidence
for the nature of the sulfur moieties.
NMR detection of sulfur functionalities
Direct bonding to sulfur has little effect on the chemical shifts of spin-active carbon
and hydrogen nuclei, as the three elements have similar relative electronegativi-
ties.145 In the absence of a deshielding effect upon chemical shifts, analysis of the
1JCH coupling of adjacent C-H bonds is the best way to analyse sulfur in an
NMR spectrum. Orientation of the sulfur lone pairs increases the 1JCH values
of adjacent C-H bonds, as interaction with the filled p-orbitals decreases the s-
character of the C-H bonds. Interaction with π-systems has a similar effect.137,145
1JCH values can be obtained from fully-coupled HSQC spectra (and strong HMBC
data), but as it is common practice to conduct decoupled HSQC experiments, there
are few literature references. Bonding to oxygen similarly affects 1JCH values,
but the electronegativity of the nucleus also significantly deshields adjacent nuclei,
facilitating indirect observation of the nucleus through the changes in chemical shift.
Only when the sulfur itself is bonded to a more electronegative element are chemical
shifts significantly affected. As observed in 73 and its spectroscopic model, the
sulfur lone-pair can act as a fourth substituent, thereby forming a chiral centre and
inducing diastereotopic splitting of adjacent methylenes. The deshielding oxygen
substituent induces downfield shifts of ca. 0.5 ppm in the 1H spectrum, while dioxy-
substituted sulfones can deshield chemical shifts by ca. 1 ppm, relative to aliphatic
chemical shifts.146 Formation of the oxygen-adduct of 73 during HRESIMS analysis
illustrates the potential danger of relying solely upon MS data for confirmation of
molecular formula(e). In the absence of isolation of 74, the sulfide analogue 73 may
have been mischaracterised and falsely reported.
Sulfur functionalities in the marine environment
While the sulfur functionalities of lehualides H and K (72 and 75) have been
previously encountered in lehualides C and D (67 and 68), the methyl sulfide
and sulfoxide functionalities present in lehualides I and J (73 and 74) appear
to be unprecedented in metabolites from sponges of this genus. Sulfoxides and
sulfides are reported rarely from marine organisms, although there have been
numerous examples reported from terrestrial plants including methionine and
cysteine sulfoxides from brassicaceous and alliaceous vegetables,140,147 and trisulfides
from the roots of some angiosperms.148 Examples from sponge literature include
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psammaplin N (76),149 eudistomin K (77),150 didemnolines A–D (78–81),138 and
the sulfide benzylthiocrellidone (82) from Crella spinulata.151
O
N
N
H
S
OH
Br
HO
Me
O
76
N
H
N
S
O
Br O
H2N
77
Formation of disulfide species, as is suspected in the case of 75, has also been
encountered in the marine environment. Psammaplin A (83), isolated from a
Tongan specimen of Psammaplysilla sp.,152 was the first example of a disulfide
species originating from a marine sponge. The isolation of lehualides E–K (69–
75), particularly in light of the sulfur functionalities present in the latter members
of the class, adds to the diversity of chemical functionality obtained from Plakortis
sponges.
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X = H 79
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Br
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4.2.4 α- and γ-Pyrone metabolites from marine invertebrates
Lehualides A–K are the stand-alone pyrone metabolites from Plakinidae sponges,
although the heterocycle function has been encountered within a variety of
sponge metabolites and cultures of microbial sponge symbiotes. Examples include
nocapyrone A (84), discovered within cultures of the Nocardiopsis strain HB383,
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isolated from a Halichondria panacea specimen. Successful ex-host culturing also
allowed biosynthetic characterisation of the γ-pyrones via feeding experiments with
13C-labeled acetate, propionate, and methionine. Feeding of 1-13C-propionate led
to an enhancement of the 13C NMR signals of C-1 and C-3, while 1-13C-acetate
enhanced the carbon resonances of C-5 and C-7. The signal of C-15 was enhanced
after feeding with SMe-13C-methionine, indicating that the C-1 methoxy substituent
is derived from S-adenosylmethionine (SAM).153 These observations led Schneeman
and co-workers to propose the initial formation of an α-pyrone, which tautomerises
into the γ-pyrone in the course of methylation by an O-methyltransferase.153
O
O
OMe
OH
4
1
15
84
Marine fungi have produced many pyrone metabolites, such as the phenethyl-
α-pyrone derivatives from a marine Aspergillus niger strain (EN-13).154 The
endophytic fungus was isolated from the inner tissue of the brown algae Colpomenia
sinuosa, cultured ex vivo to yield four pyrone metabolites, and three cyclo-
dipeptides.154 Similar ex vivo culturing of another endophytic A. niger strain (MA-
132), isolated from the marine mangrove plant Avicennia marina, afforded the
α-pyrone metabolites nigerapyrones A–H.155 Similar to lehualides A and B, the
nigerapyrones have tails with varied regiochemistry about the methyl-substituted
double bonds. The structures of nigerapyrones F–H (85–87) terminate with a phenyl
function.155
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85
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O
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The new α-pyrone nigrosporapyrone (88) was isolated from cultured Nigrospora
sp. fungus (PSU-F5) harvested from an Annella sp. sea fan.156 The fungus
Microsphaeropsis sp. was isolated from the Mediterranean sponge Aplysina
aerophoba and subsequent investigation yielded the γ-pyrones microsphaerones A
(89) and B.157 Investigation of other marine invertebrates has also yielded examples
of this heterocycle. Isolated from the Mediterranean mollusc Placida dendritica
99
(order Sacoglossa), placidenes C–F (90–93) exhibit α-pyrone groups, differing from
plakinid polyketides in that they comprise entirely of propionate groups.158
More akin to the lehualides, recent isolates from another mollusc, Aplysiopsis
formosa, the aplysiopsenes have a mixed acetate/propionate pathway.159 Polypro-
pionate skeletons are frequently uncovered within marine gastropods: Chilean
specimens of Siphonaria lessoni yielded the α-pyrone norpectinatone in addition
to acyclic congeners,160 while collections of Siphonaria diemenensis from Sydney
Harbour, Australia yielded the α-pyrone diemenensin A (94).161 Like lehualides A
and E–K, 94 bears a C-4 hydroxyl and an olefinic methyl at C-5, yet differs in
methylation in place of oxygen substitution at C-3.
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Oxidative degradation of α-pyrone tautomers is frequently encountered, particularly
in C-3 carbon-substituted systems. Kong et al. observed transformation of 3,6-
alkyl-substituted 4-hydroxy-α-pyrones into 3-furanone substrates following storage
of the metabolites in CDCl3 at ambient temperatures for 11 days.162,163 Scheme 4.3
depicts their proposed mechanism, which entails C-3 oxidation by O2, followed by
hydrolysis of the lactone, decarboxylation of the C-2 carboxylate and intramolecular
cyclisation. Popplewell et al. proposed a similar degradation pathway for
similarly substituted oxylipin pyrone substrates from a New Zealand red macroalgae
Phacelocarpus labillardieri.66 To circumvent such degradation lehualides E–K were
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stored frozen in benzene/ethanol solutions, a more practical storage method than
some methods previously employed.66
O
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O2                                                             H2O
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O
OHO
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O
OHO
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H
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HO
O
Cyclisation
Decarboxylation
- H2O
O
O
HO
Scheme 4.3 Mechanism for degradation of pseudopyrone B into furanone 3 as proposed
by Kong et al.162
4.2.5 Biogenesis of the lehualides
The polyketide derivation of the lehualides is apparent; the skeletons primarily
comprise fully reduced acetate monomers, with little post-translational modification
required to introduce chemical functionalities such as the C-2 methoxy groups. The
terminal phenyl group of 65, 66 and 69–71 involves a phenylacetate chain starter
unit. Incorporation of propionate monomers into the predominantly acetate-based
chain introduces the C-5 methyl substituent of the α-pyrone ring, and the tri-
substituted ∆8,9 alkene of lehualides E–G (69–71). Installation of the α-pyrone
occurs during cleavage of the final module from the ACP domain.
Occurrence of the four different sulfur functionalities in lehualides H–J pose
interesting biosynthetic questions. While synthetic introduction of C-S bonds
often involves (facile) attack of an electrophilic carbon by a sulfur nucleophile,
biological formation of C-S bonds is more complex. Multiple sulfur cofactors
have been identified in biological systems, these include coenzymes A and M,
SAM, thiamine pyrophosphate, biotin, molybdopterin, lipoic acid and N-(7-
mercaptoheptanoyl)threonine phosphate.164 Introduction of thiol functionalities to
the lehualide polyketide skeleton is most probably analogous to the conversion
of L-cysteine and sulfoactaldehyde into coenzyme M. As depicted in Scheme 4.4,
sulfoactaldehyde is attacked by the cysteine SH nucleophile forming a thiazolidine
adduct. The new C-N bond undergoes reductive ring-opening generating S-
(sulfoethyl)-L-cysteine. Pyridoxyl-P assists β-elimination in the 2-aminoacrylic acid
portion generating coenzyme M and ammoniumpyruvate.165
The uneven number of carbons in the backbones of lehualides H–J indicates
chain-truncation within the structures, similar to that observed by Yong et al..166
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Cysteine       Sulfoacetaldehyde
Coenzyme M    Ammoniumpyruvate
Scheme 4.4 Thiolation of sulfoactaldehyde by L-cysteine to form coenzyme M.
The lehualides may share a common phenylacetate starter unit, with incomplete
reduction of an adjacent acetate group allowing for oxidative cleavage of the alkene
producing an aldehyde function. A similar reaction to that above between L-cysteine
and the new aldehyde functionality in the polyketide can be envisaged generating
a monomeric form of lehualide K (75). As would be the case in organic synthesis,
the thioacetate of lehualide H (72) could easily form via nucleophilic attack of an
electrophilic centre such as ethanoic acid by the thiol function of the polyketide
product. Similarly, enzyme-mediated methyl transfer to the thiol group would give
rise to the sulfide lehualide I (73). Oxidation of the methylsulfide group forming
the sulfoxide functionality present in lehualide J (74), and hypothetically a sulfone
moiety, could proceed by a host of enzymatic processes. Synthetic experimentation
with the heme enzyme chloroperoxidase of Caldariomyces fumago and the vanadium-
dependant bromoperoxidase of Ascophyllum nodosum has proven the applicability
of the enzymes to a range of synthetic substrates and such enzymes could play a
role in this biosynthesis.167
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4.2.6 Concluding remarks
Analysis of the HMBC spectra of screening fractions from the Plakortis specimen
PTN3_20A was of great import identifying the potential for structural novelty
within the extracts and selection of this sponge for further evaluation. Further use
of the HMBC NMR spectrum in the early stages of purification led to determination
of the non-protonated α-pyrone substructure, further demonstration of the value in
analysing HMBC spectra early on in the isolation process.
The isolation of lehualides E–K has added to chemical knowledge pertaining to
spectral characteristics of substituted pyrone systems. Structural elucidation of
the fully-substituted α-pyrone system of lehualides E–K (69–75) presented a
challenge. Similarly unprotonated systems have previously been proposed on the
basis of chemical shifts alone, however, the substitution pattern here allowed for the
indisputable establishment of the α-pyrone substructure.
The suite of sulfur functional groups isolated during this study are of interest
biosynthetically and from a characterisation perspective. Unequivocal identification
of the moieties containing the NMR-silent 32S nucleus was provided by generating
model compounds for comparison of their 1H and 13C NMR spectra. Although in
agreement with the proposed structures, this experience highlights the necessity of
structural determination via some means other than NMR spectroscopic analysis.
Finally, as encountered throughout this work, investigation of metabolites from
infrequently identified organisms is double-edged. The benefits of expedient isolation
of new metabolites are countered by the realities of isolation, especially when the
metabolites in question are potentially structurally unstable. This also impacted on
the quantities of isolated material available for biological assessment.
104
4.3 Cyclic peroxides from a plakinid sponge
Identified as a species of Plakinastrella or Plakortis, the sponge specimen PTN3_19D
(Figure 2.9), was collected at a depth of 12–15 m from the horizontal ceiling of a
large cave on ‘Eua Island in November 2008. The specimen formed thick, dense
encrustations 0.5–1.5 cm thick, appearing smooth but with a rough reticulated
surface covered in wide shallow nodules ca. 3 mm high. The black-grey exterior
contrasted against the tan-pink interior, which turned grey during methanol
extraction, and the texture was dense and cork-like. The abundant diod spicules
(40–60 µm 1–1.5 µm, Figure 4.27) were isolated via centrifuge following HNO3
treatment of the tissue, aiding classification of the specimen as a plakinid sponge. As
with the Plakortis specimen which yielded the lehualides, unsuccessful recollection
attempts were made in the Vava’u group. The nondescript appearance and growth
of the specimen in dimly-lit caves may have again been contributing factors leading
to specimens going unnoticed.
Figure 4.27 A diod spicule recovered from the plakinid sponge PTN3_19D.
4.3.1 Isolation and identification of cyclic peroxides
The MeOH extracts of the frozen screen sample of PTN3_19D were partitioned
over HP20 resin beads, generating fractions of 30%, 75% and 100% Me2CO in H2O.
HMBC NMR analysis of the less polar 75% and 100% Me2CO in H2O fractions
showed the presence of several closely related compounds containing multiple
deshielded diastereotopic methylenes correlating to oxycarbonyls (δC 170–174 ppm)
and oxyquaternary centres (δC 80–84 ppm). Similarly deshielded methyl doublet
and singlet signals shared HMBC correlations with the same oxyquaternaries (Figure
4.28). The 1H and 13C NMR spectra also showed the presence of saturated alkyl
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systems, evidenced by COSY and HMBC correlations. This interesting combination
of NMR correlations suggested that this plakinid specimen would be ideal for
an NMR-guided isolation. Furthermore, reports of plakinid isolates displaying
antifungal activity168–171 indicated that any isolates could be suitable for analysis
by chemical genetic methods in Saccharomyces cerevisiae yeast.
cO
O H3CO O CH3
da b
e
H H H H
Figure 4.28 Correlations evidencing the methyl-substituted oxyquaternary centres and
nearby diastereotopic methylenes and oxycarbonyls present in the HMBC spectrum of the
Me2CO in H2O screen fraction of PTN3_19D.
Following initial partitioning of the crude methanol extracts over HP20, the non-
polar fractions were subjected to further reversed-phase chromatography (HP20SS,
Me2O in H2O). Analysis by 1H NMR of the non-polar 80–100% Me2CO in H2O
fractions showed retention of the diastereotopic methylene signals associated with
the oxygenated quaternary centres, indicating relatively non-polar compounds
despite the oxygenation.
Relatively good separation was apparent on silica gel TLC plates, however the
oxygenated functionalities were anticipated to be acid-sensitive, as such DIOL was
chosen as a normal-phase material for further purification. Batch elution on DIOL
resulted in elution of the closely related compounds in the CH2Cl2 fraction, indicative
of significant lipophilicity within the structures. As the structures were deficient
in a chromophore, the choice of chromatographic methods for the isolation of the
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metabolites was limited. Cyclic peroxides epiplakinic acid I (95), its methyl ester
derivative (96), plakortolide X (97) and an unusual 1-hydroxy-1,2-dioxane (98) were
all isolated via LH20 size-exclusion chromatography followed by cycles of bench-top
DIOL chromatography with mixtures of hexanes, CH2Cl2 and MeOH. Although
DAD-HPLC was used successfully in the isolation of the lehualides, the technique
could not be applied here, excepting final purification of the 5α,8α-epidioxysterols
(27) and (28) (C18 HPLC, MeCN in H2O). A summary of the overall isolation
strategy for the cyclic peroxides is depicted in Figure 4.29.
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Epiplakinic acid I (95)
Epiplakinic acid I (95), [α 25.2D +1.9 (c 0.068, CHCl3), was isolated as a colourless
oil. Positive-ion mode HRESIMS analysis of 95 generated a [M + Na]+ pseudo-
molecular ion peak at m/z 365.2668, suitable for the formula C20H38O4, which
required two degrees of unsaturation. This was supported by negative-ion mode
HRESIMS analysis of the compound. Analysis of the 1H and 13C data showed
a carboxylic acid carbonyl (δC 174.3), two oxyquaternary centres (δC 86.8, 84.0),
two isolated deshielded diastereotopic methylenes [(δC 55.7, δH a 2.45, b 2.25) and
(δC 39.9, δH a 1.70, b 1.53)], a third diastereotopic aliphatic methylene (δC 36.8,
δH a 1.26, b 1.06), resonances corresponding to an extended aliphatic chain, two
methyl singlets [(δC 23.9, δH 1.45) and (δC 23.3, δH 1.29)], an aliphatic methine
(δC 34.5, δH 1.28), an aliphatic methyl doublet (δC 19.7, δH 0.83) and a terminal
aliphatic methyl triplet (δC 11.6, δH 0.84). All but one hydrogen atom was
accounted for by the fully-coupled HSQC spectrum; with corroborating evidence
for an acid functionality indicated by 13C NMR and IR spectra (νmax 3428 (OH),
1717 (C=O) cm 1).
As illustrated by Figure 4.30, HMBC NMR correlations were observed from the
protons of a methyl singlet CH3-18 (δC 23.9, δC 1.45) to methylenes CH2-2 and
CH2-4 [(CH2-2: δC 44.1, δH a 2.80, b 2.72) and (CH2-4: δC 55.7, δH 2.45, 2.25)] and
oxyquaternary C-3 (δC 84.0). This established connection between the methyl singlet
CH3-18 and the non-protonated oxyquaternary centre, and the adjacent positioning
of methylenes CH2-2 and CH2-4. A weak COSY correlation between H3-18 and H2-2
confirmed the CH2-2–C-3 bond, corroborated by an HMBC correlation from H2-2
to C-3. Further HMBC correlations from the protons of H2-2 to a carbonyl C-1
(δC 174.3) extended the linear segment C-1 to C-4. The absence of further spectral
correlations to the carbonyl C-1 indicated an acid function.
OH3C
HO
O
1 3
18
4
HH
HMBC
COSY
Figure 4.30 Salient COSY and HMBC NMR correlations establishing the C-1 to C-4
linkages in 95, and methyl substitution of C-4. Dashed arrows indicate weak correlations.
The second methyl singlet CH3-19 (δC 23.3, δH 1.29) displayed HMBC correlations
to a second oxyquaternary C-5 (δC 86.8), and methylenes CH2-4 and CH2-6 (δC 39.9,
δH a 1.70, b 1.53). This established substitution of the non-protonated C-5 with the
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methyl singlet CH3-19, and adjacent positioning of the methylenes CH2-4 and CH2-6
(Figure 4.31). Corroborating HMBC correlations were observed from H2-4 to both
quaternary centres, C-3 and C-5, confirming the linear sequence from C-1 to CH2-6.
O O CH3
HO
O
1 3 5 7
18
19
HH
HMBC
Figure 4.31 Salient HMBC NMR correlations establishing the C-3 to C-6 linkages of 95,
and methyl substitution of C-5.
COSY correlations clearly established the connectivity between the terminal methyl
triplet CH3-17 (δC 11.6, δH 0.84), aliphatic methylene CH2-16 (δC 29.73, δH 1.11),
methine CH-15 (δC 34.5, δH 1.28), its methyl doublet substituent CH3-20 (δC 19.7,
δH 0.83) and a second aliphatic methylene CH2-14 (δC 36.8, δH a 1.26, b 1.06).
This series was corroborated by HMBC correlations from methyl doublet CH3-20
to the methine CH-15 and the adjacent methylenes CH2-14 and CH2-16. Selective
excitation of CH3-17 with a 1D TOCSY experiment over mixing times of 20–80 ms,
confirmed connection between the protonated centres (Figure 4.32).
CH3
CH3
17
14
20
HMBC
COSY
Figure 4.32 COSY and HMBC NMR correlations establishing γ-methyl-substituted motif
C-14 to C-17 of 95.
A C9 methylene chain beginning with CH2-6, terminating at CH2-14, was established
by a series of sequential COSY and HMBC correlations. Selective irradiation of both
methylene centres (CH2-6 and CH2-14) and subsequent revelation of the other in
a series of 1D TOCSY experiments with mixing times of 20–120 ms confirmed the
connection (Figure 4.33).
As all of the protons of the molecular formula were accounted for, a cyclic structure is
required to account for the final degree of unsaturation associated with the molecular
formula. Two of the oxygen atoms were incorporated into the acid functionality,
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Figure 4.33 1D TOCSY correlations establishing the C9 methylene chain of 95.
implying substitution of the oxyquaternaries C-3 and C-5 with different oxygen
atoms. A peroxide linkage between the oxyquaternary centres is therefore proposed,
completing the structure of 95.
The 1,2-dioxolane core of 95 is consistent with common Plakortis and Plakinastrella
metabolites, the plakinic and epiplakinic acids. The classes are diastereomeric in
their orientation of alkyl substituents about the 1,2-dioxolane nucleus, cis in plakinic
acids, and trans in the epiplakinic acids. Comparison of the 1H and 13C NMR
chemical shifts of the methyl groups in known plakinic and epiplakinic acids was
consistent with trans configuration of the methyl groups in 95.171 The cis orientation
of methyls within plakinic acids increases diastereotopic differentiation of the CH2-
4 protons in the 1H NMR spectra, and the C-5 methyl substituent has a higher
chemical shift relative to the analogous positions in epiplakinic acids.114,123
Trans orientation of CH3-18 and CH3-19 about the 1,2-dioxolane nucleus of 95 was
confirmed by a series of 1D NOE experiments. Selective irradiation of H-4a and H-
4b gave exclusive enhancement of H3-19 and H3-18 respectively, while irradiation of
the H3-18 and H3-19 methyls resulted in reciprocal enhancements of the methylene
protons, and only weak enhancement of the other methyl (Figure 4.34).
O OH3C CH3
HO
O
HbHa
18
51
19
1D NOE
Figure 4.34 1D NOE correlations used to establish relative stereochemistry in the 1,2-
dioxolane nucleus of 95. Double headed arrows indicate reciprocal correlations, and dashed
arrows indicate weak correlations.
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Epiplakinic acid I methyl ester (96)
The methyl ester 96 eluted earlier from DIOL than its acid analogue 95. Analysis
by positive-ion mode HRESIMS revealed a [M + Na]+ pseudo-molecular ion peak
at m/z 371.2790, which correlated to the formula C21H39O5. This established the
presence of an additional CH2 equivalent in the structure, relative to 95. Comparison
of 1D and 2D NMR data showed compounds 95 and 96 to be identical in structure
and relative stereochemistry, except for the presence of a methoxy singlet (CH3-21:
δC 52.0, δH 3.69) in 96. The observation of an HMBC correlation from it (CH3-21)
to an ester carbonyl (C-1: δC 171.4) confirmed the methyl ester function (Figure
4.35).
O O
H3CO
O 18
51
19
21 HMBC
Figure 4.35 HMBC NMR correlation establishing the C-21 methyl ester moiety of 96.
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Plakortolide X (97)
Plakortolide X (97), [α 24.6D +0.0 (c 0.08, CHCl3), was isolated as a colourless
oil. The apparent lack of rotation may indicate the isolation of a racemic mixture.
Positive-ion mode HRESIMS analysis of 97 revealed a [M + H]+ pseudo-molecular
ion peak (m/z 349.2355) correlating to the molecular formula C20H38O4, which
required three degrees of unsaturation. A [M H] ion peak was observed at m/z
325.2379 by negative-ion mode analysis, confirming this formula. Evident in the
1D and 2D NMR data was conservation of the γ-methyl branched alkyl chain seen
in 95 and 96. The oxygenated end of the molecule displayed NMR resonances
significantly different from those of 95 and 96, indicating a different arrangement of
functionality. The absence of an OH stretch in the IR spectrum and the continued
presence of an oxy-substituted carbonyl (δC 174.3) and an additional oxy-substituted
methine (δC 81.3, δH 4.46) suggested the presence of a lactone.
Strong HMBC correlations were observed from the protons of a methyl singlet, CH3-
18 (δC 25.9, δH 1.39) to three carbon centres; oxymethine CH-3 (δC 81.3, δH 4.46),
oxyquaternary C-4 (δC 83.0) and an isolated methylene CH2-5 (δC 40.5, δH a 2.17,
b 1.71). These correlations established attachment of the methyl singlet to the
non-protonated C-4, and the bonds from CH-3 to C-4 and between C-4 and CH2-5.
COSY correlations between the methine CH-3 and a second diastereotopic methylene
CH2-2 (δC 34.3, δH a 2.92, b 2.62) extended the substructure. HMBC correlations
from the protons of CH2-2 to the oxycarbonyl C-1 (δC 174.3) indicated linkage from
C-1 to C-2, firmly establishing the C-1 to C-5 terminus of the molecule (Figure
4.36).
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Figure 4.36 COSY and HMBC correlations establishing the C-1 to C-5 linkages in 97.
Further evidence of the bond between C-4 and the isolated methylene CH2-5 was
given by HMBC correlations from the protons of CH2-5 to the oxyquaternary C-
4 and oxymethine CH-3, further extending the δ-methyl branched carbon chain
(Figure 4.37). The remaining methyl singlet CH3-19 (δC 22.4, δH 1.29), also
showed strong HMBC correlations to CH2-5, its non-protonated attachment point
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C-6 (δC 80.3) and a further methylene CH2-7 (δC 41.0, δH 1.48). Corroborating
HMBC correlations were observed from H2-5 to C-6 and CH2-7. These correlations
fully established the 4,6-dimethyl-substituted carbon chain with oxy-substitution at
carbonyl C-1 and at CH-3, C-4 and C-6 (Figure 4.38).
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Figure 4.37 COSY and selected HMBC correlations confirming the C-3 to C-5 connections
in 97. Dashed arrows indicate weak correlations.
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Figure 4.38 HMBC correlations establishing the linkages from C-5 to C-7 in 97.
The remaining carbon resonances of the molecule included one methine, eight
methylenes and two methyl groups. These centres were readily assembled into
the γ-methyl substituted alkyl chain observed in 95 and 96 through interpretation
of COSY and HMBC correlations. The attachment of this chain to CH2-7 was
confirmed by selective irradiation of the methylenes H2-7 and H2-14 with a 1D
TOCSY experiment. Over mixing times of 20–120 ms the other resonance was
revealed, confirming the connection between the C-1 to C-7 and C-14 to C-17
segments.
The γ-methyl substituted alkyl chain, C-8 to C-20, accounted for all other protons
associated with the molecular formula, however, two degrees of unsaturation
remained and four oxygenated linkages required incorporation via three oxygen
atoms. These criteria are satisfied by formation of a bicyclic structure, with a
lactone linkage between C-1 and C-4, and a peroxy bridge between C-3 and C-6 as
seen in the plakortolide skeleton (Figure 4.39).
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Figure 4.39 1D TOCSY correlations in 97, confirming connection between the segments
C-1 to C-7 and C-14 to C-17. Incorporation of the two final degrees of molecular
unsaturation completes the structure of 97.
Selective irradiation of H3-18 and H-3 during 1D NOE experiments gave reciprocal
enhancement of these resonances, confirming the configurations at C-3 and C-4, and
the cis fusion of peroxy lactone bicycle. Reciprocal 1,3-diaxial correlations observed
between H-3 and H-5a, and weaker correlations between H3-18 and H-5a, placed
the resonances on the same side of the six-membered 1,2-dioxane ring, while H3-19
shared a strong NOE correlation with H-5b and a weaker correlation with H-5a.
Following 1D NOE irradiation of H3-19 and H3-18, enhancement of neither methyl
singlet was observed, indicating that the two methyls occupy opposing faces of the
1,2-dioxane ring (Figure 4.40).
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Figure 4.40 Stereochemistry about the bicyclic nucleus of 97 as evidenced by selected
1D NOE correlations. Double headed arrows indicate reciprocal correlations.
The plakortolide class has primarily been isolated from sponges identified as
Plakinastrella sp. although some examples have been reported from specimens
identified as Plakortis sponges. Comparison of the NMR spectral data of 97
with that of plakortolide T,166 as shown in Table 4.12, supported the structural
assignment of 97. A complete tabulation of the NMR spectroscopic data for 97 can
be found in Table 4.13.
Fusion of the plakortolide bicycle at C-3 and C-4 is exclusively cis, although
varied configuration at C-6 forms two diastereomeric carbon skeletons, which
display significant differences in 1H chemical shift of CH2-5 and the C-4 methyl
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substituent.172 Orientation of the C-4 and C-6 methyls on opposing faces decreases
diastereotopic differentiation of the H2-5 protons, and 1H NMR chemical shift of the
C-4 methyl increases ca. 0.1 ppm.124 Hydrolysis of the peroxide bridge produces
another structural variant, the seco-plakortolide diols, which have been reported as
both true isolates and as synthetic degradation products of plakortolides.124 One can
easily distinguish the peroxide and diol forms through analysis of the H2-5 1H NMR
shifts. Ring strain in the peroxide form increases the diastereotopic differentiation
of H-5a and H-5b relative to the diol form. Furthermore, the 1H NMR shifts of the
C-4 and C-6 methyl groups are deshielded by ca. 0.1 ppm in plakortolides, relative
to seco-plakortolides.124
Table 4.12 Comparison of Salient NMR Chemical Shifts in Plakortolide T166 relative
to those of Plakortolide X (97).
97* Plakortolide T† Difference‡
O
O
O
O
H
1
3
18 19
6
Pos mult
13C
δ (ppm)
1H
δ (ppm)
13C
δ (ppm)
1H
δ (ppm)
13C
∆δ (ppm)
1H
∆δ (ppm)
1 C 174.3 174.9 0.6 0.00
2 a CH2 34.5 2.92 34.5 2.91 0.0 -0.01
b 2.62 2.62 0.0
3 CH 81.2 4.46 81.3 4.45 0.1 -0.01
4 C 83.0 83.3
5 a CH2 40.7 2.17 40.8 2.17 0.1 0.00
5 b 1.71 1.71 0.00
6 C 80.2 80.5 0.3
18 CH3 26.0 1.39 26.4 1.39 0.4 0.00
19 CH3 22.5 1.29 22.6 1.29 0.1 0.00
*CDCl3, 1H 600 MHz; 13C 150 MHz.
†CDCl3, 1H 500 MHz; 13C 125 MHz.
‡∆δ = δPlakortolide T δ97
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Cyclic peroxide 98
Isolated as colourless oil, positive- and negative-ion mode HRESIMS analysis of
98, [α 24.6D +4.1 (c 0.03, CHCl3), indicated a molecular formula of C21H40O5;
[(m/z 395.2771 [M + Na]+, ∆ –0.8 ppm) and (m/z 371.2790 [M H] , ∆ –1.9
ppm)]. This formula required the incorporation of an additional oxygen atom,
relative to compounds 95–97. Evident in the 1D and 2D NMR data was conservation
of the γ-methyl branched alkyl chain. However, the oxygenated terminus of
the molecule displayed NMR resonances differing again from those observed in
the spectra of compounds 95–97, indicating a further variation in functional
arrangement. In particular, the chemical shift of one of the oxyquaternary centres
had increased significantly to δC 100.9 ppm, from the δC 80–84 ppm observed in the
previous three compounds. An OH stretch was observed in the IR spectrum (νmax
3374 cm 1), which in combination with an oxy-substituted carbonyl (δC 174.7; νmax
1717 cm 1) was again suggestive of a carboxylic acid functionality.
As illustrated in Figure 4.41, correlations were observed in the COSY experiment
between the aliphatic methyl doublet CH3-19 (δC 16.2, δH 0.99), methine CH-4
(δC 32.7, δH 1.99) and the diastereotopic methylene CH2-5 (δC 37.3, δH a 1.66,
b 1.41). The C-19–C-4–C-5 bonds were confirmed by HMBC correlations from
the methyl doublet CH3-19 to the methine CH-4 and the adjacent methylene
CH2-5. A third HMBC correlation was observed from CH3-19 to the highly
deshielded oxyquaternary C-3 (δC 100.9), whose chemical shift is consistent with
dioxy-substitution. These correlations established the connections from C-3 to C-5.
3
CH3
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19
O
5
H H
HMBC
COSY
Figure 4.41 COSY and selected HMBC correlations evidencing the C-3 to C-5 connections
and methyl substitution of C-4 in 98.
An isolated diasterotopic methylene CH2-2 (δC 39.4, δH a 2.89, b 2.55) displayed
HMBC correlations to C-4 and C-3, confirming the C-3–C-4 bond and connection
between CH2-2 and C-3. HMBC correlations from both protons of the methylene
CH2-2 were observed to the oxy-substituted carbonyl C-1 completing the γ-methyl
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substituted carbon chain C-1 to C-5. Strong HMBC correlations were observed from
the methyl singlet CH3-20 (δC 20.1, δH 1.34) to the methylene CH2-5, its attachment
point the oxyquaternary centre C-6 (δC 81.1) and another methylene CH2-7 (δC 40.6,
δH 1.42). These were corroborated by HMBC correlations observed from H2-5 to
both C-4 and C-6. As shown in Figure 4.42, these correlations established the
linear connectivity from C-1 to C-7 with oxycarbonyl substitution at C-1, dioxy-
substitution at C-3 and monooxygenation at C-6.
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Figure 4.42 HMBC correlations proving the connections C-1 to C-4 and C-5 to C-7 and
methyl substitution of C-6 in 98.
A series of sequential COSY and HMBC correlations established the aliphatic chain
extending from CH2-7 to CH3-18, with methyl substitution at CH-16. Connection
between the protonated centres H2-7 to H3-18 was proven via irradiation of H2-7,
H2-14 and H3-18 with 1D TOCSY experiments over mixing times of 20–200 ms, as
shown in Figure 4.43.
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Figure 4.43 The completed linear structure of 98 as evidenced by COSY, 1D TOCSY
and selected HMBC correlations. Double headed arrows indicate reciprocal correlations.
The presence of five oxygen atoms in the molecular formula, implied that C-1, C-3
and C-6 are substituted by different oxygens. As only two hydrogen atoms remained
from the molecular formula, another degree of unsaturation required incorporation.
Formation of a six-membered cyclic peroxide function bridging from the hemi-acetal
centre C-3 to C-6, and an acid function at C-1 satisfied these requirements. The
strong, reciprocal NOE correlations observed between methine CH-4 and the C-6
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substituent, CH3-20, are consistent with their 1,3-diaxial positioning on the six-
membered peroxide ring. The methyl H3-20 and CH-4 shared further strong NOE
correlations with H-5b, while the C-4 substituent H3-19 correlated strongly with H-
5a and weakly with H-5b. NOE enhancement was not observed between H3-19 and
H3-20, indicating that they occupied opposing faces on the 1,2-dioxane ring (Figure
4.44).
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Figure 4.44 1D NOE correlations evidencing the 1,3-diaxial positioning of CH-4 and
CH3-20 and relative configuration at C-4 and C-6 in 98. Double headed arrows indicate
reciprocal correlations.
The only other report of the 1-hydroxy-1,2-dioxane moiety of 98 is in compounds
99 and 100, metabolites isolated from a Plakortis (or Plakinastrella) specimen
collected in Guam.173 Manzo et al. reported that 99 and 100 underwent degradative
decarboxylation during the isolation process (reversed-phase HPLC in MeOH).173
Such degradation was not encountered during this study. Compound 98 also bears
structural similarity to plakorin (101),120 although differing in the position of the
hemi-acetal oxygen.
OOHOO
HO
15
16
99 ∆15,16
100
OO
MeO
O
OMe
101
While the configuration at C-4 and C-6 in 98 was readily assigned by NOE
correlations, configuration of C-3 was more difficult to determine, and was assigned
through spectroscopic comparison with methyl capucinoate (102). Isolated from a
Caribbean Plakinastrella onkodes specimen,128 102 shares the methylation pattern
of 98, 99 and 100 but bears an axial hydrogen at C-3 in place of the hydroxyl
group.
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As with 98, the 1,3-diaxial orientation of H-4 and the C-6 methyl in compounds
99 and 100 was assigned on the basis of 1D NOE experiments.173 Chemical shift
comparison of 99 and 100 with 102 led Manzo et al. to position the C-3 hydroxyl
in 99 and 100 axially. The configuration at C-3 in 99 and 100 was inferred from
the downfield chemical shift of the H-5ax proton in 99 relative to 102.173 The same
argument can be applied to 98. Consistent with 1,3-diaxial interactions with a
hydroxyl function, the H-5ax proton resonance appears 0.31 ppm further downfield
in 98 and 99 compared with the corresponding proton in 102 [(98: δH 1.66,
t, J = 12.8 Hz), (99: δH 1.70, dd, J = 13.1, 13.1 Hz) and (102: δH 1.39, t,
J = 12.8)].173 Other spectral data about the peroxide cores of compounds 98–100
are virtually identical, implying conservation of relative configuration between the
three compounds. Comparison of the chemical shift differences about the cyclic
peroxide nuclei of 98 and 99 can be found in Table 4.14. NMR spectroscopic data
for 98 is detailed in Table 4.15.
Table 4.14 Comparison of Salient NMR Chemical Shifts in 98 and 99.
98* 99† Difference‡
OOHOO
HO 1 3 6
19
20
Pos mult
13C
δ (ppm)
1H
δ (ppm)
13C
δ (ppm)
1H
δ (ppm)
13C
∆δ (ppm)
1H
∆δ (ppm)
4 CH 32.9 1.99 32.7 1.99 -0.2 0.00
5 a CH2 37.4 1.66 36.6 1.67 0.8 0.01
b 1.41 1.36 -0.05
19 CH3 16.2 0.99 16.1 0.98 -0.1 -0.01
20 CH3 20.3 1.34 20.3 1.31 0.0 0.03
*CDCl3, 1H 600 MHz; 13C 150 MHz.
†CDCl3, 1H 400 MHz; 13C 75 MHz.
‡∆δ = δ99 δ98
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4.3.2 Growth inhibition of eukaryotes
Cyclic peroxides 95, 97 and 98 displayed cytotoxicity against the HL-60 cell line
(Figure 4.45).93 Using a standard 48 h cell proliferation MTT assay, 95, 97 and
98 exhibited IC50 values for growth inhibition of 13.43, 285.09 and 3.59 nmol L 1
respectively, while 5α,8α-epidioxysterols 27 and 28 showed far weaker inhibition
of the same cell line with respective IC50 values of 6.48 and 7.90 µmol L 1 (not
shown).93
Figure 4.45 MTT-assay showing inhibition of the HL-60 cell line by 95 (–•–), IC50
13.43 nmol L 1; 97 (– –), IC50 285.09 nmol L 1; and 98 (– –), IC50 3.59 nmol L 1.
The biological activities of epiplakinic acid I (95) and plakortolide X (97) were
further investigated using two strains of Saccharomyces cerevisiae yeast, a wild-type
(WT) and a drug-sensitive mutant strain (∆pdr). The ∆pdr strain carries deletions
for the transcription factor genes, PDR3 and PDR3, which regulate expression of
the pleiotropic drug resistance pump network.174 Unable to upregulate the PDR
response, the ∆pdr strain is up to 3–100-fold more sensitive to some xenobiotics
than WT yeast.175 Interestingly, 95 displayed similar inhibition of WT and the
∆pdr mutant strain, IC50 3.36 and 3.50 µmol L 1 respectively, indicating 95 is not
a substrate for the PDR pump network. Conversely, 97 was ineffective against WT,
and inhibited the ∆pdr strain (IC50 4.45 µmol L 1). This suggests that 97 is a
substrate for one of the PDR pumps; a change in biological activity that may be
due to the change in carbonyl functionality. Chemical genetic screening of 95 and
97 is discussed in Chapter 5.
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4.3.3 Organism classification
Chemotaxonomic analysis of the sponge PTN3_19D, in combination with physical
examination, points irrevocably to the plakinid genera Plakinastrella and Plakortis,
although further distinction is difficult. A larger proportion of cyclic peroxides
have been isolated from the Plakinastrella genus in comparison to Plakortis.
Epiplakinic acids and plakortolide compounds have been found almost exclusively
in Plakinastrella specimens, although the single report of the 1-hydroxy-1,2-dioxane
nucleus of compound 98 is from a specimen of Plakortis sp.173 In all these cases the
initial organism identification can be debated given the close relationship between
the genera. In the case of 99 and 100, the specimen was originally identified as
Plakinastrealla clathrata (Kilpatrick, 1911), but only one size-class of diod spicules
and few irregularly-shaped triods were observed and the organisms was eventually
reclassified as Plakortis.173
The exclusive occurrence of cyclic peroxides such as 95–98 in sponges of the Plakortis
and Plakinastrella genera may indicate singular symbiosis of specific bacteria with
sponges from the Plakinidae family, similar to that observed in Myxilla and
Haliclona sponges.52 Microbial origins for the plakinid polyketides further explains
subtle changes in metabolite profiles between specimens collected from different
environments and locations.53 In stark contrast, the 5α,8α-epidioxysterols 27 and
28 have been isolated from sponges of many orders from different locations. This
may indicate that 27 and 28 are products of sponge metabolism, which is less
affected by subtle environmental variation, or simply products of bacteria common
to both locations and sponge orders.
4.3.4 Cyclic peroxide natural products
A great number of cyclic peroxide sponge metabolites of both polyketide and
terpenoid derivation have been isolated in addition to those from plakinidae sponges,
a selection of which are detailed below.
Plakorin (101) was first isolated from an Okinawan Plakortis specimen,120 while its
C-3 epimer chondrillin (103) has been encountered in Plakortis176,177 and Chondrilla
sponges.178 Six plakorin-like metabolites were reported in 1993 from another
collection of Okinawan Plakortis sponge, the crude extracts of which displayed
potent antifungal activity.168 However, the metabolites were found to be too reactive
to allow isolation by either (preparative) TLC or HPLC (the stationary phase was
not specified), and their structures were elucidated from a semi-pure mixture.168
A specimen of Callyspongia sp. collected in New Guinea was found to contain two
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modestly cytotoxic alkyl-branched 1,2-dioxane carboxylates 104 and 105,179 sharing
great structural similarity with Plakortis isolates the plakortides.127,180
OO
MeO
O
OMe
103
O O
R
OH
O
104 R = CH(CH3)2
105 R = CH2CH3
A Thai collection of Mycale sp. yielded two norsesterterpene 1,2-dioxanes 106
and 107.181 differing by the hydroxyl and methyl substitution of C-9 and C-
10. The two compounds show diverse biological activity: inhibition of several
tumor cell lines, antiviral activity against the vesicular stomatitis virus and HSV-
1, and growth inhibition of some gram positive bacteria. An Australian collection
of the same genus afforded several similar norsesterterpene 1,2-dioxanes including
108, while an Australian Latrunculia conulosa specimen yielded several rearranged
norsesterterpenes including 109, and the aptly named pentacycle contrunculin B
(110).182
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Cyclic peroxides have widely been encountered in sponges, other marine in-
vertebrates and their predators. The ascidian Stolonica socialis has produced
metabolites most similar to those of plakinid origins.183 The stolonoxides feature
a 2,5-trans-substitued tetrahydrofuran ring adjoined by a 1,2-dioxolane carboxylate,
and a partially unsaturated long alkyl chain extending from the 5-position of the
tetrahydrofuran ring. Recent additions to the class, stolonoxide E (111) and its
diastereomer stolonoxide F, were isolated from a Spanish specimen of the ascidian.
Both terminate in an unusual cyclooctatriene function, thought to form from an
unstable terminal tetraene function. As stolonoxides A and C (112 and 113) both
posses a terminal alkene separated from an internal diene by two methylene groups,
the formation of a tetraene is not implausible. Whether formation of the 2,4,6-
cyclooctatriene moiety occurs in vivo or during isolation is uncertain, however.184
The stolonoxides all display low micromolar cytotoxicity across several mammalian
cancer cell lines including the breast cancer (MDA-MB-231), colon adenocarcinoma
(HT-29) and lung epithelial cell adenocarcinoma (A549).183
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Soft corals, such as Labophytum denticulatum and other species within the genus
have also been observed to incorporate peroxide linkages within their characteristic
cembranolide diterpene carbon skeletons giving rise to structures such as 7-
epidenticulatolide (114).185 Hydroperoxides are also encountered within the marine
environment, such as cembranoid 115 from the mollusc Planaxis sulcatus.186
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Derived from the sweet wormwood Artemisia annua, the sesquiterpene artemisinins
are the most noted terrestrial cyclic peroxide metabolites.187 Derivatives of the
parent artemisinin skeleton (116), first reported in 1971, are now the standard
treatment worldwide for Plasmodium falciparum malaria, delivering the most rapid
action of all pharmaceuticals currently available to combat the disease.188
A wide-range of monoterpene and diterpene cyclic peroxide metabolites have
also been reported from terrestrial sources, as have steroidal peroxides such as
the ubiquitous 5α,8α-epidioxysterols. These classes are encountered widely in
sponges,80 gorgonians and ascidians,83 with the peroxide function thought to form
by addition of molecular oxygen across the ∆5,7 diene. Both the 5α,8α- and 5β,8β-
epidioxysterols have been the focus of many biological studies attributing antiviral,80
cytotoxic,80,83 immunosuppressive,189 and modest antibacterial190 activities to the
carbon skeletons.
Fatty acid metabolites of both marine and terrestrial origins are final additions to
this complement of cyclic peroxides. Lipoxygenase enzymes, present within a variety
of organisms, act upon arachidonic acid and derivatives of linoleic acid producing
a number of hydroperoxy-eicosatetraenoic acids such as 117, which affect a wide
range of biological functions.191
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4.3.5 Biogenesis of cyclic peroxides from plakinid sponges
Cyclic peroxides 95–98 are of polyketide derivation, comprised predominantly of
acetate monomers with three propionate units forming the methyl side-branches.
There are two primary mechanisms proposed for formation of the cyclic peroxide
moiety. The first involves Diels-Alder cycloaddition of singlet oxygen across a
diene.192,193 Such an approach was employed in the synthesis of 6-epi-plakortolide
E,194 however, as shown in Scheme 4.6, the regiospecific mechanism cannot account
for the stereochemistry evident within some natural product classes.124 Attack of
molecular oxygen at C-6 from the bottom face installs an arbitrary 6S configuration,
and a (3E,5Z)-diene acid provides trans configuration of methyl groups as seen in
97. Yong et al.124 have noted that generation of cis plakortolides is unlikely by this
mechanism, requiring either a change in diene configuration to 3Z,5Z introducing
unfavourable steric congestion, or attack of oxygen from the top face of a 3E,5Z
precursor disallowing 6S configuration.
Diels-Alder 
favoured
Diels-Alder 
disfavoured
cis                                                                  trans
H
COOH
O O
Z Z
H
O O
Z E
COOH
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O O O H
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O
- H+- H+
Scheme 4.6 Biosynthesis of cyclic peroxides via Diels-Alder cycloaddition of molecular
oxygen as proposed by Yong et al.124
An alternate model from Ovenden and Capon rationalises biosynthesis of the
norterpene sigmosceptrellins, such as 118, in a manner comparable to oxylipin
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biosynthesis,191 and can be applied to plakinid polyketide metabolites.195 As shown
in Scheme 4.7, stereochemistry is defined in the first step where hydroperoxidation
occurs on the re or si face of a skipped diene. The adjacent carbonyl activates
the alkene to oxa-Michael addition by the hydroperoxide nucleophile, defining
stereochemistry about the C-3 position. Conceivably, the overall mechanism could
occur pre- or post-cleavage from the polyketide ACP domain. Support for the theory
of carbonyl activation can be found in the structure of 118, which bears a γ-alkene
and hydroperoxide in addition to an acid-substituted cyclic peroxide moiety. The
absence of an activating carbonyl group appears to have impeded cyclisation of the
hydroperoxide and γ-alkene functions.196
OOH O O OH
O
118
Application of the Ovenden-Capon mechanism to conjugated diene substrates
generates diastereomeric plakinic and epiplakinic acids (see Scheme 4.8). As noted
by Yong et al., migration of the ∆5 alkene to ∆4 via a 1,3-hydride shift prior to
the initial hydroperoxidation introduces unsaturation observed in the plakortide
skeleton (see Scheme 4.9). This provides a suitable electrophile for re or si attack
by the terminal carboxylic acid generating both diastereomers of the plakortolide
bicycle.124 Finally, as depicted in Scheme 4.10, the same mechanism can be invoked
in the proposed biosynthesis of the 1-hydroxy-1,2-dioxane core of 98. The presence
of a ketone at C-3 allows formation of both epimers of the hemi-acetal function.
However, the bis-1,2-dioxene polyketides, represented by 119, isolated from South
African Plakortis aff. simplex specimens question the theory of carbonyl-activated
cyclisation, or raises the possibility of cyclisation occurring by more than one
mechanism within the same substrate. The second cyclic peroxide group could be a
product of a [4+2] cycloaddition of singlet oxygen across a diene; the stereochemical
constraints discrediting this mechanism in some substrates are not present here.129
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Scheme 4.7 Proposed biosynthesis of terpenoid and polyketide cyclic peroxides via
hydroperoxidation and subsequent oxa-Michael addition across an α,β-unsaturated acid
or ester, after Ovenden et al.195
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Scheme 4.8 Proposed biosynthesis of the 1,2-dioxane nuclei of plakinic and epiplakinic
acids via hydroperoxidation and oxa-Michael addition.
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Scheme 4.10 Proposed biosynthesis of both epimeric forms of the 1-hydroxy-1,2-dioxane
nucleus of 98.
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4.3.6 Concluding remarks
Overall, this study has furthered the chemical knowledge pertaining to the cyclic
peroxide complement of plakinid sponges. Identification of the substituted peroxide
functions was facilitated greatly by analysis of HMBC spectra during organism
screening and selection. Correlations were observed from diastereotopic methylenes
to the oxyquaternary centres within the cyclic peroxide moieties and to the adjacent
oxycarbonyl centres. Identification of these oxygenated structural fragments at the
screening stage was integral to the selection of this organism for further analysis.
Examples from three different cyclic peroxide classes were encountered: compounds
95 and 96 display the 1,2-dioxane moiety of the epiplakinic acids, the peroxide
lactone bicycle of the plakortolide class is demonstrated by 97, while an uncommon
1-hydroxy-1,2-dioxane moiety was encountered in 98. These cyclic peroxides
all exhibited surprising stability to oxidative degradation, despite precedence for
degradation among similar compounds.
Metabolites 95, 97 and 98 were potently active against the HL-60 cell line, and their
assessment against other cell lines will be undertaken in the future. The decreased
sensitivity of HL-60 cells to 97 compared with 95 and 98 may reflect the absence
of the free carboxylic acid moiety, an observation that may be useful to future
development of the structures as structural leads.
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Chapter 5
Chemical Genetic Profiling of Marine
Cyclic Peroxides
The spectroscopy-guided isolation approach applied during this study requires an
unbiased assay technique for the biological characterisation of small molecules
following their isolation. The suitability of genome-wide screening techniques as
such an approach was explored. Chemical genetic profiling assays were carried out
in Saccharomyces cerevisiae yeast in an effort to elucidate the precise biological
mechanism of the cyclic peroxides presented in Chapter 4.
5.1 The biological effects of marine cyclic peroxides
Since the late 1980s, cyclic peroxide polyketides have been implicated in Ca2
modulation.120,169,173,180 Plakorin (101) was shown to increase Ca2 uptake by the
cardiac sarcoplasmic reticulum ATPase in rabbit white skeletal muscle in 1989,120
and the same activity was assigned to the plakortone class in 1996.197 Excessive
release of Ca2 inside cardiac muscle can cause sudden cardiac death in heart
failure patients.198 As such, the therapeutic potential of the plakortones in treating
some forms of heart failure prompted efforts towards the synthesis of the 2,6-
dioxabicyclo[3.3.0]octane-3-one core of the class.199 Molluscan isolates, stolonoxides
A and C (112 and 113), have been identified as inhibitors of the mitochondrial respi-
ratory chain,184 specifically affecting the function of two protein complexes that are
reliant upon Ca2 -signaling: complex II (succinate: ubiquinone oxioreductase) and
complex III (ubiquinol: cytochrome C oxioreductase).200 Similarly, the plakortides
have also been found to promote activation of the ATP-dependent sarcoplasmic
reticulum (SR) Ca2 pump.180 The antimalarial drug artemisinin (116) has also
been shown to inhibit the SERCA-type Ca2 transporter of the malaria parasite
Plasmodium falciparum.201 Although structurally distinct from plakinid isolates,
the Ca2 -modulatory activity of 116 is attributed to the peroxide moiety, and is
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thought to contribute to its antimalarial activity.201 The terpenoid metabolites 120
and the labdane 121 also inhibit P. falciparum in a manner similar to 116,195,196,202
and again the cyclic peroxide group is thought to cause these effects.
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Recent investigations of plakortide F acid (122) by gene expression analysis in
Saccharomyces cerevisiae, revealed significant changes in the levels of mRNA
encoding proteins involved in Ca2 homeostasis.169 The observed upregulation
of these genes in response to 122 provided the first evidence for the widely
acknowledged activity of this metabolite class in yeast.
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Using these studies as guides an investigation of the cyclic peroxides detailed
in Chapter 4 was embarked upon. Our aim was to characterise the biological
mechanism of the plakinid cyclic peroxides presented in Chapter 4 by chemical
genetic methods. Given the recognised lack of overlap between genes whose deletion
causes sensitivity to a condition and mRNA’s that are differentially regulated in
the presence of the condition,76 the chemical genetic profiling methods utilised here
should provide information complementary to that gained from the gene expression
profiling by Xu et al..169
5.2 Biological assessment in S. cerevisiae
The budding bakers yeast S. cerevisiae is an ideal model organism for higher
eukaryote systems. The single-celled eukaryote is inexpensive, readily available,
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easily cultured in defined media, and exhibits obvious phenotypes such as growth
inhibition and morphological changes. Furthermore, approximately 31% of the
human genes implicated in disease have an orthologue in S cerevisiae.203 The cell
cycle of S cerevisiae has been well studied and its extremely short replication time
(ca. 90 min) aids culturing in a laboratory environment, significantly decreasing
growth-based assay times. The robust organism can be stably maintained in both
haploid and diploid states, facilitating the generation of deletion strain libraries.
Yeast cells of all species are remarkably robust and resistant to many xenobiotics.
Much of this innate resistance is due to their extensive network of membrane-bound
pumps, termed the pleiotropic drug resistance (PDR) network. The PDR pumps
presumably defend the cell, acting to eject xenobiotics within the cell before they can
reach levels that affect growth.204 The transcription factor genes PDR1 and PDR3
encode the master regulators of the PDR pump network, and their simultaneous
deletion in a haploid strain (∆pdr) confers 3–100-fold greater sensitivity to inhibitory
compounds compared to a wild type (WT) strain.175 Hence, molecules which display
little or no activity in the WT can often be assessed in the drug-sensitive ∆pdr
background, when the lack of activity is due to drug efflux.
5.3 Chemical genetic profiling in S. cerevisiae
The complete deletion of anyone of around 80% of S. cerevisiae genes has no
obvious effect on cell viability,205 a phenomenon attributed to the functional overlap
exhibited by many genes, termed genetic buffering. This buffering mechanism
means the deletion of a single gene can be compensated for by other genes that
can functionally assume its role. Chemical genetic interactions are observed when
a deletion strain is exposed to a small molecule whose cellular target is encoded by
another gene that is genetically buffering the initial deletion. These interactions are
manifested as inhibition or death of the deletion strain, termed synthetic sickness or
synthetic lethality, indicating processes or pathways that are affected by the small
molecule and require compensation in its presence. In this way chemical genetic
interactions identify genetic networks that buffer the phenotype induced by the
small molecule.
Since completion of the S. cerevisiae genome sequence and functional annotation
of much of the genome,206,207 a comprehensive and ordered array of haploid and
diploid Yeast Knock-Out (YKO) strains covering the entire yeast genome have been
described.75 Each carrying deletions for a single gene, the YKO strains have been
utilised in the study of biologically active small molecules, aiding elucidation of
biological mechanisms and identification of cellular targets.208
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The presence of a unique molecular barcode within each deletion strain is integral
to chemical genetic assays used in this study. In each strain the open reading
frame is replaced by a growth-selection marker for resistance to the antifungal agent
kanamycin. The marker is flanked by two 20-nucleotide barcodes (Up and Dn tags)
unique to each yeast strain, which are adjoined on either side by a universal primer
sequence common to the strains (Figure 5.1). These features allow identification of
all deletion strains, and quantification of their relative representation from within
a mixed population by PCR amplification. Incorporation of the universal primer
sites allows tandem amplification of all barcodes, while the use of two tags makes
for more robust data.75
UP DNkanR
UP DNkanR
ORFWild type
Mutant
Figure 5.1 Deletion of the open reading frame deletion within the S. cerevisiae genome
and insertion of the kanamycin resistance marker, after Boone et al.75 In each YKO strain,
the kanamycin resistance marker is flanked by two unique molecular barcode tags, each
adjoined by universal primers.75
As depicted in Figure 5.2, under assay conditions a mixed culture containing every
deletion mutant is grown in the presence of a potential drug at a concentration that
inhibits 30% of the population - IC30. The genomic DNA is then extracted and the
tags of each strain amplified in two tandem PCR reactions for the Up and Dn tags.
The barcode amplicons of each YKO are hybridised to an oligonucleotide microarray,
which carries the the complementary barcode sequences for the tags of each YKO.
From the array, the relative abundance of each deletion strain can be quantified via
the fluorescence signal intensity of their respective barcodes. High or low intensity
of a barcode signal corresponds to high or low growth of that particular deletion
strain within the population pool.75,203,209
Mutants carrying deletions for genes that are important for growth under a
specific condition compete less effectively within the assay pool and diminish in
population size decreasing the signal intensity of their molecular barcode. Hence,
one experiment can identify the genes required for growth under a given condition,
and rank them in order of their importance to fitness, i.e. their sensitivity to the
experimental conditions. Homozygous profiling (HOP) analyses ca. 4,000 non-
essential gene deletions using the homozygous diploid deletion set in which each
strain is deleted for both alleles of a single non-essential gene.210 Interactions with
essential genes are probed via haploinsufficiency profiling (HIP), which is conducted
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using the genome-wide heterozygous diploid deletion set in which only one allele of
a given gene (essential and non-essential) is removed from a strain.76,209,211
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kanR kanR
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Competitive growth of deletion mutant pool
Experimental (drug-treated)
Genomic purification, barcode amplification
and fluorescent labelling
Hybridisation of labelled barcodes to oligonucleotide array
Control - Cy3 (green)
Experimental - Cy5 (red)
HIT!
Control (DMSO)
Cy5Cy3
Figure 5.2 Chemical genetic profiling revealing the importance of a deleted gene to strain
fitness under assay conditions, adapted from Boone et al.75 The deletion strains compete for
growth in the assay pool, and those lacking genes important for growth under experimental
conditions are out-competed and removed from the assay pool, as shown by the blue strain.
This diminishes barcode intensity of the experimental population (Cy5) relative to the
control population (Cy3) on the microarray slide. Strains unaffected by either condition
appear yellow, while those detrimentally affected appear green.
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5.3.1 Homozygous profiling
Interactions uncovered by homozygous profiling (HOP) assays cannot reveal the
primary cellular target of a bioactive molecule. Instead, synthetically sick or lethal
interactions identify “friends of the target”, genes which are related to the target
of a small molecule in either cellular function or pathway and genetically buffer its
absence. These genetic interactions point back to the unknown target in a “guilt by
association” manner.
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x
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Figure 5.3 Synthetic genetic interactions uncovered by the homozygous profiling assay.
A deletion mutant strain is viable except in the presence of a xenobiotic whose primary
target is encoded by a gene buffering the initial deletion. These interactions identify genes
related to the target of a small molecule in either cellular function or pathway.
5.3.2 Haploinsufficiency profiling
Concurrent assessment of both essential and nonessential gene interactions has the
potential to identify a cellular target directly by the mechanism of drug-induced
haploinsufficiency.212,213 This is achieved by screening the heterozygous diploid
deletion mutant library, a near complete collection that omits only a few hundred
(ca. 3%) haploinsufficient genes.213
Haploinsufficiency profiling is based on gene dosage dependence. A heterozygous
diploid mutant is deleted for one of two gene copies, halving the quantity of a
given protein that can be produced by the cell. Under normal growth conditions,
this reduced quantity of protein is sufficient to maintain proper function of the
mutant strain.212,213 However, in the presence of a small molecule which targets the
protein encoded by the heterozygous deletion, the mutant strain will be sensitised in
comparison to strains with a full complement of the protein.212,213 This phenomenon
is known as drug-induced haploinsufficiency. Synthetically lethal interactions are
142
also revealed by HIP, therefore using both homozygous and heterozygous mutant
screens is a complementary approach for identifying a cellular target.214
Display of genes Display of proteins
Mutant strain
Wild type
Mutant strain + drug
Viable
Viable
Lethal
x
Drug
x x
Drug
Figure 5.4 Depiction of drug-induced haploinsufficiency. A heterozygous deletion mutant
can only produce half the quantity of a given protein in comparison to wild type yeast.
However, the mutant remains viable except in the presence of a small molecule that targets
the protein encoded by the heterozygous deletion. This sensitises the deletion strain relative
to the wild type.
It is thought that the HIP assay is not applicable to compounds whose primary
cellular target is encoded by an essential gene that is under dosage control.212,213
Upregulation of single gene copies is thought to circumvent the haploinsufficiency
mechanism,213 potentially rendering important drug – gene-product interactions
insignificant. It now appears however, that in general, protein levels in S. cerevisiae
are not directly monitored and adjusted to a desired level.215
5.4 Preliminary studies in S. cerevisiae
As stated in Chapter 4, epiplakinic acid I (95) inhibited both haploid WT and ∆pdr
strains, with IC50 values of 3.36 and 3.50 µmol L 1 respectively and a minimum
inhibitory concentration (MIC) of 10 µmol L 1 (Figure H.1 A ). Plakortolide X
(97) was found to have no effect on the haploid WT strain but inhibited the haploid
∆pdr strain with an IC50 value of 4.45 µmol L 1, and a MIC of 10 µmol L 1 (Figure
H.1 B). These results indicate that 95 is not subject to PDR efflux, whereas 97
may be a substrate for one of the PDR pumps. The primary structural difference
between 95 and 97 is the absence of the free acid in 97, and it is fascinating that
this results in such a difference in biological activity in yeast.
Owing to the robust nature of yeast cells, compounds that affect the growth
of yeast are frequently cytostatic and inhibit their growth rather than killing
Growth curves for all dose response assays can be found in Appendix H
143
them (cytotoxic).216 Some are truly cytotoxic, however, and induce a cell death
process analogous to mammalian apoptosis.216,217 Colony-forming assays showed
that following exposure to 95 for 17 h at its MIC, the drug-treated cells were unable
to reproliferate on solid growth medium on the absence of 95. This is consistent
with 95 causing irreversible cytostatic inhibition of yeast cells or being cytotoxic.
Time-course assessment of the growth effects of 95 in WT yeast, indicated that 95
caused its effects within two hours of treatment at the MIC (Figure 5.5 A).
As cyclic peroxides are thought to affect Ca2 modulation, inhibition assays were
conducted in high and low Ca2 environments. Consistent with 95 and 97
influencing intracellular Ca2 levels, phenotypic enhancement was observed following
co-treatment of WT and ∆pdr cells with a non-inhibitory concentration of CaCl2
and 95 or 97 (Table 5.1 and Figure H.2). Ethyleneglycol tetraacetic acid (EGTA)
is a chelating ligand with a much higher affinity for Ca2 over Mg2 ions, and the
ligand was used to produce a low Ca2 environment.218 No recovery was observed
upon co-treatment of WT cultures with 95 and EGTA (Figures 5.5 B and H.3).
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Figure 5.5 The kinetics of epiplakinic acid I (95) inhibiting S. cerevisiae cells are
unchanged by the presence of EGTA. Plates were incubated for 72 h following inoculation.
A: 95 (10 µmol L 1) for 1 h B: EGTA (50 mmol L 1) and 95 (10 µmol L 1)
The observation of a significant increase in growth inhibition during co-treatment
of cells with 95 and 97 and non-inhibitory concentration of Ca2 is consistent with
95 and 97 affecting intracellular Ca2 levels. However, the absence of phenotype
recovery during co-treatment with EGTA is unexpected if the cyclic peroxides do
affect their toxicity by modulating levels of the Ca2 ion. However, the activities of
95 and 97 may also arise from release of Ca2 from intracellular stores, in addition
to influx of the ion from external sources. As such, an apparent lack of phenotype
recovery may reflect an inability for the ligand to traverse the cell membrane and
internally chelate cytosolic calcium.
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Table 5.1 Synergistic Inhibitory Effects of Cyclic Peroxides 95 and 97 and CaCl2.
Concentration
Agent Strain 95 and 97(µmolL 1)
CaCl2
(mmolL 1) Residual Growth (%) Error ( %)
95 WT 3.33 90.4 0.5
95 WT 3.33 50 13.8 0.5
97 ∆pdr 6.35 104.3 2.5
97 ∆pdr 6.35 50 4.6 9.0
5.4.1 Phenotypic profiling of the cyclic peroxides
Cellular Morphology
Changes in cellular morphology were also analysed during assessment of epiplakinic
acid I (95) and plakortolide X (97). Both compounds were found to decrease cell
size and bud formation, with a similar decrease in cell size observed in response to
CaCl2. Analysis by light microscopy showed a ca. 25% decrease in cell size in drug-
treated populations (Table 5.2 and Figure 5.6).219,220 This may be symptomatic of
cellular starvation. This was also observed using a GFP-tagged plasma membrane
reporter strain (Figure H.5).
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Figure 5.6 Epiplakinic acid I (95), plakortolide X (97) and CaCl2 cause a similar decrease
in cell size in WT and ∆pdr S. cerevisiae strains, respectively.
WT A: DMSO, 1%, 2 h B: CaCl2, 50 mmol L 1, 2h C: 95, 10 µmol L 1, 2h
∆pdr D: DMSO, 1%, 2 h E: CaCl2, 50 mmol L 1, 2h F: 97, 10 µmol L 1, 2h
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Table 5.2 Decrease in Cell Size Caused by 95, 97 and CaCl2 after 2 h.
Agent Strain Concentration Cell Size (µm) Error ( µm)
95 WT 10 µmol L 1 5.6 1.1
DMSO WT 1% 7.2 0.6
CaCl2 WT 50 mmol L 1 4.9 0.6
97 ∆pdr 10 µmol L 1 3.9 1.6
DMSO ∆pdr 1% 8.6 1.1
CaCl2 ∆pdr 50 mmol L 1 4.9 0.6
Cell cycle analyses
The eukaryotic cell cycle consists of four distinct phases: G1-phase, S-phase, G2-
phase (collectively known as interphase), and M-phase (comprising mitosis, in which
the cell’s duplicated chromosomes are divided between the two daughter cells, and
cytokinesis, when the cytoplasm is divided in half, forming distinct cells). Initiation
of each phase relies upon proper progression and completion of the previous phase,
which is ensured by the phase-boundary checkpoints. A fifth phase, G0 or stationary
phase, is entered when cells have temporarily stopped dividing. In yeast, this phase
is entered in response to periods of environmental hardship or cellular starvation.221
As depicted in Figure 5.7, progression through the mitotic cell cycle of S. cerevisiae
can be observed through bud analysis. The G1-S-phase transition is characterised by
the formation of the bud site.222 The bud develops throughout S-phase, concurrent
with DNA replication, as polarised actin migrates within the cell to the bud site,
outwardly distorting the cell membrane and directing growth of the bud in the
direction of polarisation. This continues into G2-phase. Budding yeast differ from
mammalian cells systems in that the replicated genetic material only migrates into
the bud/daughter cell during the G2-M transition. At this point the bud/daughter
cell is fully formed, and nearly the same size as the mother cell, mitosis occurs
followed by cytokinesis and the daughter cells are released.
An increase in small budded cells was observed in WT and ∆pdr cells in response
to 95 and 97, confirmed by bud index (Figure 5.8). This indicated cell cycle delay
during either the G1-S transition, or early S-phase, leading to a decrease of the G2
population. Flow cytometry analysis of WT populations treated with 95 supported
this hypothesis, revealing a 50% increase S-phase populations in cells treated with
95 at the IC50, while treatment at the MIC appeared to inhibit during G2 (Table 5.3
and Figure H.4). These different results may be due to difficulties in distinguishing
between the two phases in yeast via flow cytometry.216
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Figure 5.7 Cell cycle of S. cerevisiae after Calzone et al.223
Table 5.3 Effects of 95 on the S. cerevisiae Cell Cycle.
Phase population (%)
Agent Concentration G1 S G2
95 3.4 µmol L 1 (IC50) 30.5 40.9 58.9
95 7.0 µmol L 1 31.0 18.8 67.1
95 10 µmol L 1 (MIC) 26.9 29.9 52.3
DMSO 1% 40.4 18.4 55.6
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Figure 5.8 S. cerevisiae WT and ∆pdr cell populations displayed a small bud phenotype
when treated with 95 and 97, correlating to an increase in S-phase populations at the
expense of the G2 populations. 1 = no bud, 2 = small bud, 3 = medium, 4 = equal size.
Indicates statistical significance as determined by T-test.
A: WT cells treated with 95, 10 µmol L 1 and DMSO, 1%
B: ∆pdr cells treated with 97, 10 µmol L 1 and DMSO, 1%
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5.5 Chemical genetic profile of epiplakinic acid I
Cyclic peroxides epiplakinic acid I (95) and plakortolide X (97) were both subjected
to genome-wide homozygous profiling. The homozygous diploid deletion set was
used to assess for chemical genetic interactions with 95, while Coorey assessed
97 in a hemizygous screen using the haploid deletion set (∆pdr background).224
Subsequent analysis for haploinsufficiency in the presence of 95 was undertaken
with the heterozygous diploid deletion set. A full tabulation of the HOP and HIP
profiles of 95 can be found in Appendix I.
5.5.1 Homozygous profiling of epiplakinic acid I
Functional annotation of the S. cerevisiae genome can be used to establish functional
and physical relationships between the hits found in a chemogenomic screen.216
Grouping hits according to their gene ontology term annotation with on-line data
analysis software such as FunSpec225 or YeastMine226 has significant advantages as
all of the data used has been experimentally defined.
The removal of strains implicated in multi-drug resistance (MDR) has become
common-place prior to gene ontology-based cluster analysis, owing to the observation
that the inclusion of such genes places a bias on clusters formed within the dataset.210
Conversely, exclusion of MDR hits may lose information salient to the action of a
specific compound. For example genes involved in vesicular mediated transport are
frequently removed as their role in drug efflux recycling is thought to be compound-
non-specific. However, exclusion of these genes from the profile of a compound which
directly affected these processes would severely devalue the chemical genetic screen.
Hence, removal of MDR genes should be done with caution.216
The HOP profile of 95 identified 48 genes whose deletion caused increased sensitivity
to 95. The removal of 19 genes which frequently occur in chemical genetic screens
and five genes encoding dubious open reading frames left 21 genes displaying
chemical genetic interactions in the presence of 95.227 After removal of MDR genes,
the profile of 95 showed functional clustering in the areas of cytoskeleton binding,
vacuolar protein sorting, ribosome biogenesis, metabolism under stress conditions,
response to stress, membrane organisation, Golgi sorting and mitochondrial function
and repair, as classified by FunSpec225 and YeastMine.226 The unfiltered profile
included a number of genes involved in vacuolar protein sorting (Table 5.4). The
HOP profile of 95 did not identify any genes involved in upholding the PDR response,
consistent with 95 not being subject to PDR efflux, as indicated by its similar
activity in both the WT and ∆pdr strains.
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Table 5.4 Functional Categories of Deletion Strains Sensitive to Epiplakinic Acid I (95,
3 µmol L 1).
GO Molecular Functions p-value Gene deletion strain
Cytoskeletal actin polarisation
and cytoskeleton binding 8.844 E-06
end3∆/end3∆, hcm1∆/hcm1∆, rcy1∆/rcy1∆,
rvs161∆/rvs161∆, rvs167∆/rvs167∆, sla1∆/sla1∆,
sli15∆/sli15∆, spo74∆/spo74∆
Golgi sorting 0.002195 apl2∆/apl2∆, chs5∆/chs5∆, gos1∆/gos1∆,och1∆/och1∆, rgp1∆/rpg1∆
Membrane organisation 0.004122 hcm1∆/hcm1∆, spo74∆/spo74∆ and vac7∆/vac7∆
Metabolism under stress
0.001258
aro7∆/aro7∆, crz1∆/crz1∆, csg2∆/csg2∆,
hog2∆/hog2∆, grr1∆/grr1∆, pfk2∆/pfk2∆,
vac7∆/vac7∆
Ribosome biogenesis 0.00048 dbp7∆/dbp7∆, rsa1∆/rsa1∆, rps9b∆/rps9∆,sfp1∆/sfp1∆, tod6∆/tod6∆, yor019w∆/yor019w∆
Divalent cation and heavy
metals sensitivity 0.0009385
csg2∆/csg2∆, vps4∆/vps4∆, crz1∆/crz1∆ and
sod1∆/sod1∆
Vacuolar protein sorting
and transport 3.25 E-06
bro1∆/bro1∆, did2∆/did2∆, snf7∆/snf7,
stp22∆/stp22∆, vps4∆/vps4∆, vps24∆/vps24∆,
vps28∆/vps28∆, vps36∆/vps36∆
* Genes implicated in MDR appear in blue.
Consistent with the small-cell and small-bud phenotype, the HOP profile included
the mutant strains of cytoskeletal genes involved in bud formation and endocytosis;
SLA1, RSA1, RVS161 and RVS167. Sla1p is a cytoskeletal binding protein, required
for assembly of the cortical actin cytoskeleton. Sla1p plays an integral role in both
bud formation and endocytosis through its interactions with proteins regulating
actin dynamics. End3p forms a complex with Sla1p and Pan1p, which is involved in
endocytosis, actin cytoskeletal organisation and cell wall morphogenesis.228 Rvs161p
and Rvs167p interact to regulate polarisation of the actin cytoskeleton and are
directly involved in endocytosis and exocytosis. They also play a role in maintaining
cell polarity and viability in the event of osmotic stress or starvation. Hence,
disruption or impairment of these genes and their functions can be detrimental
to bud formation and endocytosis, consistent with the observed phenotype of 95.
Furthermore, as 95 appears to affect cell size and budding, the deletion of actin-
related genes may result in a synergistic increase in sensitivity to the compound,
down-stream of an initial chemical genetic interaction with 95. Hypersensitivity
of the deletion strains of SLA1, RSA1, RVS161 and RVS167 to 95 was validated
by a dose-response assay (Table 5.5 and Figure H.6), indicating that 95 may affect
related cellular processes, such as actin coordination and endocytosis.
Although implicated in multi-drug resistance, SFP1 is integral to ribosome biogen-
esis in yeast, and genetic deficiency of SFP1 imparts translation-specific defects,
significantly reducing the cell’s ability to synthesise ribosomes, contributing to the
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observed starvation response.229 Hypersensitivity of the deletion strain to 95 may
imply interaction of 95 with the target of rapamycin (TOR) pathway, Section 5.5.7.
Analysis was also undertaken on genes, the deletion of which appeared to confer
resistance to 95 (z-score > 2). The 44 resistant strains were submitted for gene
ontology analysis (FunSpec225), however, time constraints prevented more in depth
analysis of trends within the data. Full tabulation of the analysis can be found in
Table I.4.
Table 5.5 Growth Inhibitory Effects of 95 on Cytoskeletal Deletion Mutant Strains.
Strain Concentration (µmol L 1) Residual Growth (%) Error ( %)
BY4743 WT 3.3 (IC50) 100.3 2.0
sla1∆/sla1∆ 3.3 15.1 3.0
sfp1∆/sfp1∆ 3.3 4.8 0.5
rsa1∆/rsa1∆ 3.3 46.3 3.0
rvs167∆/rvs167∆ 3.3 46.3 5.5
5.5.2 Haploinsufficiency profiling of epiplakinic acid I
The HIP assay identified 124 genes which displayed haploinsufficiency in the presence
of 95, eight of which are classified as essential according to the Saccharomyces
Genome Database,226 (Table 5.6). Eleven genes implicated in multi-drug resis-
tance,227 and 21 genes encoding genes with an unknown function were excluded
from the profile. FunSpec225 cluster analysis of the homozygous gene profile,
and the essential genes indicated by the heterozygous array displayed functional
overlap in ribosome biogenesis (p-value = 0.00048). This may further indicate
interaction of 95 with the TOR starvation response pathway. The HIP profile also
contained many genes functioning to mitochondrial repair, cytoskeletal polarisation
and binding, ribosome generation, and plasma membrane organisation.226 The
combined HOP and HIP profiles displayed functional clustering in response to
Zn2 ions (p-value = 0.000192), and Zn2 homeostasis (p-value = 0.009733) as
determined by FunSpec.225 The 99 strains deemed to display resistance to 95 (z-
score > 2) were similarly assessed by FunSpec cluster analysis, a full tabulation of
which can be found in Table I.5. Significant insight into the biological mechanisms
of small molecules can be gained through analysis of resistant deletion strains,
and is worth undertaking. However, complete analysis and investigation of the
resistant deletion strains was prevented by the time constraints on this project.
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Table 5.6 Functional Categories of Deletion Strains Haploinsufficient to Epiplakinic
Acid I (95, 2 µmol L 1).
GO Molecular Functions Gene deletion strain*
Metal ion homeostasis ddp1∆/ddp1∆, inp52∆/inp52∆, irc7∆/irc7∆,
izh1∆/izh1∆, izh2∆/izh2∆, ybr016w∆/ybr016w∆
Cytoskeletal polarisation
and binding
abp140∆/abp140∆, cik1∆/cik1∆, ede1∆/ede1∆,
kin4∆/kin4∆, mad3∆/mad3∆, nap1∆/nap1∆,
pcl1∆/pcl1∆, rax1∆/rax∆1
Ribosomal subunit proteins asc1∆/asc1∆, crf1∆/crf1∆, rcl1∆/rcl1∆,
rpl27A∆/rpl27A∆, rpl33A∆/rpl33A∆,
rpl39∆/rpl39∆, rps14B∆/rps14B∆,
rps15∆/rps15∆, sip1∆/sip1∆,
ydr223w∆/ydr223w∆, yor019w∆/yor019w∆
RNA binding proteins prp43∆/prp43∆, rpc1∆/rpc10∆, tan1∆/tan1∆,
ygl232w∆/ygl232w∆, yra2∆/yra2∆
Mitochondrial and oxidative
stress conditions
aim2∆/aim2∆, aim14∆/aim14, crc1∆/crc1∆,
cox17∆/cox17∆, maf1∆/maf1∆, mne1∆/mne1∆,
mrm2∆/mrm2∆, mrpl11∆/mrpl11∆,
mrpl16∆/mrpl16∆, mrs1∆/mrs1∆, pxr1∆/pxr1∆,
rps7A∆/rps7A∆, yir003w∆/yir003w∆
Golgi sorting gga1∆/gga1∆, gmh1∆/gmh1∆, ste13∆/ste13∆,
tvp23∆/tvp23∆
Utilisation of alternative carbon
sources
ath1∆/ath1∆, dal7∆/dal7∆, gac1∆/gac1∆,
gal3∆/gal3∆, pyk2∆/pyk2∆, tps1∆/tps1∆,
ysa1∆/ysa1∆
Amino acid biosynthesis ado1∆/ado1∆, asi1∆/asi1∆, car2∆/car2∆,
fsh3∆/fsh3∆, gnp1∆/gnp1∆, imd3∆/imd3∆,
map2∆/map2∆, pho81∆/pho81∆, stp2∆/stp2∆,
thi12∆/thi12∆, yfr055w∆/yfr055w∆
Fatty acid biosynthesis fox2∆/fox2∆, frm2∆/frm2∆, ylr400w∆/ylr400w∆
Plasma membrane organisation ast1∆/ast1∆, azr1∆/azr1∆, erv46∆/erv46∆,
rrt8∆/rrt8∆, sur2∆/sur2∆, pmt6∆/pmt6∆,
pst1∆/pst1∆, yeh1∆/yeh1∆
Meiosis mum3∆/mum3∆, ndt80∆/ndt80∆, osw1∆/osw1∆,
slz1∆/siz1∆, ssp2∆/ssp2∆, vhs1∆/vhs1∆
DNA assembly and repair hht1∆/hht1∆, rad4∆/rad4∆, rts2∆/rts2∆,
shu1∆/shu1∆, ubr2∆/ubr2∆
Transcription rtr1∆/rtr1∆, rtr2∆/rtr2∆, ynl187w∆/ynl187w∆
Protein synthesis eug1∆/eug1∆, ost5∆/ost5∆, ptp1∆/ptp1∆,
ssa3∆/ssa3∆
Proteosome degradation pci1∆/pci1∆, yuh1∆/yuh1∆
* Essential genes appear in blue.
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5.5.3 Plakortide F acid
Comparison of the gene expression profile of plakortide F acid (122)169 and the
homozygous profile of 95 proved informative. Plakortide F acid (122) induces
upregulation of genes associated with response to stress, protein transport and
sorting, carbohydrate metabolism, organelle organisation, amino acid metabolism,
membrane organisation, cell wall organisation and sporulation. Functions pertaining
to the activity of 95, namely cell cycle and ribosome biogenesis experienced
downregulation in the presence of 122. Their study also showed an overall increase
in intracellular Ca2 and Zn2 -levels by ICP-MS.169
Only one direct overlap was observed between the RNA-expression profile of 122169
and the homozygous profile of 95 - the Ca2 -sensitive stress response transcription
factor Crz1p, which is activated in response to elevated Ca2 levels (Sections
5.5.5 and 5.5.6). Other calcium-responsive genes to experience upregulation in
the presence of 122 included those encoding membrane bound ion pumps and
ion channels. Calcium influx through the plasma membrane is mediated by the
Ca2 channels Cch1p and Mid1p, as shown in Figure 5.9. Intracellular levels are
modulated by the pumps Pmr1p and Pmc1p, with Pmr1p sequestering Ca2 and
Mg2 within the Golgi bodies. Pmc1p and the H /Ca2 exchanger Vcx1p affect
Ca2 detoxification by increasing vacuolar storage, while Vcx1p will also release
vacuolar Ca2 stores into the cytoplasm in response to hyperosmotic stress.169,226,230
Table 5.7 Functional Categories of Genes Differentially Regulated in the Presence of
Plakortide F Acid (122).
Status Functional category
Upregulated Response to stress
Transport
Carbohydrate metabolism
Transcription
Protein modification
Organelle organisation
Amino acid metabolism
Membrane organisation
Cell wall organisation
Sporulation
Downregulated Cell cycle
Ribosome biogenesis
Conjugation Translation
Amino acid metabolism
Signal transduction
Meiosis
Sensitivity of the ion channel and ATP-pump deletion strains to plakortide F acid
This is not unexpected: 7% is the highest reported overlap between the two techniques,
observed when galactose is provided as a carbon source as opposed to glucose.76
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(122) was established by Xu et al.169 The ATP-pump mutants pmr1∆/pmr1∆
and pmc1∆/pmc1∆ and the ion channel mutants cch1∆/cch1∆ and mid1∆/mid1∆
displayed hypersensitivity to epiplakinic acid I (95) relative to the WT control.
As Cch1p and Mid1p are required for passage of Ca2 into the cells, deletion of
the genes should confer resistance. Hence, sensitivity of the deletion mutants to the
cyclic peroxides is counterintuitive. However, one can imagine that the channels also
allow exit of ions from within the cell, mitigating intracellular toxicity. Xu et al. also
postulate that “Ca2 deprivation in these mutants might result in a compensatory
induction in intracellular Ca2 levels, causing 122 (and 95) to be more toxic under
these conditions”.169
Calcineurin
Crz1
Ca2+
Ca2+
Vacuole
Golgi
PMC1, PMR1, PMR2, FKS2...
Pmc1
Vcx1
Ca2+
Pmr1
H+
Cch1 Mid1
Pmr2
Li+
Na+
Figure 5.9 Depiction of the ion-channel and ATP-pump system for Ca2 homeostasis in
S. cerevisiae, adapted from Miyakawa et al.230
Another Ca2 -modulating agent, amiodarone,231 is thought to interact with Mid1p.232
Courchesne et al. observed some resistance of the mid1∆,cch1∆ double deletion to
amiodarone. Furthermore, the mid1∆/mid1∆ strain did not show the same growth
inhibition as the cch1∆/cch1∆ strain in response to amiodarone. Sensitivity of the
Mid1p and Cch1p deletion strains to 122 and 95 indicates that neither are the
cellular target of the cyclic peroxides 122 and 95. However, the compounds could
potentially interact with the membrane-bound ion channels of another divalent ion,
such the Fe2 transporter Fet3p. The Mid1p and Cch1p channels has been shown
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to be essential to iron toxicity tolerance,233 as such it is not unreasonable that a
reciprocal interaction may be occurring.
Consistent with plakortide F acid (122) increasing intracellular levels of Ca2 and
causing Ca2 stress, Xu et al. also observed hypersensitivity in the deletion strain
of genes essential to the function of calcineurin, a Ca2 /calmodulin-dependent
protein phosphatase. CNB1 encodes the regulatory subunit of the calcineurin
heterodimer in yeast and the catalytic subunit of calcineurin is encoded by the
functionally redundant genes CNA1 and CNA2.218 Mutation of both CNA1 and
CNA2, and the regulatory gene CNB1, or exposure to calcineurin inhibitors such
as FK506 and cyclosporin A compromises activity of the calcineurin phosphatase.
CRZ1 encodes a Ca2 -responsive transcription factor that directs calcineurin-
dependent transcription genes to mitigate Ca2 toxicity. Hypersensitivity to 122
was displayed by the strains crz1∆/crz1∆, cnb1∆/cnb1∆, cna1∆/cna1∆ and
cna2∆/cna2∆.169 The deletion strains crz1∆/crz1∆, and cna2∆/cna2∆ displayed
similar hypersensitivity to epiplakinic acid I (95). Slight sensitivity was observed in
the cnb1∆/cnb1∆ strain, although assessment over a more restricted concentration
range is required for definitive conclusion. Unexpectedly, the cna1∆/cna1∆ strain
did not display sensitivity to 95 (Tables 5.8, 5.9 and Figure H.7).
Table 5.8 Growth Inhibitory Effects of 95 on Ca2 -Responsive Deletion Strains.
Strain Concentration (µmol L 1) Residual Growth (%) Error ( %)
BY4743 WT 7.6 99.0 5.0
cna1∆/cna1∆ 7.6 70.5 3.0
cna2∆/cna2∆ 7.6 7.1 2.5
cnb1∆/cnb1∆ 7.6 11.5 4.5
crz1∆/crz1∆ 7.6 4.7 3.5
hcm1∆/hcm1∆ 7.6 42.3 0.5
Table 5.9 Growth Inhibitory Effects of 95 on Ca2 -Pump/Channel Deletion Strains.
Strain Concentration (µmol L 1) Residual Growth (%) Error ( %)
BY4743 WT 3.3 113.3 2.0
cch1∆/cch1∆ 3.3 56.9 1.2
mid1∆/mid1∆ 3.3 4.5 0.5
pmc1∆/pmc1∆ 3.3 69.3 5.2
pmr1∆/pmr1∆ 3.3 56.2 1.1
ygl167w∆/ygl167w∆ 3.3 3.5 0.5
The calcium-modulated protein, calmodulin is a calcium-binding protein conserved in all
eukaryotic systems. It can bind up to four calcium ions, and once activated it binds to and
regulates many different protein targets affecting a myriad of cellular responses.
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5.5.4 The Ca2 second messenger system
Calcium ions are integral to many physiologically important functions, including
cytoskeletal dynamics, and as key regulators of the protein calmodulin, the ions
play a pivotal role in muscle contraction in higher eukaryotes. The ion is an
important second messenger, relaying signals from cell surface receptors to target
molecules within the cell (in the cytoplasm or nucleus), inducing changes in
cellular activity, and amplifying the strength of the initial signal through signal
transduction cascades.§ The Ca2 second messenger system acts through cellular
traffic of the metal ions via membrane ion channels and membrane-bound ion
pumps, carefully monitoring cytoplasmic and organelle-located stores of the ion.
The second messenger must be tightly controlled as disruption to the system has
far-reaching effects, and as such, foreign molecules which in any way influence this
system can be extensively detrimental to cellular function. While Ca2 -overload
can trigger apoptosis in mammalian cells,234 decreased viability of WT S. cerevisiae
has not been reported in response to disruption of Ca2 levels alone.235 As such,
a rise in intracellular Zn2 levels could also contribute to the cellular starvation
phenotype induced by 95 and 97. Translocation studies in the Zrt1p-GFP strain do
not necessarily support this, however. In response to increased intracellular Zn2 ,
the Zn2 -specific membrane pump, Zrt1p, is rapidly endocytosed then degraded in
the vacuole.236 This response was not apparent upon exposure of the Zrt1p-GFP
strain to 95 for 40 min (Figure H.8). This may indicate that 95 does not increase
intracellular levels of Zn2 . However, if 95 does inhibit actin coordination, the lack
of Zrt1p endocytosis may be accounted for.
5.5.5 Epiplakinic acid I induces a Ca2 -related response
Translocation studies were conducted in the Crz1p-GFP strain showing nuclear
relocalisation of the GFP signal upon exposure to CaCl2 or epiplakinic acid I
(95). This indicates that 95 induces the same cellular response as a spike in
intracellular Ca2 . Coorey observed similar relocation in the Crz1p-GFP-∆pdr
strain in response to plakortolide X (97),224 consistent with 95 and 97 inducing
a spike in intracellular Ca2 . Illustrating the Ca2 -specificity of the Crz1p response,
the Crz1p-GFP displayed weak and transient nuclear relocalisation upon exposure
to Mg2 , Zn2 and Fe2 (data not shown). The calcium-modulator amiodarone also
induces translocation in the Crz1p-GFP strain,237 indicating the two compounds
§There are three main classes: hydrophilic molecules such as cAMP, cGMP, IP3, and Ca2
located in the cytosol; hydrophobic molecules, including diacylglycerol, and phosphatidylinositols
are associated with cellular membranes and diffuse from the plasma membrane into the
intermembrane space where they can affect membrane-associated effector proteins; gases, such
as NO, CO and H2S form the third division, and are capable of diffusing both through the cytosol
and across cellular membranes.
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may have similar cellular effects. Amiodarone also induces a starvation response and
decreases cell size, while flow cytometry studies with amiodarone have indicated cell
cycle delays at both S-phase and the G2-M transition as seen with 95.237
A B                        C
D                        E                        F
G                        H                        I
Figure 5.10 Translocation studies in the Crz1p-GFP strain indicating a similar response
to a rise in intracellular Ca2 and exposure to epiplakinic acid I (95).
A: DMSO (1%), 0 min B: 95 (10 µmol L 1), 0 min C: CaCl2 (50 mmol L 1), 0 min
D: DMSO, t = 5 min E: 95, t = 5 min F: CaCl2, t = 5 min
G: DMSO, t = 40 min H: 95, t = 40 min I: CaCl2, t = 40 min
Qualitative staining of WT cells with Calcium Orange fluorescent dye also indicated
an increase in cellular Ca2 levels in response to epiplakinic acid I (95). Consistent
with 95 causing an increase in intracellular Ca2 levels, the fluorescence intensity
of the Calcium Orange probe was increased in WT cells treated separately with 95
and CaCl2, relative to the DMSO control (Figure 5.11). This is in agreement with
Xu et al. who observed an increase in the intracellular levels of Ca2 and Zn2 in
WT cells exposed to plakortide F (122) by ICP-MS analysis.169
Increased Ca2 signaling is known to contribute to formation of reactive oxygen
species (ROS), and associated cellular toxicity.238 Although a significant number of
genes implicated in mitochondrial damage and response to oxidative stress displayed
sensitivity to 95 in the HOP and HIP assays, no evidence for formation of ROS was
found. To test for the formation of ROS in the presence on 95, translocation studies
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were conducted in a GFP-tagged reported strain with a red fluorescent protein
(RFP) nuclear membrane localisation marker, Yap1p-GFP-NLS-mCherry. Yap1p is
a stress response transcription factor, which normally resides in the cytoplasm and
translocates to the nucleus in response to oxidative stress. Co-localisation of the
GFP and RFP signals was not observed in response to 95, indicating that Yap1p
did not undergo nuclear relocalisation (data not shown). This suggests that 95 does
not cause the formation of ROS.
Flow cytometry analysis was also carried out in haploid WT cells using with
dichlorofluorescein diacetate (DCF-DA) and propidium iodide (PI) to study the
formation of ROS and cell death (Figure 5.12). Although PI staining in the upper left
quadrant indicated increased cell death in presence of 95, the assay did not indicate
that formation of ROS was responsible for the increase. However, PI staining is
indicative of increased cell wall permeabilisation as a consequence of cell death, and
as such this may indicate that 95 (and presumably 97) is truly cytotoxic to yeast.
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Figure 5.11 Qualitative staining of WT cells with Calcium Orange dye.
A: DMSO, 1% B: CaCl2, 50 mmol L 1 C: Epiplakinic acid I, 10 µmol L 1
Increased fluorescence intensity is indicative of Ca2 -coordination by the fluorophore, as
observed in the presence of CaCl2 (B) and 95 (C), relative to the DMSO control (A).
5.5.6 Calcineurin signaling
In S. cerevisiae calcineurin is required to maintain cell viability, becoming activated
in response to environmental conditions, including exposure to high intracellular
levels of Ca2 and Na , and to elevated temperature. In yeast (and mammals),
Crz1p is the best-characterised substrate for activated calcineurin.239,240 The
transcription factor Crz1p resides in the cytoplasm when calcineurin signaling is low,
and is dephosphorylated upon activation of calcineurin, rapidly translocating to the
nucleus where it affects cellular responses to mitigate Ca2 toxicity. In addition to
its role in yeast ion homeostasis, calcineurin is involved in recovery from G1 arrest
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caused by mating pheromones, such as α-factor,240 and is essential to the function
of deletion strains with defective cell walls.239,241
A B                           C
Figure 5.12 Flow cytometry imaging ROS formation with DCF-DA and PI in haploid
WT cells.
A: Epiplakinic acid I, 10 µmol L 1 B: H2O2, 10 µmol L 1 C: DMSO, 1%
The lower quadrants represent live cells stained with DCF-DA and cell death is indicated
by PI staining of the populations in the top left quadrant. As indicated by the controls,
the majority of the live cell population predominantly occupies the left quadrant, while a
shift to the right indicates the presence of ROS. The increased cell death observed in the
presence of 95 does not appear to be caused by the generation of ROS.
Upon activation of calcineurin, a suite of genes required for ion homeostasis is upreg-
ulated in a calcineurin/Crz1p-dependent manner. Following nuclear relocalisation,
Crz1p binds specifically to a region of 24 base pairs within the promoter regions of the
upregulated genes, termed the calcineurin dependent response element (CDRE). In
this way, Crz1p functions downstream of calcineurin to affect calcineurin-dependent
responses that mitigate Ca2 -related toxicity. Overproduction of Crz1p in WT cells
also increases tolerance to Mn2 and Li , and is known to suppress the phenotypes
of calcineurin mutants.242
The ion homeostasis genes which experience calcineurin/Crz1p-dependent regulation
include the vacuolar and Golgi-bound Ca2 and Ca2 /Mn2 -ATPases encoded by
PMC1 and PMR1 (Figure 5.9).218,242 The ion-pumps are integral to intracellular
ion homeostasis, and their Crz1p-mediated transcription is required for growth
under high Ca2 conditions. PMR2 encodes a plasma membrane Na /Li -ATPase
required for growth in the presence of high concentration of the two ions. Expression
of the pumps is induced by (high) Ca2 and Na in a calcineurin/Crz1p-dependent
manner, and in response to high osmotic stress by the high osmolarity glycerol
(HOG1) pathway. Deletion of these genes confers sensitivity to 95 (Figure H.7) and
122.
Independent of Crz1p, increased calcineurin signaling also causes depolarisation
of the actin cytoskeleton (Section 5.5.7). Mulet et al. observed formation of
small actin balls about the cellular peripheries upon brief exposure to 0.2 mol L 1
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CaCl2,241 although the effect was observed simultaneously in wt, cnb1∆/cnb1∆ and
crz1∆/crz1∆ mutants, indicating actin depolarisation is independent of Crz1p.¶
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Figure 5.13 Calcineurin signaling pathway in S. cerevisiae and activation of Crz1, adapted
from Yoshimoto et al.243 Calcineurin is activated by external stimuli, including elevated
temperature and levels of Na and Ca2 , and presence of the mating pheromone α-factor.
Calcineurin dephosphorylates Crz1, which undergoes nuclear translocation and initiates
Ca2 -dependent transcription of genes, such as FKS2, containing the CDRE in their
promoter regions. The calcineurin signaling cascade is rapidly and specifically inhibited
by the presence of immunosuppressive drug FK506.
5.5.7 Interactions between calcineurin signaling and TOR
The TOR pathway is conserved among eukaryotes, controlling cell growth in
response to nutrient availability and environmental stress. The TOR protein kinase
comprises two functionally and structurally distinct protein complexes, TORC1
(TOR complex 1) and TORC2. In yeast, TORC1 contains either TOR1 or
TOR2, whereas TORC2 contains exclusively TOR2. TORC1 is rapamycin-sensitive
and controls growth-related processes such as transcription, translation, ribosome
biogenesis, nutrient transport and autophagy in response to nutrient levels.220
Inactivation of TORC1 leads to a rapid downregulation of genes involved in ribosome
biogenesis, with the carryon effect of decreased protein synthesis and cell growth.245
TORC2 is rapamycin-insensitive and controls polarisation of the actin cytoskeleton,
acting to inhibit calcineurin-mediated depolarisation of the actin cytoskeleton. In
this way, TORC2 allows a cell to resume growth after a stress has been overcome.241
The TORC2-calcineurin relationship is mutually antagonistic, and a downstream
effect of increased Ca2 levels and calcineurin signaling is inhibition of the TOR
¶A similar phenotype is seen upon exposure to latrunculin A, known to stabilise monomeric
actin by coordinating to thymosinβ.244
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pathway (Figure 5.14).246 Calcineurin prevents TOR-mediated growth under stress
conditions in one way by inhibiting signaling between TORC2 and the proteins
Slm1p and Slm2p, which act to regulate the actin cytoskeleton organisation in
response to stress.247 Increased Ca2 levels and calcineurin signaling promote
dephosphorylation of the SLM proteins disrupting their function in actin regula-
tion.241 Hence, calcineurin-activating agents, such as 122 and potentially 95 can
initiate depolarisation of the actin cytoskeleton leading to the phenotype observed
in this study. Similarly, TORC2 phosphorylation of Slm1p and Slm2p inhibits
calcineurin-mediated depolarisation of the actin cytoskeleton and Crz1p-dependent
gene transcription.
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Figure 5.14 Antagonistic interactions between the calcineurin and TORC2 signaling
pathways after Mulet et al.241
Inactivation of the TOR pathway, or treatment with rapamycin, produces a
phenotype similar to that of epiplakinic acid I (95) and plakortolide X (97).
Rapamycin inhibits cell cycle progression, initiating arrest at the G1-S phase
boundary, and induces physiological changes consistent cellular starvation, including
reduced cell size.219 Xu et al. observed that co-treatment of cells with plakortide
F acid (122) and non-inhibitory concentrations of calcineurin-specific inhibitors
FK506 and cyclosporin A greatly enhanced the potency of 122.169 From this one
can infer that 122, and presumably compounds 95 and 97, influence a cellular
process closely related to that of FK506 and cyclosporin A, i.e. calcineurin signaling.
Additionally, cyclosporin A has a similar effect as plakinid cyclic peroxides on Ca2 -
pumping in the mammalian cardiac sarcoplasmic reticulum.120,197,248
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5.6 Mechanistic insights from phenotypic and
chemical genetic profiling
The phenotypic profiling assays carried out during this study, in combination
with the expression profile of 122, suggests that 95 disrupts intracellular Ca2
homeostasis. Translocation of the Ca2 -responsive transcription factor Crz1p was
observed in the GFP strain following exposure to 95 and the same response was
observed following addition of exogenous Ca2 to growth media (Figure 5.10). This
alone indicates that 95 causes increases in intracellular Ca2 . An overall increase in
cellular Ca2 following exposure to 95 was also shown by Calcium Orange staining
(Figure 5.11). Furthermore, the deletion strains of CCH1, CNA2, CNB1, CRZ1,
MID1, PMC1 and PMR1, which are required to mitigate Ca2 toxicity, displayed
hypersensitivity to 95 (Tables 5.8 and 5.9). Disruption of Ca2 homeostasis could
account for the phenotype caused by 95; reduced cell size and an increase in cells
with small buds. The same decrease in cell size was observed following the addition
of exogenous CaCl2 to yeast growth media (Table 5.2 and Figure 5.6).
Although the deletion strains of several genes integral to cell viability in environ-
ments of high Ca2 were revealed in the HOP and HIP profiles of 95, significant
enrichment of these functions was not indicated via FunSpec cluster analysis. It may
be that when a small molecule inhibits a process so fundamental to cellular function,
such as Ca2 signaling, that too many pathways are affected to allow statistically
significant enrichment of any one particular process. Such a phenomenon has also
been hypothesised in the case of protein synthesis inhibitors, such as pateamine
A.216 The combined HOP and HIP profiles of 95 did display enrichment in
Zn2 homeostasis (p-value = 0.009733) and response to Zn2 ions (p-value =
0.000192), although the p-values associated with the enrichment does not appear
particularly significant if disruption of ion homeostasis is the primary mechanism of
the compound. Enrichment in Zn2 regulation is, however, consistent with Xu et
al. who observed increases in intracellular Zn2 and Ca2 in response to 122. In
light of this dual increase in levels of the ions, it may be that the cyclic peroxides
are causing an increase in intracellular levels of either Zn2 or Ca2 , with a down
stream effect of interfering with homeostasis of the other. Hence, both Zn2 and
Ca2 may be responsible for inhibition of yeast cells by 95 and 97.
5.6.1 Future directions
The mechanism by which the cyclic peroxides 95, 97 and 122 raise intracellular ion
levels requires addressing. Membrane hyperpolarisation has been hypothesised in the
case of amiodarone; the amphiphilic molecule and has been shown to associate with
161
the plasma membrane of yeast cells, hyperpolarising the membrane, which may allow
influx of the ion.237 Epiplakinic acid I (95), plakortolide X (97) and plakortide F acid
(122) could also behave in this manner given their polar cyclic peroxide moieties and
aliphatic backbones. The aliphatic portions of the three compounds, particularly
the C12 and C10 carbon chains of 95 and 97, could potentially incorporate into
the plasma membrane. This could induce membrane curvature allowing both the
passage of the compounds into the cell, and influx of Ca2 and/or Zn2 into the
cytoplasm.
Interaction of 95 and 97 with membrane-bound ion pumps and channels is a likely
mechanism by which cytosolic ion levels could rise. Efforts were made during this
study towards the construction of a suite of strains carrying ion pump deletions and a
corresponding GFP reporter (Table 5.10). Once compiled, the suite of GFP/deletion
strains will be assessed for response to Ca2 and Zn2 -induced stress. ZAP1
encodes a Zn2 -responsive transcription factor, which resides in both the nucleus and
cytoplasm. Unlike Crz1p, Zap1p does not undergo nuclear translocation, however,
application of FRET dyes to Zap1p can allow in vivo observation of Zn2 traffic.249
Analysis of both transcription factors in the absence of membrane-pumps should
provide insight into the mechanism of these cyclic peroxides.
Table 5.10 Proposed Ion Pump Deletion-GFP Strains
Target genes
Target metal ion Deletion GFP-reporter
Ca2 mid1∆ Crz1p-GFP
Ca2 cch1∆ Crz1p-GFP
Ca2 pmc1∆ Crz1p-GFP
Ca2 pmr1∆ Crz1p-GFP
Ca2 cch1∆, mid1∆ Crz1p-GFP
Ca2 and Zn2 zrt1∆, zrt2∆ Crz1p-GFP
Ca2 and Zn2 cch1∆, mid1∆ Zap1p-GFP
Zn2 zrt1∆, zrt2∆ Zap1p-GFP
Imaging studies will also be undertaken to further characterise the cellular effects of
95, including actin labeling with a fluorescent phalloidin conjugate, and visualisation
of the endocytotic pathway with the fluorescent dye FM4-64FX. The effects of
increased Zn2 on cell size and the impact of exogenous Ca2 and Zn2 on bud
formation will also be assessed.
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5.6.2 Concluding remarks
In summary, phenotypic and chemical genetic assessment of epiplakinic acid I (95)
suggests that the growth inhibitory effects of 95 are caused by increased intracellular
Ca2 levels, leading to an increase in small budded cells and reduced cell size. This
verifies the work of Xu et al.169 which attributes Ca2 -modulatory behaviour to the
structurally related plakortide F acid (122). It may also be that increased levels of
intracellular Zn2 contribute to the activity of 95 and 122 in yeast.
Increases in cytosolic levels of Ca2 and potentially Zn2 may occur through
interaction with the cyclic peroxide and either a membrane-bound ion pump or
channel, or with the membrane itself. As such, generation of the ion pump deletion-
GFP strains is integral to elucidation of this mechanism, and future research will
focus on the generation of these strains. Analysis of the double deletion mutants in
particular should grant insight into the mechanism behind the activity of this class
of compounds.
Unfortunately, further characterisation may be prevented owing to insufficient
quantities of the cyclic peroxides available for analysis. This thesis has benefited
from the assessment of specimens with a small sample size, however, this is a
limiting factor for this particular arm of research. Complete characterisation of
these compounds may be postponed until recollection of the same organism, or one
containing similar metabolites.
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Chapter 6
Concluding Remarks
Natural products chemistry continues to play an important role in the identification
of new pharmaceutical leads for the development of new therapeutic agents. Using
a spectroscopy-guided isolation approach, the metabolite profiles of nine Tongan
sponge specimens were investigated during this research. Analysis of HMBC
experiments acquired from semi-purified fractions from each organism was integral
to their selection for study. In order to maximise the probability of uncovering
structural novelty in a well-explored environment, only specimens collected in
small quantities and those with sparse distribution were chosen for investigation.
While this particular facet presented challenges and restricted creative freedom
during chromatography, it was also rewarding with seventeen new metabolites
expediently isolated from five different organisms over the course of this study.
These include two hydroxybutenolide sesterterpenes 23 and 24, and the alkaloid
14-bromohomofascaplysin (29). As five of the four sponges that afforded new
metabolites were collected from ‘Eua island, further investigation of organisms from
this location in particular may be worthwhile.
Three labdane diterpenes, luakuliides A–C (33–36) were isolated from an uniden-
tified dictyoceratid sponge. The gem-dimethyl pair, characteristic of the labdane
skeleton was evident in the HMBC experiment of the screening fraction, prompting
further purification of the fractions. The luakuliide skeleton also features a hemi-
acetal moiety bridging the B-ring of the labdane bicycle. Luakuliide A (33) and its
acetal derivative (34) were found to modulate NO and TNF-α levels in macrophages,
demonstrating their immunomodulatory potential.
Investigation of two plakinid sponge specimens yielded the α-pyrones lehualides E–K
(69–75), and a series of cyclic peroxides (95–98). In both cases the observation of
heavily oxygenated sub-structures prompted further investigation of the organisms.
The non-protonated nature of the major functional groups in both the lehualides
and the cyclic peroxides makes it unlikely that either of these structural classes
would have been revealed during spectroscopic organism screening without analysis
of the HMBC experiment.
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Structural elucidation of the fully-substituted α-pyrone system of lehualides E–K
(69–75) presented a challenge. Similarly unprotonated systems have previously been
proposed on the basis of chemical shift alone, however, the substitution pattern of
the compounds found in this study allowed for the unequivocal establishment of the
α-pyrone substructure. Lehualides H–K (72–75) also demonstrate several different
sulfur-containing functional groups. The presence of the NMR-silent 32S nuclei was
determined by analysis of 1JCH couplings of adjacent methylene and methyl centres.
However, unequivocal identification of the functional groups required synthetic
modeling of the proposed structural fragments and analysis of their 1H and 13C
NMR spectra.134 Although NMR spectroscopy is an important tool to structural
elucidation, the technique has its limits. As such it is important to provide further
evidence of a structure wherever possible, be it through chemical derivatisation,
X-ray analysis of an isolated compound, or synthesis.
A variety of cyclic peroxides have been uncovered from plakinid sponges, however,
the isolation of multiple classes from one organism is less frequently observed. In this
case, three different polyketide cyclic peroxide classes, including the rare 1-hydroxy-
1,2-dioxolane metabolite 98, were encountered alongside two 5α,8α-epidioxysterols.
Cyclic peroxides 95–98 all displayed demonstrated potent inhibition of the HL-60
cell line, with the more heavily oxygenated compounds affecting greater inhibition.
As such, the significantly decreased sensitivity of HL-60 cells to 97 compared with
95 and 98 may be due to the absence of the free carboxylic acid moiety.
Isolation of secondary metabolites without knowledge of their biological potential
requires a technique capable of delivering an unbiased assessment of biological
activity. Genome-wide profiling assays were conducted in an attempt to biologically
characterise epiplakinic acid I (95), using the Saccharomyces cerevisiae homozygous
and heterozygous diploid deletion sets. This study required the development of
new laboratory techniques, and an understanding of foreign experimental concepts.
Although no definitive cellular target was determined, this study verified the widely
held opinion that plakinid cyclic peroxides disrupt cellular calcium homeostasis.
While in this instance chemical genetic screening was not successful in identifying the
precise mechanism of action of a small molecule, it has indicated specific assays that
could pinpoint the precise molecular target of the molecule. Future research into
the elucidation of this mechanism is planned, although the realities of isolation from
rare organisms may prevent these characterisation studies. While the investigation
of uncommon organisms from geographically isolated locations may yield structural
novelty, recollection difficulties can hinder the development of new bioactives.
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Chapter 7
General Experimental Procedures
Optical rotations were performed on a Autopol II Automatic Polarimeter while UV
spectra were acquired on an Agilent 8453 UV/Visible Spectrometer and IR spectra
were recorded using a Perkin Elmer Spectrum One FT-IR spectrometer. NMR
spectra were obtained using a 600 MHz Varian DirectDrive spectrometer equipped
with a triple resonance HCN cryogenic probe, operating at 600, 150 and 60 MHz
for 1H, 13C and 15N nuclei, respectively. All HSQC spectra were acquired without
carbon-decoupling. Spectra were recorded in CD3OD (Cambridge Isotopes), CDCl3
(Merck), (CD3)2SO (Cambridge Isotopes) and C6D6 (Cambridge Isotopes), with
chemical shifts δ (ppm) referenced to the residual solvent peak [(CD3OD: δC 49.00,
δH 3.31), (CDCl3: δC 77.16, δH 7.26), ((CD3)2SO: δC 39.52, δH 2.50) and (C6D6:
δC 128.06, δH 7.16)].250 HRESIMS measurements were obtained using a Waters Q-
TOF PremierTMTandem Mass Spectrometer.
GFP and RFP cell studies were performed on a Perkin Elmer EvoTec OPERA. GFP
and RFP were excited using 488 nm and 561 nm with emission fluorescence collected
through 520/35 and 600/40 bandpass filters respectively. Cells were imaged using an
Olympus IXF1 optical microscope operating with a CC12 Soft Imaging System. Cell
growth was quantified using a using a Wallac EnVision 2102 Multilabel Plate Reader
(Perkin Elmer) while cell population studies were performed on a FACS CantoTMII
Flow Cytometer (BD HTS) and manipulated on FlowJo version 7.6.1 flow cytometry
analysis software (Tree Star Inc., Ashland, OR, USA). Cultures were concentrated
using an Eppendorf 5810 Centrifuge and a 5415 R Microcentrifuge and suspended
with a TallBoys Standard Vortex Mixer and an Eppendorf MixMate plate mixer.
2,3-Dihydroxypropoxypropyl-derivatised silica gel (DIOL) was used for all normal-
phased column chromatography while Supelco dianion HP20 and HP20SS polystyrene
(divinylbenzene) resins were used for reversed-phase column chromatography unless
otherwise stated. Size exclusion chromatography was performed using Sephadex
LH20. HPLC-grade CH2Cl2 (Merck) and MeCN (Fluka) were used for general
puposes and for HPLC purification, all other solvents (including H2O) were distilled
from glass immediately prior to use. TLC analyses were performed using Machery-
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Nagel Alugram Sil G/UV254 plates. The plates were analysed by fluorescence
quenching under UV light (λ = 254 nm) followed by dipping in 5% H2SO4 in
MeOH then dipping in 0.1% vanillin in EtOH and heating. Chemical reagents
were purchased from Sigma-Aldrich and Penta International Corporation, unless
otherwise specified, and used without further purification.
7.1 Isolation of new diterpenes from PTN3_45E
7.1.1 Animal material
A garlic-odoured specimen, PTN3_45E (96 g) was collected from the vertical
rock sides of Tu’ungasika Island in the Vava’u group, at a depth of 12–15 m in
November 2009. The specimen was frozen immediately and maintained at –18 C
until extraction. A voucher specimen (PTN3_45E) has been deposited at the School
of Chemical and Physical Sciences, VUW, Wellington.
7.1.2 Extraction of PTN3_45E
A frozen 24 g sample was extracted twice in 100 mL MeOH overnight. The filtered
extracts were passed through a column of 40 mL HP20 resin in reverse order and
the combined eluents were diluted 1:1 with 200 mL H2O. The diluted eluent was
passed through the column again, further diluted with 400 mL H2O to 25% MeOH
and passed through the column once more. The column was washed with H2O then
eluted generating three 100 mL fractions of 30%, 75% and 100% Me2CO in H2O of
10.5 mg, 70.7 mg and 121.5 mg respectively.
Further reversed-phase purification of the 75% Me2CO in H2O fraction was
undertaken on HP20SS, generating Me2CO in H2O fractions of 30–100% Me2CO.
The 80% Me2CO in H2O HP20SS fraction was further partitioned over HP20SS
resin with 70–80% Me2CO in H2O in 2% intervals. Analysis by TLC (5% MeOH in
CH2Cl2) indicated two metabolites of similar polarity were present in the 70% and
72% Me2CO in H2O fractions (rf. 0.32 and 0.35). Resolution of the metabolites was
achieved by reversed-phase HPLC (C18, 85% MeCN in H2O) with 23 (0.0007 g) and
24 (0.0015 g) eluting at 10 and 12 min respectively.
iso-Secothorectolide (23): Clear oil, 0.7 mg; 1H and 13C NMR data, see Table
C.1; HRESIMS m/z 439.2458 [M + Na]+ (calcd for C25H36O5Na, 439.2460; ∆ –0.5
ppm); m/z 415.2487 [M H] (calcd for C25H35O5, 415.2484; ∆ 0.3 ppm).
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1-Hydroxyluffarin Q (24): Clear oil, 1.5 mg; 1H and 13C NMR data, see Table
C.2; HRESIMS m/z 439.2458 [M + Na]+ (calcd for C25H36O5Na, 439.2460; ∆ –0.5
ppm); m/z 415.2476 [M H] (calcd for C25H35O5, 415.2484; ∆ –0.8 ppm).
7.2 Isolation of known terpenes from PTN4_10B
7.2.1 Animal material
The odorous sponge specimen PTN4_10B (125 g) was collected using SCUBA from
a vertical rock face at a depth of ca. 15 m on Fakalotula¯ island in the Vava’u group
in November 2009. The specimen was frozen immediately and maintained at –18 C
until extraction. A voucher specimen is deposited at the School of Chemical and
Physical Sciences, VUW, Wellington.
7.2.2 Initial extraction of PTN4_10B
A frozen 16.0 g sample was extracted twice for 20 h in 100 mL MeOH at room
temperature. In reverse order the extracts were passed through a column of 40
mL HP20 resin, the combined eluents were diluted 1:1 with 200 mL H2O, passed
through the column again, further diluted with 400 mL H2O to 25% MeOH and
passed through the column once more. The column was washed with H2O then
eluted, generating three 100 mL fractions of 30%, 75% and 100% Me2CO in H2O.
The Me2CO in H2O fractions (39.3 mg, 65.8 mg and 96.2 mg respectively) were
evaporated to dryness under reduced pressure and subjected to 1D and 2D NMR
analysis.
The crude NMR spectra of the 100% Me2CO in H2O fraction was dominated by two
compounds identified as ambliol B (25) and luffariellolide (26). Bench-top column
chromatography of the lipophilic fraction (DIOL, CH2Cl2/20% MeOH) yielded
CH2Cl2 fractions rich in ambliol B (25) and spectroscopically pure luffariellolide
(26, 11.3 mg). Further bench-top purification afforded ambliol B (7.3 mg, 75%
hexane in CH2Cl2).
Ambliol B (25): Clear oil, 7.3 mg; [α 17.5D +67.6 (c 0.06, CHCl3); 1H and 13C
NMR data, see Table C.3.
Luffariellolide (26): Clear oil, 11.3 mg; [α 17.5D +4.9 (c 0.1, CHCl3); 1H and 13C
NMR data, see Table C.4.
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7.3 Isolation of 14-bromohomofascaplysin
7.3.1 Animal material
The slimy green sponge, PTN3_20B (40 g) was collected from the interior of a large
cave at a depth of 12–15 m on ‘Eua Island in November 2008. The specimen was
frozen immediately then stored at –18 C until extraction. A voucher specimen is
deposited at the School of Chemical and Physical Sciences, VUW, Wellington.
7.3.2 Extraction of PTN3_20B
A frozen 20.5 g screening sample of PTN3_20B was extracted twice overnight for
18 h with 100 mL MeOH at room temperature. The filtered extracts were passed
through a column of 40 mL HP20 resin in reverse order and the combined eluents
were diluted 1:1 with 200 mL H2O. The diluted eluent was passed through the
column again, further diluted with 400 mL H2O to 25% MeOH and passed through
the column once more. The column was washed with H2O then eluted generating
three 100 mL fractions of 30%, 75% and 100% Me2CO in H2O (13.0 mg, 98.6 mg
and 90.0 mg respectively).
The 75% and 100% Me2CO in H2O fractions were further partitioned over HP20SS
and the fractions (30%, 40%, 50%, 60%, 70% 80% and 100% Me2CO in H2O) anal-
ysed by 1H NMR. The 50% and 60% Me2CO in H2O HP20SS fractions were further
purified by bench-top chromatography (DIOL, hexane/CH2Cl2/EtOAc/MeOH/H2O)
with small quantities of the charged 14-bromohomofascaplysin (29) eluting slowly
from the column in the 10% MeOH in H2O fraction.
14-bromohomofascaplysin (29): Clear oil, ca. 700 µg; 1H and 13C NMR data, see
Table C.7; HRESIMS m/z 407.0395 [M + H]+(calcd for C21H16N2O2Br, 407.0395;
∆ 0.0 ppm).
7.3.3 Me2CO-free extraction of PTN3_20B
The remaining 19.5 g of PTN3_20B was extracted twice overnight for 18 h in 100 mL
MeOH, and the extracts were partitioned over HP20 resin. The column was eluted
with eight fractions ranging from 30–100% MeOH in H2O, which were analysed
by 1H NMR. Further 2D analysis was performed in an attempt to identify either
14-bromohomofascaplysin or 14-bromofascaplysin, although neither compound was
identified by these methods.
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7.4 Isolation of halenaquinone
7.4.1 Animal material
A red liver-coloured sponge specimen, PTN3_21D (50 g) was collected using
SCUBA from the horizontal ceiling of a large cave at a depth of 12–15 m on ‘Eua
Island in November 2008. The specimen was frozen immediately and maintained at
–18 C until extraction. A voucher specimen is deposited at the School of Chemical
and Physical Sciences, VUW, Wellington.
7.4.2 Extraction of PTN3_21D
The frozen sample (22.0 g) was extracted twice for 20 h in 100 mL MeOH at room
temperature. In reverse order the filtered extracts were passed through a column
of 40 mL HP20 resin, the combined eluents were diluted 1:1 with 200 mL H2O,
passed through the column again, further diluted with 400 mL H2O to 25% MeOH
and passed through the column once more. The column was washed with H2O
then eluted generating three 100 mL fractions of 30%, 75% and 100% Me2CO in
H2O (41.5 mg, 95.4 mg and 53.5 mg respectively). The 75% and 100% Me2CO in
H2O fractions were evaporated to dryness under reduced pressure and subjected to
1D and 2D NMR analysis. Normal-phase chromatography of the 75% Me2CO in
H2O HP20 fraction (DIOL, hexane/CH2Cl2/EtOAc/MeOH) and subsequent NMR
analysis showed concentration of the signals of interest in the 75% hexane in CH2Cl2
fraction. Subsequent reversed-phase HPLC (C18, 90% MeCN in H2O) yielded
halenaquinone (31) (10.1 mg) as a red solid.
Halenaquinone (31): red solid, 10.1 mg; 1H and 13C NMR data, see Table C.8.
7.5 Isolation of luakuliides A–C
7.5.1 Animal material
The dictyoceratid sponge sample PTN3_21E (90 g) was collected at 12–15 m from an
unlit cave on ‘Eua Island in November 2008. The specimen was frozen immediately
and maintained at –18 C until extraction. A second collection PTN3_50B (42 g)
was made from a similar cave location at Shark’s Tooth, Kitu’s in the Vava’u Island
group in November 2009. A voucher specimen is deposited at the School of Chemical
and Physical Sciences, VUW, Wellington.
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7.5.2 Screening extraction of PTN3_21E
A 23 g sample was extracted while frozen in MeOH and partitioned over HP20
according to laboratory protocol (Appendix A). 1D and 2D NMR analysis of the
100% and 75% Me2CO in H2O fractions (105.2 mg, 120.8 mg respectively) revealed
the presence of two closely related metabolites. Further reversed-phase fractionation
of both fractions was undertaken over HP20SS resin producing fractions of Me2CO
in H2O (30–100%, 10% intervals). 1H NMR analysis of the 60% and 70% Me2CO
in H2O HP20SS fractions revealed luakuliide A (33, 92.7 mg) in exceptionally high
spectroscopic purity.
The 100% Me2CO fraction was further partitioned (DIOL, hexane/CH2Cl2/EtOAc)
generating a steroid rich fraction (4.7 mg, 50% hexane in CH2Cl2). Bench-top
chromatography of the 90% Me2CO in H2O fraction (DIOL, CH2Cl2/EtOAc) yielded
methyl-acetal analogue of luakuliide A, 34 (16.1 mg), while the 80% Me2CO in H2O
HP20SS fraction contained a mixture of the two compounds.
Ethanol extraction of PTN3_21E
The remaining 67 g of PTN3_21E were extracted twice overnight in 200 mL EtOH
and the extracts were partitioned over HP20 generating 30%, 75% and 100% Me2CO
in H2O fractions. Compound 33 was clearly present within the extracts, however,
the methyl-acetal analogue 34 was absent, indicating it was an artifact of MeOH
extraction.
Derivatisation of luakuliide A (33): Luakuliide A (33, 5.0 mg) was dissolved
in 5 mL 10% CDCl3 in MeOH and maintained at 4 C for 72 h. 1H NMR analysis
showed quantitative conversion to the methyl-acetal analogue 34.
7.5.3 Extraction of PTN3_50B
The 42 g sample was extracted twice overnight in 200 mLMeOH and partitioned over
40 mL HP20 according as above. The 100% and 75% Me2CO in H2O fractions were
partitioned over HP20SS with 30–100% Me2CO in H2Omixtures (10% intervals). As
previously observed, the 80–100% Me2CO in H2O fractions contained compounds
33 and 34, while the 70% and 60% Me2CO in H2O HP20SS fractions appeared
to contain previously unencountered resonances, and was further partitioned over
DIOL (hexane/CH2Cl2/EtOAc). The 33% EtOAc in CH2Cl2 fraction was then
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partitioned by HPLC (C18, 70% MeCN in H2O) with the butenolide diterpenes 35
and 36 eluting between 4.0–4.7 min.
The 100% Me2CO HP20SS fraction was devoid of both 33 and 34, and subjected to
further normal-phase chromatography (DIOL, hexane/CH2Cl2/EtOAc). The minor
terpenoid metabolites eluted in the 20% EtOAc/CH2Cl2 fraction, HPLC purification
of which (C18, 70% MeCN in H2O) yielded 35 and 36, eluting closely at 4.2 and
4.5 min. Fractions from different collections of the two butenolide metabolites were
combined and subjected to further chromatographic purification by HPLC (C18,
70% MeCN in H2O) generating ca. 600 µg of both 35 and 36.
Normal-phase chromatography of the 70% Me2CO in H2O HP20SS fraction (DIOL,
CH2Cl2/EtOAc) yielded an uncharacterised labdane diterpene in the 2.5% EtOAc in
CH2Cl2 fraction, which was also identified within previously acquired spectra from
the ‘Eua specimen.
Luakuliide A (33): Clear oil, 92.7 mg; [α 25.4D 10.8 (c 18.5, CHCl3), UV
(MeOH) λmax (log ￿), 213 (2.90); IR (film) νmax 3385, 2923, 2851, 1727, 1458, 1376,
1161, 1027 cm 1; 1H and 13C NMR data see Table 3.2; HRESIMS m/z 341.2097
[M + Na]+ (calcd for C20H30O3Na, 341.2093; ∆ 1.2 ppm).
Luakuliide A methyl-acetal (34): Clear oil, 16.1 mg; [α 25.4D –75.0 (c 0.14,
CHCl3), UV (MeOH) λmax (log ￿), 215 (3.89) nm; IR (film) νmax 2954, 2926, 2860,
1727, 1460, 1377, 1274, 1073, 999 cm 1; 1H and 13C NMR data see Table 3.3;
HRESIMS m/z 355.2257 [M + Na]+ (calcd for C21H32O3Na, 355.2249; ∆ 2.3 ppm).
Luakuliide B (35): Clear oil, ca. 600 µg; UV (MeOH) ) λmax (log ￿), 235 (3.80),
295 (3.73); IR (film) νmax 3250, 2928, 2853, 1687, 1647, 1561, 1440, 1221, 1094 cm 1;
1H and 13C NMR data see Table 3.4; HRESIMS m/z 373.1996 [M + Na]+ (calcd for
C20H30O5Na, 373.1991; ∆ 1.3 ppm).
Luakuliide C (36): Clear oil, ca. 600 µg; UV (MeOH) λmax (log ￿), 235 (3.80),
295 (3.73); IR (film) νmax 3250, 2928, 2853, 1687, 1647, 1561, 1440, 1221, 1094 cm 1;
1H and 13C NMR data see Table 3.2; HRESIMS m/z 373.1990 [M + Na]+ (calcd for
C20H30O5Na, 373.1991; ∆ –0.3 ppm).
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7.6 Isolation of lehualides E–K
7.6.1 Animal material
The Plakortis sponge PTN3_20A (36.0 g) collected was using SCUBA from the
horizontal ceiling of a large cave at a depth of 12–15 m on ‘Eua Island in November
2008. The specimen was frozen immediately and kept at –18 C until extraction.
The surface of the corky specimen is covered in wide shallow nodules ca. 3 mm
high, and the organism forms small oval pendant encrustations. Diod spicules of
180–250 µm in length were recovered following HNO3 digest of the organic material.
A voucher specimen (PTN3_20A) has been deposited in the collection of Dr James
Bell at the School of Biological Sciences, VUW, Wellington.
7.6.2 Initial extraction of Plakortis sp. PTN3_20A
The frozen sample (21.0 g) was extracted twice for 14 h in 100 mL MeOH at room
temperature. The second extract, followed by the first, were passed through a
column of 40 mL HP20 resin, the eluents combined and diluted with 200 mL H2O.
The diluted eluent was passed through the column again, further diluted to 25%
MeOH and passed through the column once more. The column was washed with
H2O then eluted generating three 100 mL fractions of 30%, 75% and 100% Me2CO
in H2O. The 75% and 100% Me2CO in H2O fractions were evaporated to dryness
under reduced pressure then analysed by 1D and 2D NMR.
Sub-samples of the 75% Me2CO in H2O fraction (ca. 40 mg) were further partitioned
over 3 mL reversed-phase resin (HP20SS) with MeOH and H2O. The columns were
washed with 20 mL H2O then eluted generating 10 mL fractions of Me2CO in H2O
(30–100%, 10% intervals). The 50–100% Me2CO in H2O fractions were assessed by
1H NMR (CDCl3). The 80% Me2CO in H2O HP20SS fractions were evaporated
to dryness then further partitioned over DIOL (CH2Cl2/EtOAc/MeOH). The 100%
CH2Cl2 fractions of the DIOL column was partitioned on reversed-phase HPLC (C18,
85% MeCN in H2O) with lehualides F and G (70 and 71) eluting at 6.5 and 10.5
min respectively (2.8 mg, and 14.5 mg total).
Sub-samples of the 100% Me2CO fraction (ca. 40 mg) were partitioned over 3
mL HP20SS resin with MeOH and H2O, the columns were washed with 20 mL
H2O then eluted generating 10 mL fractions of Me2CO in H2O (30–100%, 10%
intervals). The 80% Me2CO in H2O fractions from the HP20SS columns were
evaporated to dryness then further purified with bench-top DIOL chromatography
(hexane/CH2Cl2/EtOAC). Bench-top SiO2 chromatography (CH2Cl2/EtOAc) of the
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CH2Cl2 DIOL fraction, followed by normal-phase HPLC (DIOL, 4% IPA in hexane)
of the 2.5% EtOAc in CH2Cl2 SiO2 fraction yielded lehualide H (72, 700 µg) eluting
at 16.1 min.
7.6.3 Second extraction of Plakortis sp. PTN3_20A
The remaining 15 g of Plakortis sp. was extracted from frozen with 100 mL MeOH
for 14 h. The extract was filtered and the sponge tissue extracted for a further 14
h with 100 mL MeOH. The second extract was filtered and loaded onto 40 mL of
equilibrated HP20 resin beads followed by the first extract. The combined eluents
diluted 50% with H2O and re-loaded onto the column, the eluent was further diluted
50% with H2O and passed through the column once again. The column was washed
with 100 mL H2O, and eluted with 100 mL fractions of 30%, 75% and 100% Me2CO
in H2O. Further reversed-phase partitioning of the 100% Me2CO HP20 fraction
over HP20SS generated eight Me2CO in H2O fractions, 30–100% in 10% Me2CO
increments.
Normal-phase bench-top chromatography (DIOL, CH2Cl2/EtOAc/MeOH) of the
combined 80% Me2CO in H2O HP20SS fractions followed. The 100% CH2Cl2
fractions were evaporated to dryness and subsequent NMR analysis showed that the
signals of interest were concentrated within the fractions. Subsequent reversed-phase
HPLC (C18, 85% MeCN in H2O) of the 100% CH2Cl2 fraction yielded lehualides
J (74, 500 µg), H (72, 800 µg), I (73, 646 µg) and E (69, 540 µg). Two related
metabolites bearing terminal α-pyrone and thioacetate moieties were also recovered,
although not fully characterised.
The 100% Me2CO HP20SS fractions were further partitioned over DIOL (CH2Cl2/
EtOAc/MeOH) with lehualide K (75) eluting late in the 100% CH2Cl2 fractions.
Iterative cycles of bench-top chromatography (DIOL, hexane/CH2Cl2) yielded
lehualide K in ca. 85% purity (2.12 mg). Partitioning of the 60% and 70% Me2CO in
H2O HP20SS by reversed-phase HPLC (C18, 75% MeCN in H2O) afforded lehualide
J (74, 1.95 mg total).
Lehualide E (69): Clear oil, 540 µg; UV (MeOH) λmax (log ￿), 235 (3.80), 295
(3.73); IR (film) νmax 3250, 2928, 2853, 1687, 1647, 1561, 1440, 1221, 1094 cm 1;
1H and 13C NMR data, see Table 4.1; HRESIMS m/z 385.2399 [M + Na]+ (calcd
for C24H32O4Na, 385.2398; ∆ 0.2 ppm).
Lehualide F (70): White solid, 2.8 mg; UV (MeOH) λmax (log ￿), 235 (3.81),
282 (3.70) nm; IR (film) νmax 3250, 2929, 2854, 1686, 1648, 1560, 1439, 1220, 1094
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cm 1; 1H and 13C NMR data, see Table 4.2; HRESIMS m/z 393.2042 [M + Na]+
(calcd for C23H30O4Na, 393.2042; ∆ 0.0 ppm).
Lehualide G (71): White solid, 18.3 mg; UV (MeOH) λmax (log ￿), 235 (3.44),
291 (3.55) nm; IR (film) νmax 3250, 2926, 2854, 1686, 1649, 1563, 1439, 1276, 1094
cm 1; 1H and 13C NMR data, see Table 4.3; HRESIMS m/z 421.2355 [M + Na]+
(calcd for C25H34O4Na, 421.2355; ∆ 0.0 ppm).
Lehualide H (72): White solid, 1.5 mg; UV (MeOH) λmax (log ￿), 255 (3.68),
297 (4.29) nm; IR (film) νmax 2925, 2853, 1709, 1690, 1651, 1569, 1458, 1227, 670
cm 1; 1H and 13C NMR data, see Table 4.4; HRESIMS m/z 407.1864 [M + Na]+
(calcd for C20H32O5SNa, 407.1868; ∆ –1.0 ppm).
Lehualide I (73): Clear oil, 646 µg; UV (MeOH) λmax (log ￿), 249 (3.12), 297
(3.96) nm; IR (film) νmax 2926, 2854, 1712, 1652, 1570, 1460, 1370, 1229, 699 cm 1;
1H and 13C NMR data, see Table 4.5; HRESIMS m/z 379.1920 [M + Na]+ (calcd
for C19H32O4SNa, 379.1919; ∆ 0.3 ppm).
Lehualide J (74): Clear oil, 2.0 mg; [α 19.1D 0.0 (c 3.69 10 3, CHCl3), UV
(MeOH) λmax (log ￿), 249 (2.88), 288 (3.52) nm; IR (film) νmax 2925, 2855, 1713,
1652, 1569, 1458, 1371, 1228, 1098, 699 cm 1; 1H and 13C NMR data, see Table
4.6; HRESIMS m/z 395.1868 [M + Na]+ (calcd for C19H32O5SNa, 395.1868; ∆ 0.0
ppm).
Lehualide K (75): Clear oil, 2.1 mg (impure); UV (MeOH) λmax (log ￿), 240
(3.41), 296 (3.60) nm; IR (film) νmax 2926, 2852, 1690, 1651, 1569, 1458, 1227, 672
cm 1; 1H and 13C NMR data, see Table 4.8; HRESIMS m/z 705.3477 [M + Na]+
(calcd for C36H58O8S2Na, 705.3471; ∆ 0.9 ppm).
7.6.4 Preparation of spectroscopic model compounds
Preparation of octanethiol: 1-bromooctane (5.95 mL, 34.20 mmol) was stirred
in 30 mL MeOH under ambient conditions. Thiourea (3.91 g, 0.05 mol) was dissolved
in 30 mL H2O then added to the 1-bromooctane solution. The reaction was heated
to reflux for 3.5 h, then allowed to cool to room temperature. KOH (4.83 g, 0.09
mol) was added and the reaction heated at reflux for a further hour to hydrolyse
the isothiouronium salt. The reaction was cooled to room temperature, extracted
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twice with 30 mL CH2Cl2, the aqueous phase washed with 3 mL concentrated HCl
and re-extracted with 30 mL CH2Cl2. The combined organic fractions were dried
with MgSO4, filtered and evaporated under reduced pressure. The crude product
was distilled under reduced pressure affording octanethiol in high purity as judged
by 1H NMR.
Preparation of octylthioacetate: Octanethiol (0.89 g, 6.10 mmol) was stirred
under ambient conditions, treated with a molar excess of acetic anhydride (15.00
mL, 159.00 mmol) then heated with stirring to 90 C overnight. The reaction was
cooled to room temperature, placed on ice and quenched with 20 mL H2O. Addition
of H2O induced separation of the alkyl product and the aqueous phase was further
extracted twice with 20 mL Et2O. The organic phase was dried over MgSO4, filtered
and evaporated under reduced pressure. The crude product was then distilled under
reduced pressure affording octylthioacetate in an 80% yield (0.92 g, 4.90 mmol).
Octylthioacetate: Colourless liquid, IR (film) νmax 698 cm 1; 1H NMR (CDCl3,
600 MHz) δ 2.86 (2H, t, J = 7.5 Hz, H-1), 2.32 (3H, s, SC(O)CH3), 1.55 (2H, quin, J
= 7.6 Hz, H-2), 1.33 (2H, quin, J = 7.4 Hz, H-3), 1.23–1.30 (8H, m, H2-4–H2-7), 0.87
(3H, t, J = 6.5 Hz, H-8); 13C NMR (CDCl3, 150 MHz) δ 196.3 (SC(O)CH3), 30.9
(SC(O)CH3), 31.9 (C-1), 30.8 (C-2), 29.6 (C-4–C-7 ), 29.30, 29.29, 29.22, 29.0 (C-
3), 22.8 (C-5), 14.3 (C-8); HRESIMS [M + Na]+ m/z 199.1133 (calcd for C9H20OS,
199.1138; ∆ –2.0 ppm).
Preparation of dimethyloctylsulfide: Octanethiol (0.42 g, 2.88 mmol) was
stirred under ambient conditions in 20 mL MeOH. 1.2 equivalents of MeI were
added and the reaction was heated at reflux for 30 min. The reaction was cooled
to room temperature, quenched with 20 mL H2O, and the reaction mixture was
extracted twice with 20 mL Et2O. The organic phase was dried over MgSO4, filtered
and evaporated under reduced pressure affording the dimethylation product in a
90% yield.
Dimethyloctylsulfide: Colourless liquid, 1H NMR (CDCl3, 600 MHz) δ 3.72 (2H,
t, J = 7.8 Hz, H-1), 3.33 (6H, s, S(CH3)2), 1.78 (2H, quin, J = 6.6 Hz, H-2), 1.44
(2H, quin, J = 6.6 Hz, H-3), 1.30 (2H, quin, J = 6.6 Hz, H-4), 1.20–1.28 (6H, m,
H-5–H-7), 0.81 (3H, s, H-8); 13C NMR (CDCl3, 150 MHz) δ 43.6 (C-1), 31.7 (C-2),
29.0 (C-3), 28.9 (C-4), 28.3 (C-5), 25.6 (S(CH3)2), 24.3 (C-6), 22.7 (C-7), 14.2 (C-8);
HRESIMS [M + H]+ m/z 175.1523 (calcd for C10H23S, 175.1520; ∆ 1.7 ppm)
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Preparation of methyloctylsulfide: Octanethiol (0.5 mL, mmol) was stirred
under ambient conditions in 20 mL MeOH. One equivalent of MeI was added, and
the reaction was heated at reflux for 20 min. The reaction was cooled to room
temperature, quenched with 20 mL H2O, and the reaction mixture was extracted
twice with 20 mL Et2O. The organic phase was dried over MgSO4, filtered and
evaporated under reduced pressure affording the mono-methylation product in a
40% yield.
Methyloctylsulfide: Colourless liquid, IR (film) νmax 698 cm 1; 1H NMR
(CDCl3, 600 MHz) δ 2.48 (2H, t, J = 7.2 Hz, H-2), 2.09 (3H, s, H-1), 1.58 (2H,
quin, J = 7.2 Hz, H-3), 1.37 (2H, quin, J = 7.2 Hz, H-4), 1.23–1.30 (8H, m, H-5–H-
8), 0.88 (3H, t, J = 7.2 Hz, H-9); 13C NMR (CDCl3, 150 MHz) δ 34.2 (C-2), 31.8
(C-8), 29.15 (C-5), 29.13 (C-7), 29.1 (C-3), 28.8 (C-4), 22.6 (C-6), 15.5 (C-1), 14.0
(C-9).
Preparation of methyloctylsulfoxide A: Methyloctylsulfide (0.5 mL, 2.6
mmol) was stirred in 30 mL MeOH, after which 1.5 equivalents (4.0 mmol) KIO4 in
3 mL H2O were added and the cloudy solution stirred at room temperature for 12 h.
Methyloctylsulfoxide was produced in 100% yield. No purification was performed.
Preparation of methyloctylsulfoxide B: Methyloctylsulfide (0.5 mL, 2.6
mmol) was stirred in 30 mL MeOH, and treated with 1.5 equivalents (4.0 mmol) 30%
H2O2 aqueous solution. The reaction was stirred for 12 h under ambient conditions
affording the sulfoxide product in 100% yield. No purification was performed.
Methyloctylsulfoxide: White crystalline solid; IR (film) νmax 1027, 748 cm 1;
1H NMR (CDCl3, 600 MHz) δ 2.73 (1H, ddd, J = 14.9, 9.8, 5.8 Hz, H-2a), 2.64 (1H,
ddd, J = 16.2, 9.3, 5.8 Hz, H-2b), 2.56 (3H, s, H-1), 1.75 (2H, quin, J = 7.0 Hz,
H-3), 1.44 (2H, sept, J = 8.4 Hz, H-4), 1.22–1.34 (8H, m, H-5–H-8), 0.88 (3H, t, J
= 7.1 Hz, H-9); 13C NMR (CDCl3, 150 MHz) δ 54.9 (C-2), 38.7 (C-1), 31.9 (C-8),
29.3 (C-5), 29.2 (C-7), 28.9 (C-4), 22.8 (C-6), 22.7 (C-3), 14.2 (C-9); HRESIMS
[M + Na]+ m/z 199.1129 (calcd for C9H20OS, 199.1133; ∆ –2.0 ppm).
Preparation of methyloctylsulfone: Methyloctylsulfide (0.5 mL, 2.6 mmol)
was stirred in 25 mL CH2Cl2 with excess of 3:1 activated MnO2:KMnO4. The
suspension was stirred for 96 h, filtered, and the residue washed with a 1:1 mixture
of MeOH and CH2Cl2. The filtrate was evaporated affording a white crystalline
solid in 100% yield. No further purification was deemed necessary.
178
Methyloctylsulfone: White crystalline solid; IR (film) νmax 1273, 1141, 1128,
1117, 765, 749 cm 1; 1H NMR (CDCl3, 600 MHz) δ 3.00 (2H, t, J = 8.4 Hz, H-2),
2.89 (3H, s, H-1), 1.85 (2H, quin, J = 7.8 Hz, H-3), 1.44 (2H, quin, J = 7.2 Hz,
H-4), 1.24–1.34 (8H, m, H-5–H-8), 0.88 (3H, t, J = 7.2 Hz, H-9); 13C NMR (CDCl3,
150 MHz) δ 55.0 (C-2), 40.5 (C-1), 31.8 (C-8), 29.14 (C-5), 29.05 (C-6), 28.5 (C-4),
22.7 (C-7), 22.6 (C-3), 14.2 (C-9).
7.7 Isolation of new cyclic peroxides
7.7.1 Animal material
The sponge PTN3_19D was collected from the horizontal ceiling of a large cave
at a depth of 12–15 m on ‘Eua Island and frozen immediately. Identified as a
plakinid sponge species (order Homosclerophorida), the specimen forms thick, dense
lobule encrustations 0.5–1.5 cm thick, appearing smooth but with a rough reticulated
surface covered in wide shallow nodules ca. 3 mm high in some places. The texture is
dense and cork-like, and the black-grey exterior contrasts against a tan-pink interior,
which turns grey in alcohol. The abundant diods are 40–60 µm 1–1.5 µm, triods
were not observed. A voucher specimen is deposited in the School of Chemical and
Physical Sciences, VUW, Wellington.
7.7.2 Initial extraction of PTN3_19D
A 26 g sample of PTN3_19D was extracted twice for 14 h in 100 mL MeOH at room
temperature then filtered. The second extract, followed by the first were passed
through a column of 40 mL HP20 resin, the eluents combined and diluted with 200
mL H2O. The eluent was passed through the column again, further diluted to 25%
MeOH with 400 mL H2O and passed through the column once more. The column
was washed with H2O then eluted, generating three 100 mL fractions of 30%, 75%
and 100% Me2CO in H2O. The 75% and 100% Me2CO in H2O fractions (88.4 mg
and 155.3 mg respectively) were evaporated under reduced pressure and analysed by
1D and 2D NMR. Sub-samples of the 75% and 100% Me2CO in H2O fractions (ca.
40 mg) were further partitioned over 3 mL reversed-phase resin (HP20SS) resin with
MeOH/H2O. The columns were washed with 20 mL H2O then eluted generating 10
mL fractions of Me2CO in H2O (30–100% Me2CO, in 10% increments). Further
purification of the 70–100% Me2CO in H2O fractions by DIOL oil chromatography
(hexane/CH2Cl2/MeOH) gave a mixture of cyclic peroxides and long-chain fats
within the different CH2Cl2 fractions.
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NMR spectra of the 50% CH2Cl2 in MeOH DIOL fraction indicated steroidal content
and the fraction was purified further on DIOL (hexane/CH2Cl2). The 40% hexane in
CH2Cl2 fraction was again partitioned over DIOL and purification of the 20% hexane
in CH2Cl2 fraction by reversed-phase HPLC (C18, 90%MeCN in H2O) yielded 5α,8α-
epidioxy sterols 27 (652 µg) and 28 (537 µg) with retention times of 29 min and 39
min respectively.
The 25% hexane in CH2Cl2 DIOL fraction was found to contain epiplakinic acid I
(95) in high spectroscopic purity. Analysis of the 2.5% MeOH in CH2Cl2 fraction
revealed compound 98 in reasonable purity. Attempts were made to further purify
both compounds, however, the lipophilic nature of the long-chains induced co-elution
on reversed phase. Further partitioning over DIOL (hexane/CH2Cl2) at 0.5 drop
sec 1 collecting 2 mL fractions was not observed to increase spectroscopic purity.
The non-polar 60% hexane in CH2Cl2 fractions generated by the initial DIOL column
were partitioned by HPLC (C18, 95% MeCN in H2O). Fractions collected in between
chromophore peaks were rich in the cyclic peroxide metabolites. Size-exclusion
chromatography (LH20, 1.5 m, MeOH) was utilised to remove the residual long-
chain fat contamination from the HPLC dregs, 170 fractions were collected with
the material of interest eluting in fractions 37–41. The combined LH20 fractions
were partitioned over DIOL (hexane/CH2Cl2) with epiplakinic acid I methyl ester
(96) eluting early in CH2Cl2 and plakortolide X (97) eluting in the 75% hexane in
CH2Cl2 fractions.
7.7.3 Second extraction of PTN3_19D
Following accidental defrost, the remaining 75 g of PTN3_19D was extracted twice
in MeOH and partitioned over HP20 as above. Analysis of the 100% and 75%Me2CO
in H2O fractions (69.3 mg and 252.4 mg) by 1H and HMBC NMR confirmed the
presence of the cyclic peroxides epiplakinic acid I (95) and plakortolide X (97)
although in lower concentration than observed in the initial screening evaluation.
One step of normal-phase purification was performed on the 100% Me2CO fraction
(DIOL, hexane/CH2Cl2/10% MeOH).
The 75% Me2CO in H2O HP20 fraction was partitioned over HP20SS generating
ten fractions of 30–100% Me2CO in H2O. The 85% and 90% Me2CO in H2O
fractions were combined and partitioned again on HP20SS over a smaller window
generating fractions of 75%, 80%, 82%, 84%, 86%, 88% and 90% Me2CO in H2O.
The metabolites were all found to co-elute within the 75% and 80% Me2CO in H2O
fractions, which were subsequently partitioned on normal-phase. Epiplakinic acid I
(95, ca. 2 mg) eluted in 100% CH2Cl2.
180
5α8α-epidioxysterol 27: Clear oil, 652 µg; [α 24.6D –0.1 (c 0.044, CHCl3); UV
(MeOH) λmax (log ￿), 222 (3.73), 275 (2.94) nm; IR (film) νmax 3391, 2957, 2929,
2871, 1734, 1460, 1381, 1278, 1126, 969, 766 cm 1; 1H and 13C NMR data, see Table
C.5; HRESIMS m/z 465.3345 [M + Na]+ (calcd for C21H40O5Na, 465.3379; ∆ 0.9
ppm), m/z 477.3135 [M + Cl] (calcd for C29H46O3Cl, 477.3145; ∆ 2.1 ppm).
5α8α-epidioxysterol 28: Clear oil, 537 µg; [α 24.6D –0.4 (c 0.036, CHCl3); UV
(MeOH) λmax (log ￿), 228 (2.84) nm; IR (film) νmax 3366, 2929, 2870, 2362, 1717,
1629, 1467, 1381, 1270, 1047, 936, 748 cm 1; 1H and 13C NMR data, see Table
C.6; HRESIMS m/z 439.3188 [M + Na]+ (calcd for C21H40O5Na, 439.3192; ∆ 0.9
ppm),m/z 451.2979 [M + Cl] (calcd for C27H44O3Cl, 451.2976; ∆ –0.7 ppm).
Epiplakinic acid I (95): Clear oil, ca. 3.5 mg; [α 25.2D +1.9 (c 0.068, CHCl3); UV
(MeOH) λmax (log ￿), 273 (2.70) nm; IR (film) νmax 3388, 2928, 2920, 2854, 1717,
1464, 1374, 1220, 1024 cm 1;1H and 13C NMR data, see Table 4.10; HRESIMS m/z
365.2668 [M + Na]+ (calcd for C20H38O4Na, 365.2664; ∆ –1.1 ppm), m/z 341.2692
[M H] (calcd for C20H37O4, 365.2692; ∆ –2.3 ppm).
Epiplakinic acid I methyl ester (96): Clear oil, ca. 500 µg; UV (MeOH) λmax
(log ￿), 273 (2.70) nm; IR (film) νmax 3388, 2928, 2920, 2854, 1717, 1464, 1374,
1220, 1024 cm 1;1H and 13C NMR data, see Table 4.11; HRESIMS m/z 371.2790
[M + Na]+ (calcd for C21H39O5Na, 371.2797; ∆ –1.9 ppm).
Plakortolide X (97): Clear oil, 1.21 mg; [α 24.6D 0.0 (c 0.08, CHCl3); UV (MeOH)
λmax (log ￿), 275 (2.80), 282 (2.57) nm; IR (film) νmax 2928, 2921, 2854, 1782,
1717, 1463, 1381, 1270, 1167, 1073 cm 1;1H and 13C NMR data, see Table 4.13;
HRESIMS m/z 349.2355 [M + H]+ (calcd for C19H34O4Na, 349.2355; ∆ –0.6 ppm),
m/z 325.2379 [M H] (calcd for C20H37O4, 325.2374; ∆ –1.5 ppm).
Compound 98: Clear oil, 856 µg; [α 24.6D +4.1 (c 0.03, CHCl3); UV (MeOH)
λmax (log ￿), 280 (3.05) nm; IR (film) νmax 3374, 2928, 2920, 2854, 1717, 1464,
1374, 1220, 1143 1024 cm 1;1H and 13C NMR data, see Table 4.15; HRESIMS m/z
395.2771 [M + Na]+ (calcd for C21H40O5Na, 395.2773; ∆ –0.8 ppm),m/z 371.2790
[M H] (calcd for C21H39O5, 371.2797; ∆ –1.9 ppm).
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7.8 Biological evaluation of cyclic peroxides
7.8.1 Yeast strains
All strains were derived from a 15% glycerol stock stored at –80 C. The deletion
strains (Table 7.1) were streaked out onto 10 cm diameter agar plates containing
synthetic complete (SC) medium or synthetic deficient in uracil medium (SD–
ura), supplemented with the appropriate antibiotics to ensure selective growth;
200 µg mL 1 Geneticin antibiotic (G418, Gibco, Invitrogen) and/or 100 µg mL 1
mourseothricin antibiotic (Nat, Werner BioAgents). The diploid BY4743 strain
was streaked onto yeast extract peptone dextrose (YPD) agar and the diploid
deletion strains were grown on YPD agar supplemented with G418 antibiotic (200
µg mL 1). The GFP-localised strains were streaked out onto 10 cm diameter agar
plates containing SD–histidine medium. The freshly plated strains were incubated
at 30 C for 48 h to allow the formation of single colonies then stored at 4 C.
Growth media
Y7092 (wt) was cultured in SC medium; homozygous deletion strains were cultured
in 5 mL SC + with 200 µg mL 1 G418 antibiotic; ∆pdr was cultured in 5 mL SD–ura
+Nat 100 µg mL 1; haploid strains with GFP-localisation markers were cultured
immediately prior to use by serial-dilution in SD–his; and BY4743 was cultured in
5 mL SC. YPD was used during assessment of 29 as a growth inhibitor and during
transformation procedures (refer Appendix B for growth media recipies).
7.8.2 Preliminary assay protocols
Liquid-phase dose-reponse assays
Three 5 mL aliquots of SC, SD–ura or YPD growth media were inoculated with
different single colonies of a given yeast strain and cultures were grown to saturation
overnight in a rotating drum at 30 C.251 The saturated cultures were diluted
to 5 105 cells mL 1 in fresh media (SC, SD–ura or YPD), as determined by
haemocytomer, and 99 µL aliquots were added to 96-well tissue culture plates in a
triplicate format. Seven point, half-log serial dilutions of compounds 29, 95 and 97
(10.00–0.10 mmol L 1) were prepared from 10.00 mmol L 1 working stocks dissolved
in DMSO. A 1 µL volume of diluent was added per well, giving a final concentration
range of 100.00–0.01 µmol L 1. DMSO (1% final concentration) was added to one
well as a control.
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Table 7.1 Yeast Strains Used During this Study.
Strain Ploidy Genotype Origin
yCG 117
haploid
MATα can1∆1::STE2pr-
Sp_ HIS5; lyp1∆;
ura3∆0::NAT;
leu2∆0; his3∆;
met1∆50; LYS2+
Starting lab
strain
8025-α
haploid
MATα can1∆::STE2pr-Sp_
his5 lyp1 ∆::STE3pr_LEU2
his3∆1 leu2∆0 ura3∆0
LYS2+
yCG 112
∆pdr
haploid
MATα pdr1∆::NAT
pdr3∆::URA3
can1∆::STE2pr-Sp_
HIS5; lyp1∆::STE3pr-
Sp_LEU2; his3∆1 leu2∆0
ura3∆0
yCG 198
BY4743 (wt)
diploid
MATa/MATα
his3∆1/his3∆
leu2∆0/leu2∆0
lys2∆0/+met15∆0
/+ura3∆0/ura3∆0
Starting lab
strain
sla1∆/sla1∆, rsa1∆/rsa1∆, crz1∆/crz1∆,
hcm1∆/hcm1∆, sfp1∆/sfp1∆,
pmc1∆/pmc1∆, ygk167w∆/ygl167w∆,
rvs167∆/rvs167∆, pmr1∆/pmr1∆,
cch1∆/cch1∆, mid1∆/mid1∆
cna1∆/cna1∆, cna2∆/cna2∆, cnb1∆/cnb1∆
diploid
Homozygous deletion strains
with G418 resistance
Homozygous
deletion set
(Open
Biosystems)
Crz1p-GFP diploid
MATa-Crz1p-GFP-HIS5
his3∆1 leu2∆0 met15∆0
ura3∆0
MATa-GFP
Library
(Invitrogen)
Zrtp-GFP diploid
MATa-Zrt1p-GFP-HIS5
his3∆1 leu2∆0 met15∆0
ura3∆0
MATa-GFP
Library
(Invitrogen)
Zap1p-GFP diploid
MATa-Zap1p-GFP-HIS5
his3∆1 leu2∆0 met15∆0
ura3∆0
MATa-GFP
Library
(Invitrogen)
Yap1p-GFP mCherry haploid
MATα-Yap1p-GFP-
HIS5 can1∆::STE2pr_
URA3 lyp1∆::mCherry
yCG 379
Mrh1p-GFP + mCherry/NLS-RS2 haploid
MATα-Mrh1p-GFP-
HIS5 can1∆::STE2pr_
URA3 lyp1∆::mCherry/
NLS-RS2
yCG 321
Plates were mixed by vortexing for 1 min at 950 rpm and incubated at 30 C for a
maximum of 18 h. After incubation, cells were resuspended by vortexing, and their
growth was quantified by measuring optical density (OD) at 590 nm. Residual
growth (%) was calculated for each concentration using the formula ((ODexp –
ODblank / ODDMSO – ODblank)*100). Results are reported as the mean standard
error for two independent experiments performed in triplicate. The IC50 values were
determined using SigmaPlot and the MIC values were inferred from the plots.
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Cytotoxicity assays
Colony forming assay: Stationary-phase cultures of WT cells and ∆pdr were
diluted to 5 105 cells mL 1 in fresh SC or SD–ura, then treated with either 95
(wt) or 97 (∆pdr) at final concentrations of 10 and 100 µmol L 1. Rapamycin
(2.00 nmol L 1) and cycloheximide (3.35 µmol L 1) served as positive controls for
cytotoxic and cytostatic activity respectively, with DMSO acting as the negative
control. The drug-treated cells were vortexed then incubated at 30 C for 18 h. The
cells were washed with fresh media and inoculated onto solid agar plates of SC or
SD–ura medium then incubated for 48 h at 30 C. The plates were inspected visually
for colony growth and compared to the controls. Colony growth indicated cytostatic
inhibition by the experimental compound and the absence of growth was indicative
of cytotoxicity or irreversible inhibition.
Kill curve: The effective rate of cytotoxicity was measured by removing 1 µL
aliquots from each dilution point within a dose-response assay and spotting them
onto a 10 15 cm rectangular YPD plate hourly from 0 to 6 h and once more after
24 h. As there was a set volume rather than a set cell count spotted, the DMSO
control is expected to show increased growth with time relative to the drug-treated
cultures. The plate was incubated for 24 h and inspected visually for colony growth.
The assay was performed for 95 and 97 with WT and ∆pdr cultures respectively.
Inhibition in the presence and absence of Ca2 : To determine the effect of
Ca2 concentration upon the cytotoxicity of 95 and 97, inhibition assays in high and
low environments of Ca2 (50 mmol L 1 CaCl2 and 100 mmol L 1 EGTA). Dose-
response assays were performed in triplicate over a narrow concentration range (30–1
µmol L 1 final concentration) against the WT and ∆pdr strains in the presence of
95 and 97. Three growth conditions were tested: inhibitory agent; agent + 50
mmol L 1 CaCl2; and agent + 100 mmol L 1 EGTA. As with the kill curve assay,
1 µL aliquots from each dilution point within the assays were removed and spotted
onto a 10 15 cm rectangular YPD plate hourly at t = 0–6 and 24 h. The plate
was incubated for 24 h and inspected visually for colony growth. The assay was
performed for 95 and 97 with WT and ∆pdr cultures respectively. Residual growth
of the dose-response assays was calculated after 17 h incubation and the IC50 values
calculated for the different conditions (Figures H.2 and H.3). Dose-response assays
were performed against the WT and ∆pdr strains with 95 and 97 in high and low
Ca2 environments.
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Cell cycle inhibition studies
Analysis by bud index: Fresh overnight cultures of haploid WT and ∆pdr cells
were diluted to 5 105 cells mL 1 in fresh SC or SD–ura, then treated with either
95 (wt) or 97 (∆pdr) at their MIC (10 µmol L 1 final concentration). DMSO
served as a negative control. At 2, 4 and 6 h time-points, 10 µL aliquots were
removed, diluted 1:100 in H2O and 10 µL samples of the populations were assessed
by haemocytometer. Cell counts were made at each time-point, and the individual
cells were scored according to bud size corresponding to their stage in the cell cycle.
Cells were visually assessed and imaged at t = 2 and 4 h and the assays were repeated
periodically to assess potential degradation of the inhibitory agents 95 and 97.
Cell cycle analysis by flow cytometry: Three fresh overnight cultures of
haploid WT cells were diluted to 5 106 cells mL 1 in fresh SC and cultured for
a further 4 h to mid-log growth phase. Aliquots were taken and diluted to give
1 mL cultures 1 107 cells mL 1. Cells were treated with DMSO and 95 at 10, 7
and 3.4 µmol L 1 and incubated at 30 C for 4 h. Cells were pelleted and washed
with 5 mL Tris HCl buffer (50 mmol L 1) and resuspended in 1.5 mL H2O. To each
1.5 mL sample, 3.5 mL absolute EtOH was added as a fixative (70% EtOH final
concentration) and the cells were incubated at 4 C overnight. Cells were pelleted,
EtOH removed and the cells were washed twice with 2 mL Tris HCl buffer (50 mmol
L 1), resuspending each time by sonication. Cells were treated with 1.25 mL RNase
solution (diluted 10-fold in 50 mmol L 1 Tris HCl buffer) and incubated for 2 h at
37 C with shaking. The cells were again pelleted, the RNase solution was removed,
and then treated with 2 mL of fresh pepsin solution for 5 min at room temperature.
100 µL aliquots were then added to 2 mL solutions of SytoxGreen (1 µmol L 1
in Tris HCl buffer), placed on ice and imaged immediately. A FACScan flow
cytometer was used to visualise cells and CellQuest Pro software (BD Biosciences)
was used to generate contour plots for each sample. Flow cytometry cell population
data was manipulated with FlowJo version 7.6.1 flow cytometry analysis software.
Populations were manually gated according to the untreated control and recorded
as percentage of total population within the sample.252
RNase stock solution, 10x:
RNase 100 mg
NaOAc (3 mol L 1) 333 µL
H2O 9.7 mL
Pepsin solution:
Pepsin 50 mg
HCl (1 mol L 1) 550 µL
H2O 9.45 mL
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Analysis of reactive oxygen species formation by flow cytometry Overnight
liquid cultures of haploid WT and ∆pdr cells were diluted to 1 107 cells mL 1 in
fresh SC medium. In duplicate, 100 µL aliquots of WT and ∆pdr culture were
treated with experimental and control agents for 1 h in microcentrifuge tubes. Wild-
type and ∆pdr cells were treated by 95 and 97 respectively and positive controls of
both strains were treated with 1 µL aliquots of 1 mmol L 1 H2O2 and DMSO then
incubated for 30 min at 30 C. DCF-DA was added (50 µmol L 1 final concentration)
and the cells were incubated for a further 15 min. The cultures were placed on ice,
diluted with 400 µL H2O, and co-stained with 6 mg mL 1 propidium iodide prior to
visualisation. Cells were visualised on the FACScan flow cytometer and CellQuest
Pro software (BD Biosciences) was used to generate contour plots for each sample.
Cell population data obtained from the flow cytometer was modelled on FlowJo
version 7.6.1 flow cytometry analysis software. Populations were manually gated
according to the untreated control and recorded as percentage of total population
within the sample.
7.8.3 Chemical genetic profiling of epiplakinic acid I
Homozygous profiling by microarray
A 0.5 mL aliquot of the homozygous deletion set pool was inoculated into 10 mL
SC and supplemented with 10 µL G418 (200 mg mL 1 in a 50 mL falcon tube. The
culture was incubated overnight at 30 C in a rotating drum. Five parallel 10 mL
cultures SC were seeded with 5 106 cells from the fresh culture of the YKO pool.
Four of the cultures were treated with 95 to final concentrations of 4, 3, 2 and 1
µmol L 1 and a 100 µL aliquot of DMSO served as control in the fifth culture. The
cultures were incubated for 10 generations ca. 15 h at 30 C in a rotating drum.
It was determined that 3 µmol L 1 of 95 inhibited cellular growth by 30% (IC30)
relative to the DMSO control. The cultures treated with DMSO and 3 µmol L 1
95 were then diluted to 5 106 cells in 10 mL fresh SC, treated again DMSO or 95
and cultured for a further 10 generations.
Cell populations were determined by haemocytometer and duplicate 1.5 mL aliquots
of both control and 95-treated cultures were pelleted for 2 min at 10,000 rpm in
microcentrifuge tubes and the supernatant discarded. Genomic DNA was then
extracted from the cell pellets in accordance with the Master PureTMYeast DNA
Purification Kit. The cell pellets were resuspended in 300 µL of yeast cell lysis
solution by vortexing then incubated at 65 C for 15 min then placed on ice for 5
min. A 150 µL aliquot of MPC protein precipitation reagent was added to each lysed
sample, mixed by vortex for ca. 10 s and the cellular debris pelleted by centrifugation
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at 10,000 rpm for 10 min.
The supernatant was transferred into a clean microcentrifuge tube and the genomic
DNA was precipitated out by the addition of 500 µL IPA. This was mixed by
inverting the tube and the DNA pelleted by centrifugation at 10,000 rpm for 10
min. The DNA was washed twice with 70% EtOH solution then dried briefly at room
temperature. The DNA was dissolved in 35 µL Tris EDTA buffer and incubated
at 65 C for 10 min. A 1 µL aliquot of RNase (5 µg mL 1) was added to each
microcentrifuge tube and the samples were incubated at 37 C with shaking for 30
min.
The duplicate samples were combined and H2O was added to a final volume of 0.5
mL. The DNA was extracted with 500 µL of phenol/CHCl3/isoamyl alcohol mix
(25:24:1). The phases were emulsified by vortex and separated by centrifugation
for 10 min at 16,000 rpm. The organic layer was removed and the aqueous phase
washed with 500 µL of CHCl3. 1 mL EtOH and 40 µL NaOAc were added to the
aqueous layer and shaken gently. The DNA was precipitated during incubation for
25 min at 4 C, and the pellets recovered following centrifugation (10 min, 13,000
rpm). The DNA pellets were washed twice with 70% EtOH then dissolved in 35 µL
Tris EDTA (10 min, 60 C) and maintained at 4 C until further use.
The DNA was quantified using a Hoechst 33258 dye and calf thymus as the DNA
standard. Four separate PCR reactions were conducted with 100 ng of starting
DNA template. These consisted of the Up and Dn tags for both the control and
experimental DNA samples. The Up tags were labeled with Cy3-dye markers and
Dn tags with Cy5. The experimental conditions and primer sequences are shown
below.
Primer sequences:
D1 5 -CGGTGTCGGTCTCGTAG- 3
U1 5 -GATGTCCACGAGGTCTCT- 3
D2comp-Cy3 or -Cy5 5 -Cy [3/5]-CGAGCTCGAATTCATCGAT- 3
U2comp-Cy3 or -Cy5 5 -Cy [3/5-GTCGACCTGCAGCGTACG- 3
PCR primer combinations:
Control DNA (no compound) Up tag PCR Primers U1 and U2comp-Cy3
Dn tag PCR Primers D1 and D2comp-Cy3
Experimental (compound) Up tag PCR Primers U1 and U2comp-Cy5
Dn tag PCR Primers D1 and D2comp-Cy5
Each PCR reaction was performed in 60 µL final volume, containing 1.5 mmol L 1
MgCl2, 0.2 mmol L 1 dNTPs, and 1 µmol L 1 primers. PCR Master Mix was made
up as follows. Four negative controls were also prepared with 4.0 µL H2O in place
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of DNA.
Table 7.2 PCR Master Mix
Volume (µL)
Component 1 9 (1 array)
10x Platinum taq buffer 6.0 54.0
50 mmol L 1 MgCl2 1.8 6.2
5 mmol L 1 (each) dNTPs 2.4 21.6
Platinum taq (5 units µL 1) 0.2 1.8
H2O 40.8 367.2
Total volume 51.2 460.8
PCR reaction components, 8 0.2 mL tubes:
Labelled primer (25 µmol L 1) 2.4 µL
Unlabelled primer (25 µmol L 1) 2.4 µL
Master mix 51.2 µL
DNA (25 ng µL 1) or H2O 4.0 µL
PCR conditions:
94 C 3 m
94 C 30 s
50 C 30 s 38 cycles
72 C 30 s
72 C 5 m
10 C hold
A 5 µL aliquot of each PCR condition was combined with 1 µL loading dye and run
on a high resolution 4% MetaPhor Agarose gel with 1.5 µL 10-bp ladder (Invitrogen)
checking for both contamination and amplification of the 56-bp Up and Dn tags.
A 20 µL aliquot of blocking primer mix (12.5 µL, 100 µmol L 1 U1 primer; 12.5
µL, 100 µmol L 1 D1 primer; 12.5 µL, 100 µmol L 1 U2 block; 12.5 µL, 100
µmol L 1 D2 block; 50 µL H2O) was combined with 55 µL each PCR product.
The complimentary oligonucleotide sequences bind with the priming regions of the
PCR products preventing them from binding with each other and allowing them to
hybridise to the microarray. The barcode tags were precipitated by adding 24 µL
NaOAc (3 mol L 1, pH 5.2), 600 µL EtOH and 1 µL 5 mg mL 1 linear acrylamide
to initiate precipitation. Solutions were mixed by vortex and the PCR products
precipitated at –20 C over 2 h.
Blocking primer sequences:
D2block 5 -ATCGATGAATTCGAGCTCG
U2block 5 -CGTACGCTGCAGGTCGAC
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The PCR products were recovered by centrifugation at 13,000 rpm at 4 C for 30
m and at washed at 4 C with 70% EtOH. The EtOH was removed and the PCR
products and washed were dried briefly in the dark, at room temperature, then
redissolved 50 µL H2O and maintained at –20 C until hybridisation.
DNA hybridisation to microarray slide: The 50 µL PCR products were
combined with 50 µL filter-sterilised 2x hybridisation buffer (2 mol L 1 NaCl, 20
mmol L 1 Tris HCl pH 7.5, 1% Triton X-100. DTT (1 mmol L 1 final concentration)
was added to the hybridisation buffer immediately prior to use. The buffer and PCR
products were pipetted gently to mix, avoiding bubbles, and the hybridisation mix
was denatured at 95 C for 2 min.
A 100 µL aliquot of hybridisation mix was applied to the gasket slide avoiding bubble
formation. The microarray slide was placed active side down, on to gasket slide, the
chamber was assembled and rotated gently to ensure wetting of the entire slide and
continuous movement of the hybridsation mix. The slide was then rotated at a
moderate speed for 4 h at 42 C in a hybridisation oven. After baking, the gasket
slide was removed, rinsed 5 times (210 mL H2O, 90 mL SSPE and 0.15 mL Triton X),
centrifuged to remove residual H2O and dried in the dark with SiO2 dessicant. The
microarray slide was sent to Les McNoe at Otago Genomics Facility, Department of
Biochemistry, University of Otago.
Microarray data analysis: GenePix 6.0 (Molecular Devices, Sunnyvale, CA,
USA) was used to align the microarray image and extract data from the image file.
The GenePix results file (.gpr file) was opened in a spreadsheet program and the
control spots, spots flagged as poor quality, and those corresponding to essential
gene deletions were removed. The Up and Dn tags were separated into separate
worksheets and saved as .txt files. Each .txt file was uploaded into the web-based
SNOMAD software (standardisation and normalisation of microarray data) and
normalised according to the median F635 (Cy5) and median F532 (Cy3) data
columns (as the data types “ONEintensities” and “TWOintensities”, respectively).
Transformation parameters are as follows; Perform and Graph the transformation
in Steps 3, Log transformation (Log base 2), 4, calculation of mean log (intensities)
and log (ratios), and 5, local mean normalization across element signal intensity,
(Span 0.3, Trim 0.1).253 The data was submitted for processing and the results were
copied into a fresh worksheet. Data spots with low (<500) median F532 scores
were removed to reduce the level of noise in the data, and replicates were removed
using a “replicate removal” script.254 The normalised log ratios for tag replicates
were averaged, and z-scores (x-mean/standard deviation) were calculated. The data
was sorted by z-scores, with z-scores <–3.0 denoted as a probable significant hit.
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Database searches: Gene hits were categorised according to their molecular and
biological functions and their cellular components using the web-based program
FunSpec225. The Saccharomyces Genome Database226 was used to define the
molecular and biological functions of gene hits and to analyse the synthetic lethal
interactions of each genetic hit.
Haploinsufficiency profiling by microarray
The essential and nonessential gene cassettes of S. cerevisiae were assessed simul-
taneously for haploinsufficiency in the presence of 95. All practical proceedings
were the same as for the HOP, however 2 µmol L 1 95 was found to elicit a 30%
growth reduction of the heterozygous deletion pool relative to the DMSO control.
Data analysis differed in that values corresponding to essential genes were included
during processing.
Microarray validation by dose-response: The sensitivity of homozygous dele-
tion strains sla1∆/sla1∆, rsa1∆/rsa1∆, crz1∆/crz1∆, hcm1∆/hcm1∆, sfp1∆/sfp1∆,
rvs167∆/rvs167∆,mid1∆/mid1∆, cna1∆/cna1∆, cna2∆/cna2∆ and cnb1∆/cnb1∆
to epiplakinic acid I (95) was assessed by dose-response relative to the diploid wild-
type starting strain BY4743. The same general protocol as above was followed
during these validation assays with half-log dilutions from 100–0.1 µmol L 1 final
concentration. The ion-pump deletion mutants pmc1∆/pmc1∆, pmr1∆/pmr1∆ and
cch1∆/cch1∆ were also assessed relative to the diploid WT strain with an eight-
point dilution across two orders of magnitude; 30, 20, 10, 3, 2, 1 and 0.03 µmol L 1
final concentration.
Microarray validation by single-concentration growth inhibition: Slow
growing strains (sla1∆/sla1∆, rsa1∆/rsa1∆, sfp1∆/sfp1∆ and rvs167∆/rvs167∆)
were assessed for inhibition relative to the WT at the IC30 value used for the
microarray experiment, and at the WT IC50. Overnight cultures were prepared in
triplicate from different single colonies and incubated for 18 h at 30 C in a rotating
drum. The strains were diluted to 5 104 cells mL 1 in 2 mL fresh SC supplemented
with G418 antibiotic (200 µg mL 1). Nine 99 µL aliquots of each culture were added
to a 96-well tissue culture plate and treated in triplicate at 3.5 and 3.0 µmol L 1.
DMSO, 1 µL, served as control. Optical density measurements were taken hourly (t
= 0–8 h) and again at 20 h to quantify growth relative to the BY4743 WT strain.
190
7.8.4 Imaging studies
Prior to all imaging studies, GFP-labelled strains were cultured overnight on solid
agar plates (SD–his). Cells were transferred into 384-well clear bottomed microtitre
plates (Perkin Elmer Cell Carrier) by pipette and four 50 µL liquid cultures
(SC) were made by serial dilution. Cultures were inoculated with control and
experimental agents and incubated for a given period at 30 C imaging with the
OPERA microscope at specified time points.
Assessment of the nuclear-cytoplasmic ratio: The plasma-membrane protein
GFP strain Mrh1p-GFP with nuclear membrane marker NLS-RS2/mCherry was
cultured overnight on solid nutrient medium (SC-his). Cells of the GFP/mCherry
strain were transferred into a 384-well clear bottomed microtitre plate (Perkin Elmer
Cell Carrier) by pipette and a four-point serial dilution of 50 µL liquid cultures (SC)
was made in duplicate. Cultures were inoculated with 1% DMSO control and 95 at
the MIC concentration then incubated for 4 h, imaging at 2 and 4h.
Translocalisation of Crz1p-GFP in response to Ca2 : Freshly cultured
Crz1p-GFP cells were transferred from solid medium into a 384-well clear-bottomed
microtitre plate as above. Parallel serial dilutions (50 µL liquid SC) were prepared
over four points and cultured for 2 h prior to exposure to 1% DMSO, 50 mmol L 1
CaCl2 and 10 µmol L 1 95. Cells were imaged at 5 min intervals from t = 0–40
min.
Specificity of Crz1p-GFP translocation to Ca2 : Freshly cultured Crz1p-
GFP cells were transferred from solid medium into a 384-well clear-bottomed
microtitre plate as above. Parallel serial dilutions (50 µL liquid SC) were prepared
over four points and cultured for 2 h prior to exposure to 1% DMSO, 50 mmol L 1
of the following metal salts: CaCl2, MgCl2, ZnSO4, CuSO4 and KCl, and 10 µmol
L 1 95. Cells were imaged at 5 min intervals from t = 0–40 min.
ROS induction with H2O2 in the Yap1p-GFP/mCherry strain: Freshly
cultured Yap1p-GFP/mCherry cells were transferred into a 384-well clear-bottomed
microtitre plate as above. Four, parallel serial dilutions (50 µL liquid SC) were
prepared over four points and cultured for 2 h prior to exposure to 1% DMSO, 50
mmol L 1 CaCl2, 10 µmol L 1 95, and 1 mmol L 1 H2O2. Cells were imaged at 5
min intervals from t = 0–40 min.
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Effect of epiplakinic acid I upon membrane-bound ion pumps: Cultures
of the Zrt1-GFP, Zap1-GFP and Crz1-GFP strains were prepared as stated above
and transferred into 4-point serial dilutions of liquid SC in a clear-bottomed 384-well
microtitre plate. The three GFP strains were simultaneously exposed to 1% DMSO
control, 50 mmol L 1 CaCl2, MgCl2 and ZnSO4 and 10 µmol L 1 95. Response to
these species was assessed at 5 min intervals from t = 0–40 min.
Quantification of intracellular Ca2 levels: Calcium Orange (Molecular
Probes, Invitrogen) was used to quantify changes in the level of intra-cellular Ca2
upon exposure to 95 relative to the DMSO control. Thee 5 mL SC cultures of the
diploid WT BY4743 strain were incubated at 30 C in a rotating drum for 18 h then
diluted to 5 105 cells mL 1 in fresh SC. Cultures were treated with 95 at the MIC
(10 µmol L 1), and DMSO served as positive control. As per the methods of use
protocol, following 4 h exposure to 95 and DMSO control, cells were resuspended
by vortexing and three 300 µL aliquots of each experimental condition were were
individually transferred into fresh microcentrifuge tubes, and incubated 30 min in
the presence of Calcium Orange (5 µmol L 1). Emission intensity was measured in
two ways: Cells were washed twice with H2O to remove free ligand and resuspended
in 100 µL and the emission intensity of the probe measured (excitation 549 nm,
emission 576 nm). Emission intensity of the cell/dye suspension was also measured
to determine the effects of cell loss during the washing process.
7.8.5 Transformation of 8025-α strain
Plasmid purification: Cultures of bacteria expressing the pRS-316 plasmid were
grown overnight in 2 mL LB supplemented with 2 µL ampicillin. The cells were
harvested and subjected to RNA digest and the extracted plasmids were purified
with the Invitrogen Plasmid Preparation kit. Purity of the extracted plasmid was
determined by gel electrophoresis (1% agarose). The plasmid was stored at –20 C
prior to use in transformation.
Preparation of yeast cell cultures for transformation: Cells from a fresh
overnight culture of the yeast strain 8025-α were diluted to 2.5 108 in 150 mL pre-
warmed YPD and incubated with shaking at 30 C for 4 h in 250 mL conical flasks
to achieve mid-log growth of the culture. After 4 h growth the OD590 was measured
and duplicate 25 mL aliquots of the culture (1.75 108 cells) were washed twice with
25 mL H2O. The cells were harvested by centrifuge and resuspended in 1 mL H2O,
transferred into microcentrifuge tubes, washed again with H2O and 570 µL aliquots
of cell concentrate (108 cells) were further diluted in H2O to a total volume of 1 mL
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then harvested by centrifuge. To each microcentrifuge tube 360 µL transformation
mix (including plasmid DNA) was added and the yeast cells resuspended by vortex.
Transformation mix:
PEG 3350 50% w/w 240 µL
LiOAc 1 mol L 1 36 µL
single-stranded carrier DNA 2.0 mg mL 1 50 µL
Plasmid DNA in H2O 34 µL
Heat-shock was applied by placing the microcentrifuge tubes in a 42 C water-bath
for 40 min, after which the tubes were centrifuged at 10,000 rpm for 30 s and the
supernatant was removed by pipette. The cell pellet was resuspended in 1 mL YPD
and incubated for 3 h at 30 C with shaking. A 150 µL aliquot of transformed cell
culture were plated onto YPD agar, and the remainder harvested and resuspended in
150 µL YPD and plated similarly. Plates were incubated for 36 h at 30 C and four
transformants were randomly selected then streaked again on YPD then incubated
for 24 h at 30 C.
7.8.6 Attempted transformation of zrt1∆/zrt1∆ and
cch1∆/cch1∆ strains
Plasmid purification: As above, bacteria expressing the pMT 2932 and 2916
plasmids encoding the URA3 MX cassette were cultured overnight in 2 mL LB
supplemented with 2 µL ampicillin. The cells were harvested and the plasmids
extracted and purified as per the Invitrogen Plasmid preparation kit. Restriction
digests were performed on both plasmids.
Restriction digest as performed in microcentrifuge tubes:
Plasmid DNA in H2O 50 µL
10x Buffer 2 5 µL
EcoR1 enzyme 1 µL
BamH1 enzyme 1 µL
Bovine serum albumin 0.5 µL
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Appendix A
Sponge Screening and Cyclic Loading
Protocol
A.1 Cyclic loading and backloading
Cyclic loading is a technique developed by Northcote and West255 and was frequently
employed during this research. The technique was used to fractionate crude
extracts of organisms during the screening process, separating the undesirable non-
polar fats and highly polar salts and carbohydrates from the intermediate polarity
compounds of interest, i.e. secondary metabolites. This laboratory employs PSDVB
(poly(styrene-divinylbenzene)) cross-linked polymeric resin beads as the stationary
phase. PSDVB is a macro-porous, rigid resin which is chemically inert and stable
across a large pH range, and can be reused a number of times without decreased
performance. The beads are devoid of polar functional groups so irreversible binding
or degradation of polar substrates has not been observed.
As depicted in Figure A.1 the crude (MeOH) extract is passed through a PSDVB
column, allowing adhesion of non-polar metabolites within the extract to the column.
The eluent is diluted 1:1 with H2O and re-cycled through the column iteratively,
diluted 1:1 with H2O at each stage. Increased eluent polarity facilitates adsorption
of increasing polar metabolites to the stationary phase, in effect the opposite of
conventional chromatography. After adhesion of the desired material to the column,
it is eluted with mixtures of H2O and an organic modifier of decreasing polarity,
commonly 30%, 75% and 100% Me2CO in H2O.
The 30% and 75% Me2CO in H2O fractions are then backloaded onto the screening
column using the same cyclic technique, the column is air dried and then eluted
with organic solvent. This generates fractions devoid of H2O which can be easily
evaporated under reduced pressure.
This laboratory uses water-miscible solvents such as MeOH and Me2CO, which are
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Figure A.1 A depiction of the cyclic loading process.
considerably more environmentally friendly than the halogenated solvents frequently
used in other approaches such as liquid-liquid partitioning. Large quantities of eluent
are generated during the procedure - the major draw-back of the technique. For a 20
g screening sample of sponge, 4.1 L of eluent is produced. However, an automated
set-up is is available for large-scale extractions using an HPLC pump system.
A.2 Screening protocol
Equipment required (per screen)
1 screening column loaded with 40 mL of HP20 resin beads equilibrated in MeOH.
Standard Preparation
Prepare an NMR quantification standard of 100 µL nitromethane in 5 mL CDCl3.
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Voucher sample preparation
Take a voucher specimen of ca. 10 g of the crude sponge material ensuring that
both the ectoderm and the endoderm are represented. Label and store the voucher
sample in 75% IPA in H2O.
Extraction
• Extract 20 g of crude sponge material in 100 mL MeOH overnight.
• Filter the first extract and set aside.
• Re-extract the sponge material (and any filter paper/celite as necessary) in
100 mL MeOH overnight.
• Filter the second extract. Keep all sponge material (and any filter paper/celite
as necessary) until the screen is complete at which time it may be discarded.
A.3 Cyclic loading
• Pass the second extract through the screen column with a flow rate of ca. 10
mL min 1.
• Pass the first extract through the screen column with a flow rate of ca. 10 mL
min 1. Combine both eluents.
• Dilute the combined eluents with 200 mL H2O. Pass the diluted eluents back
through the screen column at a flow rate of ca. 10 mL min 1.
• Dilute the eluent with 400 mL H2O. Pass the diluted eluent back through the
screen column at a flow rate of ca. 10 mL min 1. The eluent should be kept
until the screen is complete at which time it may be discarded.
Elution
• Elute the screen column with 100 mL of H2O at a flow rate of ca. 10 mL
min 1. The H2O eluent can be discarded immediately.
• Elute the screen column with 100 mL of 30% Me2CO in H2O at a flow rate of
ca. 10 mL min 1.
• Elute the screen column with 100 mL of 75% Me2CO in H2O at a flow rate of
ca. 10 mL min 1.
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• Elute the screen column with 100 mL of Me2CO at a flow rate of ca. 10 mL
min 1.
Backloading the 75% Me2CO Fraction
• Dilute the 75% Me2CO fraction with 100 mL H2O. Pass the diluted eluent
through the backloading column at a flow rate of ca. 8 mL min 1.
• Dilute the eluent with 200 mL of H2O. Pass the diluted eluent back through
the backloading column at a flow rate of ca. 8 mL min 1. The eluent should
be kept until the screen is complete at which time it may be discarded.
• Elute the backloading column with 100 mL of Me2CO.
Backloading the 30% Me2CO Fraction
• Dilute the 30% Me2CO fraction with 100 mL of H2O. Pass the diluted eluent
through the backloading column at a flow rate of ca. 8 mL min 1.
• Dilute the eluent with 200 mL of H2O. Pass the diluted eluent back through
the backloading column at a flow rate of ca. 8 mL min 1. The eluent should
be kept until the screen is complete at which time it may be discarded.
• Elute the backloading column with 100 mL of Me2CO.
A.4 Processing and NMR analysis
Processing the 75% Me2CO Fraction
• Rotary-evaporate the Me2CO eluent of the backloading column to dryness and
transfer to a pre-weighed sample vial. Evaporate to dryness and record the
mass.
• Prepare an NMR sample of the sample in 500 µL CD3OD in a 5 mm NMR
tube with 10 µL of the nitromethane standard.
NMR Analysis of the 75% Me2CO Fraction
• Run a 1H spectrum of the sample using the standard 1H experiment with 64
transients (ca. 4 min)
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• Run a COSY spectrum of the sample using the standard gCOSY parameter
set. (ca. 20 min)
• Run a fully-coupled HSQC spectrum of the sample using the standard H-
coupled HSQCad parameter set. (ca. 5 1/2 h)
• Run a fully-coupled HMBC spectrum of the sample using the standard H-
coupled gHMBC parameter set. (ca. 8 1/4 h)
Processing the 30% Fraction
• Rotary-evaporate the Me2CO eluent of the backloading column to dryness and
transfer to a pre-weighed sample vial. Evaporate to dryness and record the
mass.
Processing the 100% Fraction
• Rotary-evaporate the Me2CO eluent of the screen column to dryness and
transfer to a pre-weighed sample vial. Evaporate to dryness and record the
mass.
• Prepare an NMR sample of the sample in 700 µL of CDCl3 in a 5 mm NMR
tube with 10 µL of the nitromethane standard.
NMR Analysis of the 100% Fraction
• Run a 1H spectrum of the sample using the standard 1H experiment with 64
transients (ca. 4 min).
• Run a COSY spectrum of the sample using the standard gCOSY parameter
set. (ca. 20 min).
• Run a fully-coupled HSQC spectrum of the sample using the standard H-
coupled HSQCad parameter set. (ca. 5 1/2 h).
• Run a fully-coupled HMBC spectrum of the sample using the standard H-
coupled gHMBC parameter set. (ca. 8 1/4 h).
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A.5 Spicule analysis
• Submerge a 1 cm3 piece of extracted sponge in 3 mL HNO3 in a glass test
tube. Ensure that both ecto- and endo-derms are represented in the tissue
sample.
• Monitor decomposition of the organic tissue (ca. 24 h).
• When the organic matter is dissolved, dilute the acid with 5 mL H2O.
• Centrifuge for 5 min to pallet the spicules.
• Remove the aqueous solution and wash the recovered spicules with 5 mL H2O.
Repeat the washing procedure twice more.
• Air dry the spicules for 24 h then analyse by SEM.
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Appendix B
Yeast Growth Media
YPD liquid media
Liquid volume (total) 1000 mL 800 mL
Yeast extract 10 g 8 g
Peptone 20 g 16 g
Adenine 0.12 g 0.096 g
Agar 20 g 16 g
Autoclave and cool to 65 C, add 40% glucose solution to a final concentration of 2$
and antibiotics as required.
SD liquid media
Liquid volume (total) 1000 mL 800 mL
2x Agar solution
Agar 20 g 16 g
H2O 500 mL 400 mL
2x SD solution
H2O 500 mL 400 mL
Yeast nitrogen base 1.7 g 1.36 g
Monosodium glutamate 1 g 0.8 g
Required amino acids 2 g 1.6 g
Autoclave and cool the 2x agar and 2x SD solutions to 65 C, and combine the
solutions while stirring, add 40% glucose solution (5% final concentration) and
supplements as required.
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Appendix C
NMR Data for Known Compounds
Table C.1 1H and 13C NMR Data (600 MHz, CDCl3) for iso-Secothorectolide (23).
13C 1H
Position δC mult 1JCH (Hz) δH mult J (Hz)
O
O
O
HO
H OH
1
25
24
3
23
22
21
20 18
14
10
6
23
1 170.2 C
2 146.1 C
3 69.0 CH 146 4.80 brs
4 a 34.8 CH2 128 2.85 brd
b 129 2.80
5 147.5 CH 154 6.54 t 6.6
6 124.3 C
7 24.7 CH2 128 2.29 t 7.0
8 26.7* CH2 128 2.04–2.10 m
9 123.0 CH 151 5.10 m
10 136.7 C
11 39.71** CH2 120 1.95 brt 8.4
12 26.73* CH2 128 2.04–2.10 m
13 123.5 CH 151 5.09 m
14 135.3 C
15 39.68** CH2 120 1.93 brt 8.4
16 26.54* CH2 128 2.04–2.10 m
17 124.1 CH 151 5.08 m
18 131.5 C
19 25.7 CH3 125 1.67 s
20 17.9 CH3 125 1.60 s
21 16.16 CH3 125 1.57 s
22 16.2 CH3 125 1.59 s
23 194.5 CHO 175 9.4 s
24 147.51 CH 188 6.20 brs
25 119.1 CH § 6.12 brs
* and **Assignment interchangeable
§Signal unresolved and immeasurable
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Table C.2 1H and 13C NMR Data (600 MHz, CDCl3) for 1-Hydroxyluffarin Q (24).
13C 1H
Position δC mult 1JCH (Hz) δH mult J (Hz)
OO OH
1 25
3
24
23
22
21 19
15
11
7
24
1 171.5 C
2 117.8 CH 184 6.09 s
3 168.3 C
4 26.1 CH2 122 2.16 m
5 26.8 CH2 120 2.06 quin 7.5
6 120.9 CH 161 5.70 brd 5.1
7 135.21 C
8 27.0** CH2 2.05–2.11 m
9 32.7 CH2 128 2.12 m
10 124.2 CH 151 5.10 brt 7.6
11 137.5 C
12 39.9 CH2 123 1.97 m
13 26.9** CH2 2.05–2.11 m
14 123.5 CH 152 5.12 brt 6.8
15 136.1 C
16 39.8 CH2 123 1.97 m
17 26.95** CH2 2.05–2.11 m
18 124.5 CH 151 5.08 brt 7.6
19 131.5 C
20 25.9 CH3 124 1.67 s
21 17.8 CH3 124 1.59 s
22 16.24* CH3 124 1.60 s
23 16.21* CH3 124 1.60 s
24 16.1 CH3 125 1.59 s
25 91.4 CH 168 5.31 s
* and **Assignment interchangeable
Table C.3 1H and 13C NMR Data (600 MHz, CDCl3) for ambliol B (25).
13C 1H
Position δC mult 1JCH (Hz) δH mult J (Hz)
OH
O
H1
5
10
11
13
15
16
18
19   20
17
25
1 a 21.4 CH2 125 1.59 brd
b 126 1.34 td 14.0, 4.4
2 a 22.4 CH2 128 1.56
b 126 1.46
3 a 36.8 CH2 124 1.64 td
b 128 1.09 brd 13.4
4 39.1 C
5 76.4 C
6 a 25.5 CH2 122 1.71 td 14.0, 4.2
b 126 1.41 dt
7 a 24.6 CH2 126 2.08 tt 17.8, 4.0
b 127 1.25 m
8 40.5 CH 120 1.58 d 7.1
9 37.5 C
10 35.1 CH 127 1.70 quin 4.5
11 a 40.2 CH2 125 1.64 m
b 126 1.29 m
12 18.1 CH2 125 2.36 dt 9.8, 8.0
13 126.2 C
14 138.6 CH 202 7.2 s
15 111.1 CH 174 6.25, s
16 142.8 CH 202 7.35, s
17 23.7 CH3 123 1.01 s
18 24.6 CH3 124 0.86 s
19 14.3 CH3 123 0.95 d
20 21.0 CH3 124 1.13 s
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Table C.4 1H and 13C NMR Data (600 MHz, CDCl3) for Luffariellolide (26).
13C 1H
Position δC mult 1JCH (Hz) δH mult J (Hz)
O O
HO
24
25
23
22
21
20 19
17
13
9
1
4
6
26
1 19.7 CH2 123 1.56 ddd 12.1, 6.2, 6.0
2 32.9 CH2 124 1.90 t 6.1
3 39.9 CH2 125 1.41 ddd 9.0, 6.1, 2.6
4 35.1 C
5 137.2 C
6 127.1 C
7 28.1 CH2 130 2.06 m
8 40.4 CH2 128 2.00 m
9 136.5 C
10 123.4 CH 150 5.10 t 7.0
11 26.6 CH2 127 2.08 q 7.7
12 39.8 CH2 128 2.02 m
13 137.6 C
14 122.1 CH 151 5.12 t 7.2
15 25.3 CH2 125 2.31 q 6.9
16 27.9 CH2 125 2.45 brs
17 169.4 C
18 117.8 CH 181 5.86 s
19 171.5 C
20 99.1 CH 173 5.99 s
21 28.8* CH3 124 0.97 s
22 28.8* CH3 124 0.97 s
23 20.0 CH3 125 1.59 s
24 16.2 CH3 124 1.63 s
25 16.3 CH3 124 1.62 s
*Indistinguishable
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Table C.5 1H and 13C NMR Data (600 MHz, CDCl3) for 5α,8α-Epidioxysterol (27).
13C 1H
Position δC mult 1JCH (Hz) δH mult J (Hz)
1 a 34.8 CH2 128 1.95 td 13.5, 3.4
b 129 1.69 dtd 13.2, 3.4
2 a 30.2 CH2 125 1.84 dd 12.9, 3.9
b 125 1.53 q 14.0, 3.9
3 66.6 CH 144 3.81 s
4 a 37.1 CH2 141 2.11 ddd 13.9, 5.3, 1.9
b 125 1.94 dd 13.1, 11.3
5 82.3 C
6 135.5 CH 168 6.14 d 8.5
7 130.9 CH 170 6.51 d 8.7
8 79.6 C
9 51.2 CH 130 1.49 t 5.1
10 37.0 C
11 a 23.5 CH2 127 1.50 dd 10.1, 7.0
b 127 1.21 dd 18.6, 3.2
12 a 39.5 CH2 127 1.96 d 14.4
b 124 1.23 brd 5.8
13 44.7 C 1.23 brd 6.0
14 51.8 CH 123 1.56 m
15 a 20.8 CH2 125 1.77 dtd 7.4, 12.2, 3.2
b 116 1.4 dd 11.9, 6.1
16 a 29.1 CH2 126 1.69 dt 13.7, 3.5
b 127 1.34 dd 22.4, 9.8
17 56.2 CH 123 1.23 m
18 13.0 CH3 125 0.82 s
19 18.3 CH3 125 0.88 s
20 40.1 CH 126 2.03 dtd 23.6, 7.9, 2.7
21 21.3 CH3 125 1.01 d 6.4
22 137.8 CH 148 5.14 dd 15.0, 8.3
23 130.0 CH 152 5.04 dd 15.3, 8.7
24 (1) a 25.5 CH2 124 1.41 m
b 124 1.17 d 10.1
24 (2) 12.6 CH3 128 0.80 t 7.5
25 31.2 CH 127 1.52 m
26 19.1 CH3 122 0.79 d 6.7
27 21.1 CH3 124 0.84 d 6.4
†Selected correlations.
*Weak correlations.
HO
O O
1
3 5
810
11 13
17
18
20
19
21
24
26
27
27
205
Table C.6 1H and 13C NMR Data (600 MHz, CDCl3) for 5α,8α-Epidioxysterol (28).
13C 1H
Position δC mult 1JCH (Hz) δH mult J (Hz)
1 a 34.8 CH2 127 1.95 td 13.3, 3.6
b CH2 129 1.69 dt 13.7, 3.4
2 a 30.2 CH2 133 1.83 brd 12.6
b 125 1.54 m
3 66.6 CH 144 3.97 m
4 a 37.1 CH2 126 2.11 ddd 13.8, 5.1, 2.0
b CH2 127 1.91 dd 11.7, 13.6
5 82.3 C-O
6 135.5 CH 166 6.24 d 9.1
7 130.9 CH 168 6.51 d 9.1
8 79.6 C-O
9 51.2 CH 128 1.48 m
10 37.0 C
11 a 23.5 CH2 127 1.50 m
b CH2 126 1.21 m
12 a 39.5 CH2 128 1.98 d 9.4
b 126 1.22 m
13 44.9
14 51.7 CH 121 1.54 m
16 a 28.4 CH2 125 1.91 m
b 127 1.36 m
17 56.5 CH 124 1.17 quin 8.0
18 12.8 CH3 122 0.80 s
19 18.3 CH3 126 0.88 s
20 35.4 CH 123 1.36 quin 2.7
21 18.7 CH3 124 0.89 d 6.7
22 a 36.1 CH2 124 1.34 t 12.7
b CH2 124 1.00 d 6.9
23 a 23.9 CH2 1.32 m
b 1.14 m
24 39.6 CH2 1.1
25 28.1 CH2 125 1.51 m
26 22.7 CH3 125 0.86 d 6.6
27 23.0 CH3 124 0.87 d 6.6
28 33.2 CH 124 1.46 qd 11.7, 6.1
†Selected correlations.
*Weak correlations.
HO
O O
1
3 5
810
11 13
17
18
20
19
21
24
25
26
27
28
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Table C.7 1H and 13C NMR Data (600 MHz, CDCl3) of 14-Bromohomofascaplysin (29).
13C 1H
Position δC mult 1JCH (Hz) δH mult J (Hz)
N
HO
O
NH
Br
1
6
7
18
21
911
15
16
29
1 137.21 C
2 124.4 CH 165 7.90 dd 7.7, 0.9
3 130.6 CH 164 7.70 td 7.4, 0.7
4 130.9 CH 165 7.8 d 7.9
5 113.8 CH 167 8.28 d 8.5
6 141.2 C
N -1
7 124.0 CH 192 9.38 d 8.6
8 117.2 CH 175 8.83 d 8.6
9 135.0 C
10 119.1 C
11 124.5 CH 167 8.4 d 8.5
12 125.8 CH 171 7.66 dd 8.48, 1.66
13 126.7 C
14 115.6 CH 172 8.02 d 1.37
15 146.0 C
NH-2
16 131.0 C
17 143.95 C
18 77.81 C
19 50.1 CH2 130 4.20 dd 24.1, 18.6
20 205.1 C
21 28.0 CH3 128 1.98 s
Table C.8 1H and 13C NMR Data (600 MHz, d3-MeCN) of Halenaquinone (31).
13C 1H
Position δC mult 1JCH (Hz) δH mult J (Hz)
O
O
O
O
O
1
3
6
20
812
17 19
31
1 149.7 CH 211 8.37 s
2 122.7 C
3 191.5 C
4 a 36.2 CH2 125 3.05 ddd 18.7, 13.3, 5.4
b 132 2.72 ddd 18.6, 4.7, 1.9
5 b 32.7 CH2 134 2.89 ddd 13.1, 5.4, 1.9
b 131 2.25 td 13.2, 4.8
6 36.9 C
7 148.4 C
8 144.7 C
9 170.5 C
10 137.0 C
11 125.6 CH 167 9.08 s
12 130.7 C
13 184.1 C
14 139.0 CH 170 7.06 d 11.4
15 139.6 CH 170 7.08 d 11.1
16 184.5 C
17 134.0 C
18 123.8 CH 163 8.30 s
19 154.7 C
20 29.4 CH3 130 1.66 s
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Appendix D
1H NMR Spectra of Known
Compounds
208
iso-Secothorectolide
1H NMR spectrum of iso-secothorectolide (23) (600 MHz, CDCl3).
209
1-Hydroxyluffarin Q
1H NMR spectrum of 1-hydroxyluffarin Q (24) (600 MHz, CDCl3).
210
Ambliol B
1H NMR spectrum of ambliol B (25) (600 MHz, CDCl3).
211
Luffarielolide
1H NMR spectrum of luffarielolide (26) (600 MHz, CDCl3).
212
14-Bromohomofascaplysin
1H NMR spectrum of 14-bromohomofascaplysin (29) (600 MHz, CDCl3).
213
5α,8α-Epidioxysterol 27
1H NMR spectrum of 5α,8α-epidioxysterol 27 (600 MHz, CDCl3).
214
5α,8α-Epidioxysterol 28
1H NMR spectrum of 5α,8α-epidioxysterol 28 (600 MHz, CDCl3).
215
Halenaquinone
1H NMR spectrum of halenaquinone (31) (600 MHz, CDCl3).
216
Appendix E
NMR Spectra of Luakuliides A–C
217
Luakuliide A
1H NMR spectrum of luakuliide A (33) (600 MHz, CDCl3).
218
COSY spectrum of luakuliide A (33) (600 MHz, CDCl3).
219
Fully-coupled HSQC spectrum of luakuliide A (33) (600 MHz, CDCl3).
220
HMBC spectrum of luakuliide A (33) (600 MHz, CDCl3).
221
13C NMR spectrum of luakuliide A (33) (150 MHz, CDCl3).
222
Luakuliide A Methyl Acetal
1H NMR spectrum of luakuliide A methyl acetal (34) (600 MHz, CDCl3).
223
COSY spectrum of luakuliide A methyl acetal (34) (600 MHz, CDCl3).
224
Fully-coupled HSQC spectrum of luakuliide A methyl acetal (34) (600 MHz, CDCl3).
225
HMBC spectrum of luakuliide A methyl acetal (34) (600 MHz, CDCl3).
226
13C NMR spectrum of luakuliide A methyl acetal (34) (150 MHz, CDCl3).
227
Luakuliide B
1H NMR spectrum of luakuliide B (35) (600 MHz, CDCl3).
228
COSY spectrum of luakuliide B (35) (600 MHz, CDCl3).
229
Fully-coupled HSQC spectrum of luakuliide B (35) (600 MHz, CDCl3).
230
HMBC spectrum of luakuliide B (35) (600 MHz, CDCl3).
231
13C NMR spectrum of luakuliide B (35) (150 MHz, CDCl3).
232
Luakuliide B
1H NMR spectrum of luakuliide B (35) (600 MHz, DMSO)
233
COSY spectrum of luakuliide B (35) (600 MHz, DMSO)
234
Fully-coupled HSQC spectrum of luakuliide B (35) (600 MHz, DMSO)
235
HMBC spectrum of luakuliide B (35) (600 MHz, DMSO)
236
13C NMR spectrum of luakuliide B (35) (150 MHz, DMSO)
237
Luakuliide C
1H NMR spectrum of luakuliide C (36) (600 MHz, CDCl3).
238
COSY spectrum of luakuliide C (36) (600 MHz, CDCl3).
239
Fully-coupled HSQC spectrum of luakuliide C (36) (600 MHz, CDCl3).
240
HMBC spectrum of luakuliide C (36) (600 MHz, CDCl3).
241
13C NMR spectrum of luakuliide C (36) (150 MHz, CDCl3).
242
Luakuliide C
1H NMR spectrum of luakuliide C (36) (600 MHz, DMSO)
243
COSY spectrum of luakuliide C (36) (600 MHz, DMSO)
244
Fully-coupled HSQC spectrum of luakuliide C (36) (600 MHz, DMSO)
245
HMBC spectrum of luakuliide C (36) (600 MHz, DMSO)
246
13C NMR spectrum of luakuliide C (36) (150 MHz, DMSO)
247
Appendix F
NMR Spectra of Lehualides E–K
248
Lehualide E
1H NMR spectrum of lehualide E (69) (600 MHz, CDCl3).
249
COSY spectrum of lehualide E (69) (600 MHz, CDCl3).
250
Fully-coupled HSQC spectrum of lehualide E (69) (600 MHz, CDCl3).
251
HMBC spectrum of lehualide E (69) (600 MHz, CDCl3).
252
13C NMR spectrum of lehualide E (69) (150 MHz, CDCl3).
253
Lehualide F
1H NMR spectrum of lehualide F (70) (600 MHz, CDCl3).
254
COSY spectrum of lehualide F (70) (600 MHz, CDCl3).
255
Fully-coupled HSQC spectrum of lehualide F (70) (600 MHz, CDCl3).
256
HMBC spectrum of lehualide F (70) (600 MHz, CDCl3).
257
13C NMR spectrum of lehualide F (70) (150 MHz, CDCl3).
258
Lehualide G
1H NMR spectrum of lehualide G (71) (600 MHz, CDCl3).
259
COSY spectrum of lehualide G (71) (600 MHz, CDCl3).
260
Fully-coupled HSQC spectrum of lehualide G (71) (600 MHz, CDCl3).
261
HMBC spectrum of lehualide G (71) (600 MHz, CDCl3).
262
13C NMR spectrum of lehualide G (71) (150 MHz, CDCl3).
263
Lehualide H
1H NMR spectrum of lehualide H (72) (600 MHz, CDCl3).
264
COSY spectrum of lehualide H (72) (600 MHz, CDCl3).
265
Fully-coupled HSQC spectrum of lehualide H (72) (600 MHz, CDCl3).
266
HMBC spectrum of lehualide H (72) (600 MHz, CDCl3).
267
13C NMR spectrum of lehualide H (72) (150 MHz, CDCl3).
268
Lehualide I
1H NMR spectrum of lehualide I (73) (600 MHz, CDCl3).
269
COSY spectrum of lehualide I (73) (600 MHz, CDCl3).
270
Fully-coupled HSQC spectrum of lehualide I (73) (600 MHz, CDCl3).
271
HMBC spectrum of lehualide I (73) (600 MHz, CDCl3).
272
13C NMR spectrum of lehualide I (73) (150 MHz, CDCl3).
273
Lehualide J
1H NMR spectrum of lehualide J (74) (600 MHz, CDCl3).
274
COSY spectrum of lehualide J (74) (600 MHz, CDCl3).
275
Fully-coupled HSQC spectrum of lehualide J (74) (600 MHz, CDCl3).
276
HMBC spectrum of lehualide J (74) (600 MHz, CDCl3).
277
13C NMR spectrum of lehualide J (74) (150 MHz, CDCl3).
278
Lehualide K
1H NMR spectrum of lehualide K (75) (600 MHz, CDCl3).
279
COSY spectrum of lehualide K (75) (600 MHz, CDCl3).
280
Fully-coupled HSQC spectrum of lehualide K (75) (600 MHz, CDCl3).
281
HMBC spectrum of lehualide K (75) (600 MHz, CDCl3).
282
13C NMR spectrum of lehualide K (75) (150 MHz, CDCl3).
283
Appendix G
NMR Spectra of New Cyclic
Peroxides
284
Epiplakinic Acid I
1H NMR spectrum of epiplakinic acid I (95) (600 MHz, CDCl3).
285
COSY spectrum of epiplakinic acid I (95) (600 MHz, CDCl3).
286
Fully-coupled HSQC spectrum of epiplakinic acid I (95) (600 MHz, CDCl3).
287
HMBC spectrum of epiplakinic acid I (95) (600 MHz, CDCl3).
288
13C NMR spectrum of epiplakinic acid I (95) (150 MHz, CDCl3).
289
Epiplakinic Acid I Methyl Ester
1H NMR spectrum of epiplakinic acid I methyl ester (96) (600 MHz, CDCl3).
290
COSY spectrum of epiplakinic acid I methyl ester (96) (600 MHz, CDCl3).
291
Fully-coupled HSQC spectrum of epiplakinic acid I methyl ester (96) (600 MHz, CDCl3).
292
HMBC spectrum of epiplakinic acid I methyl ester (96) (600 MHz, CDCl3).
293
13C NMR spectrum of epiplakinic acid I methyl ester (96) (150 MHz, CDCl3).
294
Plakortolide X
1H NMR spectrum of plakortolide X (97) (600 MHz, CDCl3).
295
COSY spectrum of plakortolide X (97) (600 MHz, CDCl3).
296
Fully-coupled HSQC spectrum of plakortolide X (97) (600 MHz, CDCl3).
297
HMBC spectrum of plakortolide X (97) (600 MHz, CDCl3).
298
13C NMR spectrum of plakortolide X (97) (150 MHz, CDCl3).
299
Cyclic peroxide 98
1H NMR spectrum of cyclic peroxide 98 (600 MHz, CDCl3).
300
COSY spectrum of cyclic peroxide 98 (600 MHz, CDCl3).
301
Fully-coupled HSQC spectrum of cyclic peroxide 98 (600 MHz, CDCl3).
302
HMBC spectrum of cyclic peroxide 98 (600 MHz, CDCl3).
303
13C NMR spectrum of cyclic peroxide 98 (150 MHz, CDCl3).
304
Appendix H
Phenotypic Profile of 95
A
B
Figure H.1 Dose-response curves for epiplakinic acid I (95) and plakortolide X (97). 95
displays similar inhibition of both strains, while 97 only inhibits the ∆pdr strain.
A: 95, WT (–•–) and ∆pdr (– –) B: 97, WT (–•–) and ∆pdr (– –)
305
AB
Figure H.2 Activity of epiplakinic acid I (95) and plakortolide X (97) is enhanced by
high Ca2 levels.
A: 95 (–•–) IC50 4.98 µmol L 1 95 and 50 mmol L 1 CaCl2 (– –) IC50 1.88 µmol L 1
B: 97 (–•–) IC50 7.38 µmol L 1 97 and 50 mmol L 1 CaCl2 (– –) IC50 4.68 µmol L 1
306
Figure H.3 Dose-response curves for epiplakinic acid I and plakortolide X in the presence
of EGTA.
A: 95 (– –) 95 and EGTA, 10 mmol L 1 (–•–)
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Figure H.4 Epiplakinic acid I (95) causes a 50% increase in S-phase population of cells
treated at the IC50, and increases the G2 population when administered at the MIC.
A: DMSO, 1% B: 95, IC50 (3.45 µmol L 1) C: 95, MIC (10 µmol L 1)
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Figure H.5 Epiplakinic acid I (95) affects a decrease in cell size in S. cerevisiae. The
red proteins mCherry and Red Star II localise to the cytoplasm and nucleus respectively,
while the GFP-tagged Mrh1p resides in the plasma membrane.
A: DMSO (1%), 2 h, Mrh1-GFP B: DMSO (1%), 2 h, mCherry/Red Star II
C: 95 (10 µmol L 1), 2 h, Mrh1-GFP D: 95 (10 µmol L 1), 2 h, mCherry/Red Star II
Figure H.6 Hypersensitivity of cytoskeletal mutants to epiplakinic acid I (95) relative to
the BY4743 WT strain (–•–).
∆RVS167 (–￿ –) IC50 1.91 µmol L 1 ∆SLA1 (– –) IC50 1.98 µmol L 1
∆SFP1 (– –) IC50 2.80 µmol L 1 ∆RSA1 (– –) IC50 2.82 µmol L 1
308
AB
Figure H.7 Dose-response curves for epiplakinic acid I against Ca2 -responsive deletions
strains relative to the WT control.
A: WT BY4743 (–•–) ∆CNA1 (– –) IC50 3.77 µmol L 1
∆CNA2 (–￿–) IC50 3.56 µmol L 1 ∆CNB1 (–￿–) IC50 3.53 µmol L 1
∆CRZ1 (– –) IC50 3.49 µmol L 1 ∆HCM1 (– –) IC50 6.31 µmol L 1
B: WT BY4743 (–•–) ∆CCH1 (–￿–) IC50 3.60 µmol L 1
∆MID1 (– –) IC50 3.28 µmol L 1 ∆PMC1 (–￿–) IC50 5.25 µmol L 1
∆PMR1 (– –) IC50 3.36 µmol L 1 ∆YGL167W (– –) IC50 3.15 µmol L 1
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Figure H.8 Translocation studies in the Zrt1p-GFP, non-conclusive for endocytosis of
the membrane pump in response to a rise in intracellular Zn2 or exposure to 95.
A: DMSO, 0 min B: DMSO, t = 10 min C: DMSO, t = 40 min
D: 95, 0 min E: 95, t = 10 min F: 95, t = 40 min
G: ZnCl2, 0 min H: ZnCl2, t = 10 min I: ZnCl2, t = 40 min
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Appendix I
Chemical Genetic Profile of 95
Table I.1 Homozygous Profile of Epiplakinic Acid I (95).
Up Tag Dn Tag
Gene z-score Gene z-score
SLA1 -5.809413688 SLA1 -4.410560386
VPS24 -4.972817922 RPS9B -4.36002436
VPS28 -4.697856815 END3 -4.222755852
END3 -4.436000379 YER087W -3.991511202
YIL157C -4.334762811 STP22 -3.934688549
YOR019W -4.161528418 GOS1 -3.911094923
CRZ1 -4.125482084 TPS2 -3.834067429
YOR161C -4.048027013 VPS28 -3.741074729
YNL120C -4.025318625 VPS36 -3.685492132
RVS161 -3.979063015 RGP1 -3.659586023
OCH1 -3.791609729 SNF7 -3.576692859
SNF7 -3.576648865 DBP7 -3.53354966
SLI15 -3.572018966 YBL054W -3.48368878
BRO1 -3.457644953 SOD1 -3.444793226
APL2 -3.346409981 VAC7 -3.429958961
APT2 -3.269609242 GRR1 -3.37594831
VPS4 -3.205010706 YPL005W -3.362444783
HCM1 -3.123723593 SPO74 -3.304200493
SFP1 -3.110038414 RCY1 -3.290998502
PFK2 -3.029516051 RVS167 -3.204320695
VPS24 -4.972817922 CSG2 -3.171599027
DID2 -3.16113872
CHS5 -3.147043804
YLR338W -3.093662482
RSA1 -3.088253698
IRS4 -3.057798815
ARO7 -3.027509409
Bold font indicates genes with tag overlap.
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Table I.2 Haploinsufficiency Profile of Epiplakinic Acid I (95).
Up Tag Dn Tag
Gene z-score Gene z-score
YBL044W -9.434195341 OST5 -11.41086097
EDE1 -8.904361216 KIN4 -10.08904761
YKL200C -8.806319953 YLR123C -9.940118526
UBP13 -8.521427816 VHS1 -8.40816393
ENT4 -8.259266665 INP52 -7.877981485
UBR2 -7.827602252 CAR2 -7.590762838
NDT80 -7.110771208 MRM2 -7.488420803
YMR316C-A -6.806339037 RPS15 -7.405188592
YFR043C -6.655317155 MRS1 -7.323103591
ELA1 -6.592775111 EUG1 -6.945223471
YOR298W -6.477197383 YLR241W -6.693412231
YJL163C -6.472217167 SSP2 -6.651131162
THI12 -6.427515036 YDL206W -6.526193924
YER139C -6.341261909 COX17 -6.402868993
YNL187W -6.334975414 YDR223W -6.149852711
YLR202C -6.334490923 YLR269C -5.860689213
MAP2 -6.248179852 PHO36 -5.56226546
DDP1 -6.153337929 MAD3 -5.413899915
PCI8 -6.005399364 GAL3 -5.351678774
YBL083C -5.881486314 PMT6 -5.279371881
AIM2 -5.838454891 HIS3 -5.175504603
YIL077C -5.791565696 DAL7 -5.166777412
YDR084C -5.644580502 FRM2 -5.115838933
LST4 -5.626825535 RPS14B -5.023021712
AST1 -5.519434755 YER181C -5.019790686
EUG1 -5.211588583 MRPL11 -5.003391004
ERV46 -5.210483898 YUH1 -4.97076341
PST1 -5.205556664 YGL232W -4.866882063
YOR019W -5.148338476 PTP1 -4.618553681
AZR1 -5.09881151 SLZ1 -4.617101441
PYK2 -5.056831381 RPS7A -4.38453948
YIM1 -5.041111789 FOX2 -4.344719978
YPL245W -4.960736203 RAX1 -4.334933264
SSA3 -4.867248834 RPL27A -4.236754744
YFR055W -4.766419283 MSN5 -4.222920612
YMR210W -4.766383731 GGA1 -4.205278815
YKR017C -4.659871866 PRP43 -4.189182085
ATH1 -4.642439614 GMH1 -3.90118805
PHO81 -4.441089116 RAD4 -3.86603065
MAF1 -4.410447644 GAC1 -3.745939683
YOR255W -4.389717345 YSA1 -3.662090839
PCL1 -4.362060286 YGL082W -3.599448702
STE13 -4.272390889 HHT1 -3.59855679
ASC1 -4.171738708 PXR1 -3.486747419
RPC10 -4.036284207 RPL39 -3.447685757
ASI1 -4.006071145 RPL33A -3.422225152
Continued on following page . . .
Bold font indicates genes with tag overlap.
Essential genes appear in blue.
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Table I.3 Haploinsufficiency Profile of Epiplakinic Acid I Continued (95).
Up Tag Dn Tag
Gene z-score Gene z-score
CIK1 -3.741965011 YIL086C -3.212591118
RTS2 -3.886488775 TPS1 -3.410693771
YFR046C -3.826413009 DIP5 -3.385823841
PDR8 -3.754045725 YGR107W -3.132920087
YDR066C -3.677657055 IMD3 -3.116253877
GNP1 -3.660006156 NAP1 -3.110696791
YJR015W -3.656590627 YLL012W -3.110245285
YOL048C -3.646448665 MRPL16 -3.101164361
YIR003W -3.6222659 ADO1 -3.086583503
YOS9 -3.599699728 MNE1 -3.015526831
RCL1 -3.536428723
STP2 -3.501269521
YLR400W -3.420612012
CRC1 -3.409312476
SHU1 -3.28657986
SIP1 -3.285653011
FSH3 -3.2770514
ABP140 -3.235341139
YGL160W -3.114316827
YDR492W -3.096230308
YBR016W -3.095670033
YRA2 -3.020672642
SUR2 -3.000979236
Bold font indicates genes with tag overlap.
Essential genes appear in blue.
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Table I.4 Functional Categories of Deletion Strains Resistant to Epiplakinic Acid I (95,
3 µmol L 1, z-score > 2).
GO Molecular Function p-value Gene deletion strain
Phosphatidylinositol transporter
activity 0.000371781 SFH5 and CSR1
Phospholipase activity 0.000371781 PLB3, YOR022C, CSR1 and PLB3
FMN reductase activity 0.0062093 LOT6
NAD(P)H dehydrogenase
(quinone) activity 0.0062093 LOT6
High affinity zinc ion uptake and
transmembrane transporter
activity
0.0062093 ZRT1
bis(5’-Adenosyl)-triphosphatase
activity 0.0062093 HNT2
Phosphatidylserine catabolic
process 0.0062093 PLB3
Regulation of fatty acid
metabolic process 0.0062093 CSR1, PLB3 and YOR022C
Lipid transport 0.00733151 SFH5 and CSR1
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Table I.5 Functional Categories of Heterozygous Deletion Strains Resistant to Epiplakinic
Acid I (95, 2 µmol L 1, z-score > 2).
GO Molecular Functions p-value Gene deletion strain
Structural constituent of
ribosome 9.07E-05
RPS8A, RPS11A, RSM10, RPS13,
RPS18A, RPL27B, RPS2, RPS21B,
RSM22, RPS27A, RPL20A and RPS28A
SSU rRNA binding 0.00130933 RPS13 and RPS2
Inositol or phosphatidylinositol
phosphatase activity 0.00587519
INM2 and INP52
S-adenosylmethionine-
dependent methyltransferase
activity
0.00309695
RSM22, NOP2 and YNL092W
Adenyl-nucleotide exchange
factor activity 0.00320969
LHS1 and SIL1
Post-translational protein
targeting to membrane, translo-
cation
0.00748032
SBH1 and LHS1
SRP-dependent cotranslational
protein targeting to membrane
and translocation
0.00925952
SBH1 and SIL1
Structural constituent of nuclear
pore 0.00444974 NUP192 and NSP1
Translation
6.78E-05
FMT1, RPS8A, SLM5, RPS11A, RSM10,
RPS13, GCD6, RPS18A, RPL27B, RPS2,
RPS0A, RPS20, RPL40A, RPS21B, RPL39,
RSM22, RPS27A, MEF1, RPL37A, RPS30A,
RPL13B, RPL20A, YNL040W, RPL16B,
YNL122C, RPS28A, RPS6A, MSD1
and RPL43A
rRNA processing
0.00059314
RPS8A, RPS11A, RSM10, RPS13,
GCD6, RPS18A, RPL27B, RPS2,
RPS21B, RSM22, RPS27A, MEF1,
RPL20A, YNL040W and RPS28A
rRNA export from nucleus 0.000640291 NUP84, RPS18A, RPS2, and RPS28A
315
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